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Abstract 
 
A dynamic stroma that changes with alterations occurring in the epithelium is fundamental for 
the maintenance of epithelial tissue. Glucose starvation, anoxia and acidosis are characteristic 
features of the central core of most solid tumours. Myofibroblasts are stromal cells present in 
many such solid tumours including those of the colon, and they are known to be involved in all 
stages of tumour progression. HMGb1 is a nuclear protein that plays an important role in 
nucleosome stabilisation and gene transcription. Whilst HMGb1 is a nuclear protein, it has been 
reported to takes part in the immune system when passively released by necrotic cells or 
actively secreted by inflammatory cells such as dendritic cells in the extracellular milieu. The 
data presented in this thesis suggests that the microenvironmental condition of glucose 
starvation is responsible for the active release of HMGb1 from different types of cancer cell 
lines (HT29, MCF-7 and A549) under normoxic conditions. Recombinant HMGb1 (10ng/ml) was 
shown to trigger proliferation in myofibroblasts cells via activation of PI3K and MEK1/2. 
Conditioned medium collected from glucose deprived HT29 cells was shown to stimulate 
migration and invasion of colonic myofibroblasts, and these processes were significantly 
inhibited by immunoneutralising antibodies to HMGb1, RAGE and TLR-4, along with specific 
inhibitors of PI3K and MEK1/2. In addition, MMP-2 and MMP-9 two major degraders of 
basement membrane were investigated for their involvement in CCD18 myofibroblasts 
migration and invasion in matrigel membrane invasion assay setup. The data suggested that 
these proteases are not upregulated in this set up and thought not to play any major role in the 
migration and invasion of myofibroblast cells. There remains a possibility for other proteases 
being released from myofibroblasts and subsequent digestion of matrigel matrix in this set up. 
Together these data suggest that HMGb1 released from the cancer cells under glucose 
starvation is involved in stimulating the CCD18 myofibroblasts migration and invasion and that 
this was through activation of RAGE and TLR-4, resulting in activation of the MAPK and PI3K 
signalling pathways. Thus, this study suggests that HMGb1 may be released by cancer cells in 
areas of low glucose in solid tumours with the resulting activation of myofibroblasts. Therefore, 
HMGb1 may be considered as potential therapeutic target to inhibit solid tumour growth.  
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Chapter 1 
Introduction 
1. Cancer 
 
Cancer is a disease associated with morbidity and mortality and is characterised by 
uncontrolled proliferation of cells within the body. There were 14.1 million new cases and 8.2 
million deaths recorded in 2012 worldwide. Out of 8.2 million, lung cancer, liver cancer and 
colorectal cancer contributed to 1.6 million, 745000 and 723000 deaths respectively worldwide 
in 2012 (Ferlay et al. 2015). In spite of many advances in cancer research, the mortality 
associated with cancer is still a major concern. In the last couple of decades, the understanding 
of cancer at the molecular level has lead to the identification of a number of new drug targets for 
the development of novel drug therapies. Some of these drugs such as cyclin dependent kinase 
(CDK) inhibitors and brentuximab vedotin (antibody drug conjugate) targeted at CD30 antigen 
have already entered for use in clinics (de Claro et al. 2012; Sánchez-Martínez et al. 2015). 
Unfortunately, most cancers are still associated with mortality in human population around the 
world (Hanahan and Weinberg 2000).  
   
1.1 Carcinogenesis  
 
Carcinogenesis in humans can be induced by any one or combination of certain chemical, 
biological or physical damage that causes genetic changes to occur in the cells.  The process of 
carcinogenesis can be divided into three different stages; initiation, promotion, and progression.  
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The first stage of carcinogenesis is initiation, which can be a result of irreversible genetic 
alteration (Balmain and Brown 1988; Sugimura and Ushijima 2000; Califano et al. 2015).  The 
stages of initiation have been studied in a number of experimental models in vivo.  The genetic 
changes that occur during the process of initiation could arise from one or more simple 
mutations such as transitions, transversions, or small deletions (Goodman et al. 1991). Thus, 
the first stage in the development of cancer (initiation) is a common phenomenon that can occur 
spontaneously in humans. However, based on the studies carried out on rat and mouse 
systems, it appears that most initiated cells usually do not go on to develop into cancer, but may 
remain quiescent in the organism for a lifetime. It is believed that adults carry many initiated 
cells that do not develop into cancer (Pitot and Dragan 1991; Bajaj et al. 2015).  
 
The second stage of carcinogenesis is ‘promotion’ which does not involve changes in the 
structure of DNA, however it can change the expression of the genome. During the ‘promotion’ 
stage, a promoting agent (ligand) binds to a specific receptor which results in an altered 
expression of genes (Dragan and Pitot 1992). This change in expression of genes is regulated 
by the availability of the receptor and other promoting molecules in the cells. Therefore, it is 
likely that specific promoting agents would promote specific subsets of initiated cells (Pardal et 
al. 2003). Interestingly, it has been shown in many experimental models in vivo that the process 
of carcinogenesis does not always involve the stage of promotion. For example, if the dose of a 
promoting agent is substantially high, the stages of initiation and even promotion can be 
bypassed. However, in humans the stage of promotion during carcinogenesis is normally easily 
identified (Pitot et al. 1989).  
 
The final stage of carcinogenesis is progression. This is characterised by multiple molecular 
changes within the genome and karyotypic instability. The normal cells undergoing cell division 
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regulate the structure of their genome and karyotype but cancer cells are unable to do so 
(Fearon and Vogelstein, 1990). The malignant cells have capability of repeatedly altering the 
structure of their genome. This genomic shuffling becomes the basis for increased growth and 
metastatic potential, the ability to escape immune surveillance and acquired drug resistance 
(Stark 1986). A number of molecular targets for the different stages of carcinogenesis have 
been studied. These include proto-oncogenes, cellular oncogenes and tumour suppressor 
genes. However, alterations in both alleles of the tumour suppressor genes are found only in 
the progression stage of carcinogenesis (Vanden et al. 1990). 
 
1.1.1  Metastasis in cancer 
 
In spite of many advances in the cancer chemotherapy and better clinical outcomes, metastatic 
spread remains a big hurdle in treatment of this disease (Hanahan and Weinberg 2000). 
Metastasis is the process of movement of tumour cells from one organ to another distant organ 
within the body. Metastatic spread is considered as a major cause of treatment failure in most 
cancers. For example, approximately 80% of patients who died of prostate cancer had clinical 
evidence of bone metastasis (Coleman 2006). Cancer metastasis involves complex interactions 
between tumour cells and other cells with the tumour microenvironment followed by movement 
of the tumour cells via the blood or lymphatic system, eventually seeding in distant organs 
(Fokas et al. 2007). The migration of tumour cells might be effected by a combination the 
mobility of the cells together with the attractions induced by cytokines or other molecules and/or 
availability of right nutrients at the migratory site (seed and soil theory). Early in vivo work by 
Hart and Fidler (1980) demonstrated the seed and soil effect where melanoma cells were 
injected into the circulation of mice and tumour growth appeared in the lungs. Surprisingly, 
metastatic lesions did not develop at the site of where cells were injected. This suggested that 
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sites of metastatic spread are characterised by the microenvironment of the specific host tissue 
such as lungs where cancer cells are provided with all the nutrients necessary for their growth 
(Hart and Fidler 1980; Fokas, Engenhart-Cabillic et al. 2007).  
  
The steps of pathogenesis of metastatic spread include invasion in the local host tissue, 
lymphatic penetration by malignant cells and finally detachment. It has been established that 
once malignant cells enter into the lymphatic system, they can also find their way to blood 
vessels (Steeg 2006). Therefore, metastatic spread can be classified into an orderly sequence; 
invasion, intravasation, circulation, extravasation and colonization. The lymphatic channels are 
thin walled; thus, provide a negligible resistance to the penetration by the tumour cells. This is 
one of the reasons why lymphatic system has been considered as common pathway for the 
tumour cells to enter into the circulation (Chambers et al. 2002). Once the tumour cells have 
made their way into the lymphatic system, they can detach themselves and be carried away or 
remain proliferative at the site of invasion (Fidler 2003). Some tumour cells are aggregated by 
cell interactions and form large cluster of cells. Such types cells have increased potential to 
form tumours after their arrest into the circulation (Tanaka et al. 1977). In addition, during the 
circulation phase, tumour cells can interact with other tumour cells, platelets, lymphocytes and 
other host cells. The metastatic tumours have always been a cause of concern for successful 
cancer chemotherapy because of high intolerance of the drugs administered targeting more 
than one tumour type or acquired drug resistance (Carmeliet and Jain 2000; Khozin et al. 
2015).  
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1.1.2   Colon adenocarcinoma  
 
Colon adenocarcinoma is listed amongst the top ten malignancies in many countries. This colon 
cancer accounts for approximately 55,000 deaths every year in USA (Sanson‐Fisher et al. 
2000). Half of the patients who undergo surgical removal of the cancer encounter complications 
linked with metastatic spread and are consequently not expected to survive (Kamangar et al. 
2006). The management of this disease include adjuvant therapy with the synthetic drug, S-
fluorouracil (SFU). However, a number of side effects have been seen in patients taking SFU 
(Shepherd 2003).  
 
Colon cancer is a result of several genetic and epigenetic alterations, which drive the 
transformation of normal colonic epithelial cells to colon adenocarcinoma cells. This process is 
called colon carcinogenesis. During this process, the genetic and epigenetic changes have 
direct impact on molecular signature of cancer cells in which they occur. The understanding 
about the molecular genetics of colon cancer has revealed that colon carcinogenesis is 
multistep process characterized by genomic (Fearon and Vogelstein 1990). The genetic or 
epigenetic alterations in colon cancers activate oncogenes (genes that encodes for proteins like 
growth factors, growth factor receptors, transducers of growth factor responses and 
transcription factors that induce growth factors induced gene transcription) or suppress tumour 
suppressor genes (genes that regulate DNA damage repair, cell cycle arrest, mitogenic 
signalling, cell differentiation, migration and programmed cell death) in various signalling 
pathways such as mitogen activated protein kinase cascade (RAF-RAS-MAPK), transforming 
growth factor-beta (TGF-β) and Phosphatidylinositide 3-kinases-protein kinase B (PI3K-AKT) 
pathways. There are three forms of genomic instability been reported in colon cancers: 1) 
6 
 
microsatellite instability 2) chromosomal instability (gain and losses of chromosomal regions) 
and 3) chromosomal translocations (Shih et al. 2001; Vurusaner et al. 2012; Lovén et al. 2013).  
 
Previously, it was believed that adenomatous polyps were transformed into malignant tumours. 
However, now it has been suggested that hyperplastic polyps may transform into malignant 
tumours via adenoma to adenocarcinoma progression route (Jass 2004). It has been suggested 
that colorectal cancer evolves multiple molecular pathway with different morphological and 
clinical characteristics and two most common pathways are chromosomal instability and 
microsatellite instability. It has been shown that molecular and morphologically heterogenic 
hyperplastic polyps do exist and one with extensive DNA methylation are likely to have 
significant malignant potential (Jass 2007). 
 
Reportedly, about 75% of colon cancers are resistant to the growth inhibitory effect of 
transforming growth factor (TGF-β) (Elliott and Blobe 2005). TGF-β is a tumour suppressor that 
mediates its effects via a heteromeric receptor complex. This heteromeric receptor complex 
consists of type I transforming growth factor beta receptor (TGFBR1) and type II transforming 
growth factor beta receptor (TGFBR2). Upon activation, these receptors phosphorylate down-
stream signalling proteins such as Smad2, Smad3, PI3K and p38-MAPK (Markowitz and 
Roberts 1996).  The downstream transcriptional targets of TGF-β are genes involved in 
proliferation, extracellular matrix (ECM) production and apoptosis. Therefore, considering the 
central role of TGF-β in colon cancer, it may be considered as a logical target for deregulation 
of colon cancer (Fynan and Reiss 1993). 
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1.1.3 Hypoxia  
 
Hypoxia (low oxygen levels) plays an important role in tumour progression and has been 
considered as an established prognostic factor in solid tumours (Dhani et al. 2015). Most solid 
tumours are characterised by disorganised vasculature that is needed for oxygen and nutrient 
supply (Chung et al. 2010). Typically, hypoxia in tumours occurs at a distance of 100-200µM 
from the nearest vasculature (Figure 1.1) (Pugh and Ratcliffe 2003). Those cells that do not get 
enough oxygen and nutrients can eventually become necrotic or undergo apoptosis. However, 
this is not always the case in hypoxic tumours. The response to meet the stress of low oxygen 
tension in cells is facilitated by a transcription factor known as hypoxia-inducible factor (HIF). 
The transcription factor HIF-1 is composed of HIF-1α and HIF-1β subunits. Although, HIF-1β is 
constitutively expressed however the expression of HIF-1α is induced by hypoxic cells where 
oxygen concentration is less than 6% in their microenvironment (Semenza 2003). Under 
hypoxic conditions, HIF-1 gets activated after the stabilization of HIF-1α subunit, however under 
normoxic conditions, HIF-1α is rapidly degraded via ubiquitinated proteasomal degradation and 
is virtually undetectable (Pugh and Ratcliffe 2003). 
 
 
A number of HIF-1 regulated genes have been shown to play critical roles in cellular response 
to hypoxia, glycolysis, erythropoiesis, angiogenesis and vascular remodelling. In tumour cells 
loss of p53 activity has been shown to increase HIF-1α expression and transcription of 
downstream target genes including vascular endothelial growth factor (VEGF). In addition, 
activation of certain signalling pathways such as PI3K and the serine/theronine kinases protein 
B (AKT) and FKBP-rapamycin associated protein (FRAP) has been shown to induce the 
expression of HIF-1α and VEGF mRNA under normoxic conditions (Zhong et al. 2000; Li et al. 
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2015). Phosphatase and tensin homolog (PTEN) protein is encoded by PTEN gene is a tumour 
suppressor. Loss of PTEN activity also leads to increased expression of HIF-1α (Courtnay et al. 
2015). Although, molecular mechanism by which cells senses hypoxia followed by HIF-1α 
stabilisation is unclear but there are experimental evidences suggesting the requirement of 
superoxide generated in mitochondrion followed by hydrogen peroxide for the induction of HIF-1 
activity (Michiels et al. 2002).  
 
 
The regulatory mechanism behind HIF-1 stability, expression and associated pathophysiological 
consequences remains an active area of research. In normoxia, oxygen dependent prolyl-4 
hydroxylases (PHDs) hydroxylate oxygen dependant degradation domain (ODD) of HIF-1α. 
This hydroxylated HIF-1α bonds with von Hippel-Lindau protein (pVHL) followed by 26S-
proteasomal degradation (Ivan et al. 2001). The von Hippel-Lindau (VHL) protein has been 
shown to play critical role in the ubiquitination of HIF-1α. The protein binds to the stabilization 
domain of HIF-1α. It has been suggested that metal chelators such as cobalt chloride or 
desferrioxamine (iron chelator) facilitate HIF-1α stabilization by dissociated VHL from HIF-1α. 
Interestingly, hypoxia does not cause dissociation of VHL from HIF-1α, rather in hypoxia, HIF-
1α gets stabilised because its iron containing PHDs require oxygen as co-factor. Whilst oxygen 
is the limiting substrate for hydroxylation, under many pathophysiological conditions, PHD 
activity is also modulated by limiting iron and ascorbate availability (Brahimi-Horn and 
Pouysségur 2007). Another regulatory mechanism involves transactivation domain that is 
present on the C-terminus of HIF-1α. This domain is known as C-terminal transactivation 
domain (CTAD). The hydroxylation of CTAD renders the HIF-1α to the p300 co-activator which 
prevents transactivation of HIF-1α. This results in stabilisation of HIF-1α (Hirsilä et al. 2003).   
 
 
9 
 
 
 
 
 
Figure 1.1: Schematic representation of a typical solid tumour. There are well vascularised 
regions on and inside the periphery of tumour and seminecrotic areas towards the centre of the 
tumour. There is anoxic, acidic and glucose starved necrotic core in the centre of tumour (Koh 
and Powis 2012).  
 
 
Hypoxia can affect tumour growth in positive way by making tumour cells adapt to survive the 
local oxygen and nutrient deprived conditions. For example, hypoxia drives increased anaerobic 
glycolysis facilitated by increased levels of glycolyic enzymes, glucose transporters and neo-
vascularisation (Pouysségur et al. 2006). Although, a clear explanation of pro-apoptotic and 
anti-apoptotic hypoxia is still lacking, however the interplay between p53 (which appears to be 
hypoxia inducible) and HIF-1 is can not be neglected (Carmeliet et al. 1998).  
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The tumour suppressor p53 gene undergoes mutational inactivation in many cases of solid 
tumour. Under hypoxic conditions, p53 undergoes post-translational modifications and gets 
stabilised. Upon stabilisation, p53 become active and promote cell cycle regulation and 
apoptosis (Oren et al. 2002). Under severe hypoxic or anoxic conditions, p53 interacts with HIF-
1α directly or via mouse double minute 2 (Mdm2) -E3 ubiquitin-protein ligase pathway. In 
addition, in severe hypoxia or anoxia induced accumulation of p53 has been shown to inhibit 
HIF-1 transcriptional activity via Mdm2 targeted proteasomal degradation (Honda and Yasuda 
1999). In principle, once p53 is activated, it either suppresses or destroys HIF-1α. Therefore, 
increased expression of p53 and thus destruction of HIF-1α might induce apoptosis (An et al. 
1998). 
 
 It has been observed that cells surviving oxygen deficiency also usually survive apoptosis 
induced by chemotherapy (Schmaltz et al. 1998). This idea has been supported by the finding 
where vascular endothelial growth factor (VEGF) neutralizing antibodies blocked the anti-
apoptotic effect of hypoxia on HepG2 cells (Baek et al. 2000).  It has been shown that cancer 
cells secrete some factors that inhibit endothelial cell apoptosis by activating the extracellular- 
signal related kinases ERK1/2 pathway (Reinmuth et al. 2001). In addition, a number of growth 
factors such as VEGF, insulin like growth factor 2 (IGF2) and TGF-β can activate signal 
transmission that can lead to HIF-1α expression and cell survival (Tabatabai et al. 2006). This 
also includes hypoxia-induced platelet derived growth factor (PDGF) signalling and activation of 
the PI3K/Akt pathway. Therefore, HIF-1 can also stimulate autocrine signalling pathways crucial 
for cell survival under hypoxia (Zhang et al. 2003). It has been suggested that hypoxic tumours 
are more likely to acquire resistance against radiation and chemotherapy. In addition, these 
hypoxic tumour cells are more aggressive and have increased potential for invasion and 
metastasis than the normal tumour cells (Otrock et al. 2009). 
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1.2 The tumour microenvironment  
 
The tumour microenvironment has been reported to play important roles in the progression of 
cancer (McAllister and Weinberg 2014). The tumour microenvironment is a complex system and 
consists of many cell types such as endothelial cells, pericytes, smooth-muscle cells, 
fibroblasts, myofibroblasts, neutrophils and other granulocytes, mast cells, macrophages and 
dendritic cells (Brennecke et al. 2015). These cells in addition to cancer cells might contribute to 
the acquisition of hallmark traits by creating ‘tumour microenvironment’ described by Hanahan 
and Weinberg previously. In addition, lymphatic vascular system plays a crucial supporting role 
in the microenvironment of metastatic tumours (Farber and Rubin 1991; Lee et al. 2015).   
 
Whilst tumour associated fibroblasts and myofibroblasts are normal cells, they also support 
cancer in a positive way by releasing growth factors that are necessary for tumour growth (De 
Wever et al. 2008; Nagasaki et al. 2014). In addition, these cell types also constitute a 
substantial part of tumour stroma, which has an important role in the maintenance of tissue 
homeostasis (Figure 1.2) (Alcaraz and Roca-Cusachs 2015). The tumour stroma in the 
microenvironment provides structural support and facilitates the cross talk between the cells 
(Ohtani 1998). 
 
Another key constituent of tumour microenvironment is the extracellular matrix (ECM), which is 
an important regulator of normal tissue behaviour. The ECM is typically composed of collagen, 
laminin, fibronectin and proteoglycans (Bosman and Stamenkovic 2003). The ECM separates 
the endothelium and underlies endothelial cells, pericytes, fibroblasts, myofibroblasts and other 
cell types (Figure 2). In normal tissue, ECM’s role is to maintain homeostasis, which helps to 
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prevent the formation of a neoplasm (Kalluri 2003). However, in the tumour stroma, this is not 
achieved because of remodelling of the ECM. The ECM remodeling is mediated by a number of 
matrix degrading enzymes such as serine, cysteine, matrix metallproteases (MMPs) and 
endoglyosidases such as heparanase (Vlodavsky et al. 2002). 
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Figure 1.2: The tumour stroma in microenvironment showing tumour cells (transparent), 
fibroblasts (in yellow), myofibroblasts (green) and endothelial cells (in grey). The necrotic areas 
are displayed in blue colour. Hypoxia, acidic core and lack of glucose are three hallmarks of 
tumour microenvironment displayed from centre to middle regions. The MMPs released from 
stromal cells such as fibroblasts and myofibroblasts degrade ECM (shown in purple and blue 
colours). Hypoxia induced stabilization of HIF-1 (red areas) contribute to promote tumour cells 
growth and angiogenesis by facilitating the release of growth factors such as VEGF.  
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1.2.1    Extracellular matrix remodelling   
 
The ECM is an important element of tumour microenvironment and an important regulator of 
normal tissue behaviour. One of the common aspects of many solid tumours is desmoplasia. 
This is caused by morphologically and functionally altered tumour stroma in the tumour 
microenvironment (Whatcott et al. 2015). This desmoplastic response is mediated by a number 
of growth factors and cytokines such as TGF-β and PDGF. It has been shown that both are 
responsible for the induction of signalling cascade that modulates the tumour stroma (Micke 
2004). The altered expressions of α-smooth muscle actin (α-SMA), vimentin and desmin in 
fibroblasts are typical biomarkers for desmoplastic reaction in tumour microenvironment 
(Elenbaas and Weinberg 2001).   
 
In the tumour microenvironment, the ECM is remodelled to support the neoplastic cells to 
proliferate and to allow them to enter into the circulation. The remodelling of ECM characterised 
by structural disruption or modification of ECM components which modulates the cell’s ability to 
survive, proliferate and migrate (Figure 3). The ECM remodelling is mediated by cysteine 
proteases (cathepsin B) (Yan et al. 1998), aspartic proteases (cathepsin D), serine proteases 
(elastase and uPA) (Van den Steen et al. 2001) and MMPs (Matzner et al. 1985; Stamenkovic 
2003).  
 
It has been shown that most solid tumours exhibit increased expression of proteases that are 
correlated with tumour progression. However, during ECM remodelling, most of these proteases 
are produced by stromal cells of the host tissue. For example, in human breast cancer, stromal 
15 
 
fibroblasts have been reported to produce MMP-11 and urokinase plasminogen activator (uPA) 
(Pupa et al. 2002). In addition, MMP-1, 2 and 3 have been reported to be localised on the 
fibroblasts located in close proximity of invading cancer cells (Gomez et al. 1997). For example, 
extracellular matrix metalloproteinase inducer (EMMPRIN), a membrane bound glycoprotein is 
produced by cancer cells. The production of EMMPRIN stimulates stromal cells to synthesise 
MMPs in the microenvironment (Tang, et al. 2004). In addition, aspartic protease cathepsin B is 
found on plasma membrane of tumour cells and is correlated with invasion (Gangoda et al. 
2015). A study has revealed that EMMPRIN stimulates MMP-1 production by fibroblasts 
followed by binding of MMP-1 to EMMPRIN on tumour cells. This process facilitates 
degradation of ECM by tumour cells (Biswas et al. 1995).  
 
In tumour microenvironment, cancer cells stimulate stromal cells (fibroblast, myofibroblasts, 
endothelial cells, pericytes etc) to produce proteases which cleave matrix components (Figure 
1.3). This cleavage or proteolysis of ECM modifies focal adhesion and cytoskeleton of ECM and 
triggers the release of focal adhesion kinases (FAK) (Fashena and Thomas 2000). In addition, 
the proteolysis of ECM components also exposes the binding sites such as integrin binding 
sites available on ECM. Furthermore, the laminin receptor (67LR), which is overexpressed by 
various tumour cells, interacts with integrins and modulates the interaction between tumour 
cells and laminin. This process has been shown to facilitate the metastasis of tumour cells 
(Martignone et al. 1993).   
 
The ECM remodelling has a significant effect on tumour cell behaviour by stimulating various 
signalling pathways and molecules. A number of epidermal growth factor (EGF) family 
cytokines such as TGF-β, PDGF, fibroblast growth factor beta (b-FGF) and interferon gamma 
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(IFN-ᵞ) bind to various components of ECM and remain inactive until they get signals from 
matrix proteases (Stamenkovic 2003; Park et al. 1993). Therefore, an increase in the protease 
activity on the ECM can lead to the activation and release of various growth factors that can 
stimulate tumour cells in the tumour microenvironment (Streuli 1999). The remodelling of the 
ECM also has a crucial role in angiogenesis. Once released from endothelial cells, the 
angiogenic factors like VEGF can be stored in the ECM. All these processes are initially guided 
by tumour cells but later on involve the microenvironment and the host cells to participate, thus 
disrupting intracellular signalling between tumour cells and the ECM within the tumour 
microenvironment (Park et al. 1993). The tumour cells remodel the matrix to override and 
modulate the homeostatic arrangement within the microenvironment. Moreover, the 
composition of tumour stroma is equally important for therapeutic response as the tumour 
phenotype is (Pupa et al. 2002). 
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Figure 1.3: Schematic representation of tumour stroma in microenvironment showing ECM 
degradation followed by escaping of cancer and stromal cells. Hypoxia, acidic core and lack of 
glucose are three hallmarks of tumour microenvironment. The MMPs produced from cancer and 
other stromal cells (fibroblasts and myofibroblasts) can degrade ECM. This degradation of ECM 
then can facilitate migration of cells. 
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1.2.2   Cellular cross talk in the tumour microenvironment 
 
The cross talk between the cells in tumour microenvironment is linked with the progression of 
the disease. For example, hepatic sinusoidal endothelial cells enhance the interaction between 
hepatocytes and kupffer cells to exchange nutrients that is needed for neo-vascularisation 
within tumours (Bhatia et al. 1999). It has been established that tumour cells promote VEGF 
expression in hypoxic conditions (Levy et al. 1996). Therefore, hypoxia induced VEGF 
expression and subsequent formation of neo-vascularisation promotes cell survival under harsh 
conditions within the microenvironment.  
 
The expression of some angiogenic factors depends on organ specific cell-cell cross talk within 
the microenvironment. For example, interleukin-8 (IL-8) has been shown to induce proliferation 
of endothelial cells (Li et al. 2003). In contrast, the expression of IL-8 was inhibited in melanoma 
and hepatocyte co-cultures. Therefore, the expression of angiogenic factors in tumour cells is 
directly linked with individual organ specific microenvironments (Desbaillets et al. 1997).  
 
The epithelial and mesenchymal cells are the drivers of differentiation and development. 
Furthermore, it has been shown that changes in the stroma can promote epithelial 
transformation (Park et al. 2000). For example, mesenchymal and epithelial cells regulate the 
ovarian cycle before and during the reproductive period. During the menopause, any loss in the 
cross talk between mesenchymal and epithelial cells is correlated with the promotion of ovarian 
cancer. Therefore, any interference in the cell-cell interaction during embryogenesis might be 
responsible for the onset of cancer (Aboseif et al. 1999).  
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The cellular cross talk is directly linked with motility, survival and invasion. For example, 
integrins present between the cells and the ECM are responsible for the adhesion of cells to the 
ECM. A disruption in the integrin mediated adhesion facilitates cellular translocation and 
apoptosis (Frisch et al. 1996). Similarly, the pro-survival and pro-invasive signals are needed for 
survival and invasion. For example, integrins activate a number of downstream molecules such 
as FAK and MAPK/ERK pathways. The phosphorylated FAK is necessary for the survival of 
cells combating anoikis (programmed cell death due to lack of cell-cell or cell-matrix interaction) 
(Frisch et al. 1996). 
 
A number of other pathways such as PI3K, Ras, Rac, Rho and cell division cycle-42 (CDC-42) 
are involved in the regulation of cell motility within the tumour microenvironment. However, most 
of these pathways overlap in facilitating the process of motility, invasion and survival in cancer 
and stromal cells (Xue et al. 2000).   
 
1.2.3   The interstitial fluid pressure in tumours 
 
The central core of solid tumours is often necrotic due to a lack of nutrients and anoxia resulting 
from a poor blood supply. However, there is a viable rim on the periphery of this necrotic zone, 
below basement membrane of most solid tumours. Many chemotherapeutic drugs have been 
developed to target these cells and also the tumour vasculature (Shaked et al. 2006).  
 
In spite of many advances in the target-oriented chemotherapy, most therapeutic agents are 
unable to kill the cells of the viable rim of tumours. The viable rim encapsulates the hypoxic and 
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necrotic core of solid tumour and thought to be one of the reasons why most drugs cannot 
penetrate and reach to the central core of tumours (Jain 1987; Minchinton and Tannock 2006). 
There could be a couple of explanations for the viable rim escaping effective treatment. One 
could be that the microenvironment within the tumour is dynamic and keep changing. This might 
result in an increase in the interstitial fluid pressure and cells from central core coming out and 
contribute in the formation of rim. Another explanation could be linked with the work done by 
Yuval Shaked et al. (2006) which suggested that vascular disrupting agents (VDA) may induce 
acute mobilisation of circulating endothelial cells in tumours. These cells may home to the 
viable rim in the tumours and may remain there after the therapy (Shaked et al. 2006).   
 
1.2.4   Hypoxia and glucose deprivation in solid tumours   
 
The multistep development of most solid tumours involves six hallmarks of cancer reported by 
Hanahan and Weinberg previously. Recent conceptual advances have added two emerging 
hallmarks of cancer. These are reprogramming of energy metabolism and evading immune 
destruction. Unlike apoptosis or autophagy, necrosis in tumours might have direct impact on 
tumour growth and metastasis because necrotic cells might explode and release growth factors 
and other nutrients into the host tumour microenvironment. (Hanahan and Weinberg 2011). It is 
established that hypoxia is a common phenomenon that occurs in most solid tumours. 
Apparently, most hypoxic cells are resistant to radiotherapy and to a number of 
chemotherapeutic agents. It has been shown that there is a correlation between the oxygen 
levels and the response of tumours to the radiation therapy. In addition, the oxygen deprivation 
is also correlated to the metastatic potential of the tumour cells. Hypoxia has been considered 
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as one of three hallmarks of tumour microenvironment. The other two are glucose deprivation 
and acidosis (Tannock 1972; Schlappack et al. 1991; Hanahan and Weinberg 2011).  
 
The microenvironment of solid tumour is not only characterised by hypoxia but also the 
formation of acidic environment within solid tumours (Raghunand et al. 2014). In solid tumours, 
lactic acid formation and hydrolysis of adenosine triphosphate (ATP) have been found to be 
acidic and a wider range of pH (5.85-7.68) has been observed in different regions of the same 
malignant tissue with median pH of 7.0. This pH is generally lower than the surrounding normal 
tissue where median pH is 7.5. The lower pH or acidosis is correlated with the decreased 
radiation sensitivity of solid tumours. In addition, it has been shown that the cytotoxic effect of 
doxorubicin (a DNA intercalating agent) and mitoxantrone (type II topoisomerase inhibitor) was 
reduced at low extracellular pH (Wike-Hooley et al. 1984; Mahoney et al. 2003). 
 
It is clear that neoplastic tissues utilise a large quantity of glucose. For example, Walker 
carcinomas in rats were found to contain 0-5mg/ml of glucose in tumour interstitial fluid when 
compared to the normal subcutaneous interstitial fluid of rats with 90-100mg/ml of glucose 
(Woodward and Hudson 1954; Gullino et al. 1964). This might suggest that glucose passing 
through the tumour vasculature is rapidly utilised by the neoplastic cells (Wike-Hooley et al. 
1984; Graff 2014). The effect of glucose deprivation and acidosis has been shown to increase 
metastasis in murine tumour cell lines in vivo. However, the underlying mechanism of glucose 
deprivation induced metastatic spread remains unknown (Schlappack, et al. 1991). Glucose 
deprivation and hypoxia have been shown to induce the accumulation of proteasomes in the 
nucleus of cancer cells (HT29 colon cancer cells). Proteasome is a major site for protein 
degradation, which plays a key role in the proteolysis to maintain homeostasis. It has been 
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shown that glucose deprivation and hypoxia can modulate the intracellular location of 
proteasomes. Inhibiting protein degradation by selective inhibitor of proteasome has been 
shown to restore the sensitivity to topoisomerase-IIα targeted drugs in vitro and in vivo. 
Therefore, an increased proteolysis in the nucleus of cells could be the survival strategy of 
cancer cells to survive under hypoxia and glucose deprivation (Ogiso et al. 1999).  
 
1.3   High mobility group box 1 (HMGb1) protein 
 
The high mobility group (HMG) proteins are chromosomal proteins, named according to their 
ability to move electrophoretically through polyacrylamide gels. There are three main known 
superfamilies; HMGa, HMGb and HMGn. The HMGb superfamily has a functional sequence 
motif, which is called DNA binding box (Bustin 2001). HMGb1 is a non-histone protein involved 
in stabilization of nucleosomes and the bending of DNA, which facilitates gene transcription 
(Lange et al. 2008). In addition, HMGb1 is responsible for modulating the activity of steroid 
hormone receptors by participating in the maintenance of nucleosome structure. As supporting 
evidence, HMGb1-deficient mice died shortly after birth, possibly because of inactivation of 
glucocorticoid receptor responsive genes (Wei et al. 2003). The HMGb1 is expressed in all cells 
of vertebrates and in yeast, plants and bacteria (Bustin et al. 1990). The cellular localisation of 
HMGb1 could be tissue specific with notably high levels found in lymphoid tissues and testis. In 
addition, an increased level of HMGb1 has been seen in cytoplasm of the cells of the liver and 
the brain. However, HMGb1 concentration is usually more in the nuclei of the cells than the 
cytoplasm (Mosevitsky et al. 1989).   
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Structurally, HMGb1 is composed of three main domains; the A box domain and B box domain 
are homologous DNA binding pockets and a negatively charged chain of 30 amino acids 
(Figure 1.4) (Chen et al. 2004; Ellerman et al. 2007). The A box domain plays an important role 
for its antagonistic and anti-inflammatory effect whereas the B box domain has a role similar to 
that of proinflammatory cytokines (Andersson, Erlandsson-Harris et al. 2002) (Figure 1.4). The 
amino acids 150-183 on the acidic tail are responsible for binding to the receptor for advanced 
glycation end products (RAGE) (Figure 1.4) (Ellerman et al. 2007). The HMGb1 binds to the 
minor grove of DNA without sequence specificity, and induces bends in the helical structure of 
the DNA. The formation of this complex facilitates interaction between DNA and other factors 
such as p53, nuclear factor kappa β (NF-kβ), recombination activating proteins 1/2 (RAG1/2) 
and some steroid hormone receptors (Bianchi 2004). The HMGb1 also interacts with other 
molecules including RNA, Lipopolysaccharides (LPS) or endotoxins and IL-1β. Thus HMGb1 
may play a key role in facilitating the arrangement of many nucleoprotein complexes (Bianchi 
and Manfredi 2014; Keyel 2014). 
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Figure 1.4. Structure of HMGb1 protein. HMGb1 is a 215–amino acid (AA) protein of ∼30 kDa. 
HMGb1 is composed of three domains: two positively charged domains (A box and B box) and 
a negatively char Acidic tail.  A and B boxes are DNA-binding domains and B box is also 
responsible for cytokine activity by inducing macrophage secretion of proinflammatory 
cytokines. This cytokine activity is antagonized by recombinant A box.  The protein structure 
involved in the binding of HMGb1 with RAGE is located between amino acid residues 150 and 
183 (Ellerman et al. 2007). 
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1.3.1   Role of HMGb1 in disease  
 
HMGb1 does not possess signal sequence and therefore, does not transverse the endoplasmic 
reticulum. However, it is released actively by various cells such as macrophages, pituicyte and 
erythroleukemia cells (Tang et al. 2007). In addition, HMGb1 is passively released from necrotic 
or damaged cells but not from cells undergoing apoptosis, these apoptotic cells retain HMGb1 
within their nuclei (Zong et al. 2004). Therefore, apoptotic cells do not trigger inflammation even 
after the loss of the membrane (Bonaldi et al. 2003). Hence, HMGb1 can be considered as a 
critical stimulus of inflammation during cell death (Scaffidi et al. 2002). The HMGb1 has two 
lysine-rich nuclear localization sequences which direct its movement towards the nucleus of the 
cell (Bonaldi et al. 2003). Whilst it is a nuclear protein, HMGb1 is released from the cells under 
certain conditions to take part in the inflammatory process (Frank et al. 2015; Zhu et al. 2015).   
 
During inflammation, extracellular HMGb1 activates infiltrating macrophages via the RAGE 
receptor. In addition, activated macrophages/monocytes are also responsible for the release of 
HMGb1 in the extracellular milieu (Figure 1.5) (Andersson et al. 2002; Huttunen and Rauvala 
2004). There are three main steps have been suggested for HMGb1 secretion; 1) exit from the 
nucleus to the cytoplasm, 2) translocation from the cytoplasm into cytoplasmic organelles, and 
3) exocytosis. Macrophages/monocytes upon activation by proinflammatory cytokines acetylate 
HMGb1 at their lysine-rich nuclear localization sequences. This leads to the translocation of 
HMGb1 into the cytoplasmic vesicles followed by extracellular release (Gardella et al. 2002), 
(Figure 1.5).   
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It has also been suggested that HMGb1 is involved in various diseases including autoimmune 
disorders, sepsis, chronic inflammatory disease and cancer (Wang et al. 2004; Sims et al. 
2009). An increase in the concentration of HMGb1 has been observed in the plasma and 
epithelial lining fluids in patients with acute lung injury (Ueno et al. 2004). In addition, HMGb1, 
TNF-α and IL-1 β have been suggested to be involved in the pathogenesis of cutaneous lupus 
erythematosus (CLE). In CLE, HMGb1 forms a pro-inflammatory loop between tumour necrosis 
factor-α (TNF-α) and IL-1β to sustain prolonged inflammation, suggesting an important role in 
this inflammatory autoimmune disorder (Barkauskaite et al. 2007). A study revealed that anti-
HMGb1 antibody inhibited synovial inflammation by blocking HMGb1 in an experimental model 
of arthritis. However, this inhibition was independent of TNF-α pathway suggesting that TNF-α 
is not the only pathway necessary for extracellular release of HMGb1 (Pullerits et al. 2008).   
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Figure 1.5: Release of HMGb1 as a danger signal during inflammation. The figure shows a 
diagrammatic illustration of potential pathways for HMGb1 release leading to inflammatory 
responses.  HMGb1 can be released extracellularly by passive secretion from any necrotic cell 
or by active secretion from activated macrophages/monocytes (Andersson et al. 2002). 
 
 
HMGb1 has been reported to be responsible for the impairment of intestinal barrier function in 
mice (Sappington et al. 2002). In addition, HMGb1 play an important role in increasing ileal 
mucosa permeability and bacterial translocation to lymph nodes (Sappington et al. 2002). 
Furthermore, elevated levels of HMGb1 have been observed in synovial fluids of experimental 
animal models of arthritis (Andersson and Erlandsson‐Harris 2004). In addition, a clinical study 
has revealed that synovial fluid of rheumatoid arthritis patients had more elevated levels of 
HMGb1 than that of osteoarthritis patients (Taniguchi et al. 2003).  
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The hemorrhagic shock is characterised by activation of inflammatory cytokines. A clinical 
report revealed elevated levels of HMGb1 in the blood circulation of hemorrhagic shock 
patients. However, the elevated levels of HMGb1 went to normal as clinical conditions improved 
(Fan et al. 2007). In addition, the serum HMGb1 level goes significantly higher in sepsis 
patients compared to normal healthy volunteers. This observation was constant when 
compared to patients who died of sepsis versus the patients who had survived after recovering 
from sepsis (Yang et al. 2004).  
 
 
Recently, the effect of HMGb1 on fibroblasts and keratinocytes has been explored.  It has been 
shown that cytokine activity of HMGb1 stimulates keratinocyte scratch wound healing in vitro 
(Ranzato et al. 2009). In addition, HMGb1 was shown to induce proliferation and migration of 
keratinocytes via ERK1/2 pathway (Ranzato et al. 2010). To further support these findings, anti-
RAGE antibody and selective MEK1/2 inhibitor (PD98059) were used to inhibit the HMGb1-
RAGE-ERK1/2 pathway. This resulted in the inhibition of HMGb1 induced wound healing. 
Therefore, HMGb1 can be considered as a potential therapeutic target for the development of 
drugs for chronic inflammatory disease, chronic inflammatory autoimmune disorders and severe 
wounds (Ranzato et al. 2010). It has also been shown that HMGb1 stimulates vascularisation in 
chicken embryo chorioallantoic membrane in vivo, which suggests that HMGb1 plays an 
important role in angiogenesis (Mitola et al. 2006). In addition, HMGb1 triggers proliferation and 
migration of glioblastoma cells via ERK1/2 activation (Bassi et al. 2008).  However, the 
proliferation of cells can not be considered as marker for the expression of HMGb1 in vivo (Ller 
et al., 2004).  
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1.3.2   The role of HMGb1 in cancer  
 
Hanahan and Weinberg in 2000 proposed a model that defined six hallmarks of cancer. These 
are 1) unlimited replicative potential, 2) ability to develop new blood vessels, 3) escape from 
surveillance, 4) insensitivity to inhibitors of growth, 5) self-sufficiency in growth signals and 6) 
invasion and metastasis (Hanahan and Weinberg 2000). Recently, seventh hallmark has been 
proposed which is inflammation. In addition, dysregulated cellular energies within tumour 
microenvironment and evading immune destruction are two additional emerging hallmarks that 
most or may be all tumours exhibit (Hanahan and Weinberg 2011). All these hallmarks of 
cancer are linked with the levels, localisation and alterations in HMGb1 (Mantovani 2008; 
Mantovani et al. 2008). Therefore, HMGb1 is now important to understand the molecular 
biology of cancer. Several solid tumours including melanoma, prostate cancer, breast cancer, 
pancreatic cancer and colon cancer exhibit markedly elevated levels of HMGb1 (Völp et al. 
2006). These elevated levels of HMGb1 are associated with tumour formation, proliferation and 
metastasis and chemotherapeutic response. The presence of HMGb1 in the extracellular 
medium of cells is indicative of stress conditions (Lotze and Tracey 2005). 
 
 
The HMGb1 has dual role in cancer. The first role is correlated with neovascularisation in solid 
tumours (Campana et al. 2008). A rapidly growing tumour causes reduction in the microvessel 
density followed by formation of necrotic areas within the tumour. The necrotic areas within 
tumour not only produce angiogenic factor such as VEGF but also attract macrophages. The 
macrophages have been reported to release HMGb1 in stress conditions such as necrosis. In 
addition, HMGb1 binds to its receptor RAGE and activates NF-ƘB. Upon activation, NF-ƘB 
upregulates the production of certain cytokines and angiogenic factors in endothelial cells (van 
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Beijnum et al. 2008). The direct inhibition of HMGb1 with immunoneutralising antibodies has 
been reported to inhibit angiogenesis in vivo and in vitro (van Beijnum et al. 2006). It has been 
suggested that HMGb1 might have a direct impact on migration of cells because of its ability to 
modulate the adhesive properties of the cells and ECM components (Ellerman et al. 2007).  In 
addition, HMGb1 can enhance invasive and metastatic potential of tumour cells via the NF-κB 
pathway (Sasahira et al. 2008).  
 
 
The other role of HMGb1 in cancer is related to the immune response against tumours. There is 
evidence that HMGb1 is released in response to specific chemotherapy or radiation therapy 
induced conditions, and this is thought to promote immune response against tumours 
(Campana et al. 2008).  Extracellular HMGb1 has been shown to activate dendritic cells in 
murine models. Upon activation, these dendritic cells facilitate immune response against 
immunogenic apoptotic lymphoma cells (Ronchetti et al. 1999). In addition, HMGb1 has also 
been shown to trigger anti-neoplastic response from T cells (Campana et al. 2008). HMGb1 has 
been shown to induce antigrowth signals within tumours. These antigrowth signals usually act in 
two ways; a) cells may escape from the proliferation cycle and enter into the stage of 
quiescence (G0 phase) and b) permanent loss of proliferative potential by some alternations in 
their environment (Hanahan and Weinberg 2011). Contrary to this, it has been shown that MCF-
7 cells overexpressing HMGb1 progress through to S2 phase when compared with HMGb1 
knockdown MCF-7 cells (Yoon et al. 2004). However, other work has shown that HMGb1 
overexpression has been shown to suppress the growth of MCF-7 xenografts in nude mice 
(Jiao 2007).   
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Recent work has suggested an important role of HMGb1 in the survival of myeloid derived 
suppressor cells followed by suppressing the immune response against tumours. These 
myeloid derived suppressor cells are found in abundance in most cancers and are 
representative of suppressed immune system (Parker et al. 2015). The extracellular HMGb1 
due to its cytokine, chemokine and growth factor activity acts as protumour protein however, it 
does possess an ability to sustain genome stability during tumorigenesis. Thus, whilst HMGb1 
may promote tumour cell survival during the early stages of chemotherapy however on the 
contrary intracellular HMGb1 led inhibition of autophagy might increase the effectiveness of 
anticancer treatment (Kang et al. 2013).  
 
HMGb1 activates various signalling pathways such as MAPKs, protein kinase B (AKT) and 
PI3K. These pathways play important roles in proliferation and migration of normal cells and 
cancer cells. Supporting evidence includes activation of the PI3K pathway by HMGb1 in 
neutrophils and colon cancer cells (Kuniyasu et al. 2003). Furthermore, HMGb1 has been 
shown to induce toll like receptor-4 (TLR-4) mediated activation of MyD88-IRAK4-p38 and 
Myd88-IRAK4-AKT pathways. The activation of HMGb1-RAGE complex has been shown to 
activate NF-ƘB, JNK kinases and ERK1/2 pathways (Degryse, et al. 2001). In addition to RAGE 
receptor, HMGb1 binding with TLR-2 and TLR-4 receptors also has been shown to activate the 
NF-КB pathway. This suggests that NF-КB is an important signalling pathway that requires 
activation by HMGb1 (van Beijnum et al. 2008).  
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1.3.3   HMGb1 and its receptors 
 
The HMGb1 has been shown to modulate its cytokine like activity by interacting with multiple 
receptors including receptor for advanced glycation end products (RAGE) (Kokkola et al. 2005), 
toll like receptor 2 and 4 (TLR-2 and TLR-4) (Curtin et al. 2009; Kim et al. 2013), chemokine 
CXC receptor 4 (Schiraldi et al. 2012), and T cell immunoglobulin mucin 3 (TIM-3) (Baghdadi et 
al. 2013). However, RAGE is the most commonly researched receptor for HMGb1. This 
receptor belongs to immunoglobulin superfamily and is expressed in many cells including 
monocytes, macrophages, smooth muscle cells, dendritic cells (DC) and endothelial cells. The 
receptor for advanced glycation products is a receptor for multiple ligands that can therefore be 
activated by different ligands including HMGb1. However, the effects of this activation are 
dependent of the type of the cell this receptor is expressed upon. Activation of RAGE in 
monocytes/macrophages has been reported to trigger inflammatory response, neoplastic 
transformation and metastasis in neuroepithelial tumour cells (Taguchi et al. 2000). The 
fibroblasts have been shown to express RAGE and the activation of RAGE on fibroblasts was 
correlated with proliferation and migration of fibroblasts in tumour microenvironment (Liu et al. 
2010; Rojas et al. 2010). It has been shown that RAGE overexpression is associated with 
chronic degenerative disease and cancer (Tanaka et al. 2000). In addition, activation of RAGE 
by HMGb1 is associated with increased expression of the anti-apoptotic B-cell lymphoma-2 
(Bcl-2) gene, which then inhibits apoptosis (Bierhaus et al. 2005). The protein HMGb1 has been 
shown to interact with TLR-2 and TLR-4 and the activation of TLR-4 by HMGb1 was shown to 
inhibit migration of enterocytes and endothelial cells (Dai et al. 2010; Bauer et al. 2013). 
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1.3.4   Receptor for advanced glycation end products (RAGE) 
 
The receptor RAGE known to play important roles in the many diseases such as diabetes, 
arthritis, Alzheimer’s disease and cancer is localized on chromosome 6 in humans and mice 
(Wang et al. 2012).. The advanced glycation end products (AGEs) are common ligands for 
RAGE and involved in various diseases such as hyperglycaemia, renal failure and other 
inflammatory diseases. The NƐ-carboxymethylysin (CML) is one of the most common AGE 
ligands that can bind to RAGE (Wang et al. 2012). Apart from the AGEs, RAGE interacts with 
other ligands such as the S100 family of molecules (Schmidt et al. 2000). The S100 family of 
molecules have been reported to play important roles in inflammatory diseases. In addition, 
amyloid-β-peptide and β fibrils are other ligands of RAGE involved in the development of 
Alzheimer’s disease. Interestingly, RAGE itself might not be overexpressed in most cancers but 
its ligands such as S100 family and HMGb1 are generally overexpressed in most type of 
cancers. However, amyloid-β-peptide and β fibrils have not been reported in cancers but they 
are overexpressed in neurological disorders (Hofmann et al. 1999).   
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Figure 1.6: Structure of RAGE: A) The structure of RAGE consists of one V and 2 C (C1 and 
C2) domains. There is also a transmembrane domain which joins cytoplasmic tail below the 
surface membrane of cells. B) Three dimensional structure showing V, C1 and C2 domains of 
RAGE (Lin et al. 2009; G Fritz 2011) 
 
The structure of RAGE consists of one V-type and two C-type domains, a short transmembrane 
domain and a cytoplasmic tail (Figure 1.6) (Bierhaus et al. 2005). There are three major RAGE 
isoforms have been reported; full-length RAGE, expressed secretory RAGE (esRAGE) and N-
truncated RAGE (NtRAGE). However, a few other splice variants of RAGE have also been seen 
in pathological conditions. The mRNA of these splice variants lacks N terminal and C terminal 
(Yonekura et al. 2003). These splice variants have been seen on various cells including 
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endothelial cells and pericytes. However, the function of these isoforms is not fully understood 
(Schmidt et al. 1994).                           
 
The esRAGE has similar immunoglobulin domains as that of a full length RAGE but lacks exons 
10 and 11 that encode the transmembrane domain of full length RAGE. This is because 
esRAGE does express intron 9, which has a stop codon within the sequence. Therefore this 
stop codon does not allow expression of exons 10 and 11. The esRAGE has been reported to 
be secreted by cultured cells into the extracellular environment (Cheng et al. 2005). In the 
extracellular environment, esRAGE acts as decoy for many ligands which also bind to full length 
RAGE (Mahajan and Dhawan 2013). Before the discovery of esRAGE, a synthetic version of 
esRAGE was produced in baculovirus system, which was used as decoy for RAGE ligands. 
This system was used to inhibit the activation of RAGE. This synthetic version of esRAGE 
molecule has also been termed soluble RAGE (sRAGE) (Hofmann et al. 1999). 
 
The NtRAGE has a stop codon which is located on intron 1 causing the loss of exons 1 and 2. 
Therefore, NtRAGE lacks the v-type immunoglobulin domain. However, it is expressed on 
plasma membrane. Han et al. detected a 42kDa protein which was similar to the full length 
RAGE on the plasma membrane (Han et al. 2011).  However, considering the fact that NtRAGE 
lacks a signal peptide, the mechanism behind its expression on plasma membrane is unclear. 
In addition, its expression on plasma membrane does not interfere with AGE stimulated effects. 
However, its overexpression does correlate with inhibition in migration of endothelial cells. 
Therefore, it appears that NtRAGE might interact with other ligands and can interfere with 
various signalling pathways involving RAGE (Yonekura et al. 2003).  
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1.3.5   RAGE and Tumour Microenvironment  
 
Many important cells of the microenvironment such as endothelial cells, pericytes, 
macrophages, fibroblasts and myofibroblasts are known to express RAGE (Logsdon, Fuentes 
et al. 2007). Therefore, RAGE ligands generated by cancer cells are likely to influence tumour 
microenvironment. Similarly, these cells in the tumour microenvironment can also produce 
RAGE ligands and these ligands can interact with RAGE on cancer cells (Rouhiainen et al. 
2013). The most important role of RAGE that influences the tumour microenvironment is its 
ability to influence angiogenesis. It is established that angiogenesis play important roles in 
proliferation and migration of cancer cells, endothelial cells and pericytes (Papetti and Herman 
2002). A number of RAGE ligands including HMGb1 have been shown to influence endothelial 
cells (Gupta and Massagué 2006). In addition, HMGb1 overexpression was correlated with 
angiogenesis in colon cancer and inhibiting HMGb1 abrogated the formation of new vessels 
(Schlueter et al. 2005). Furthermore, expression of RAGE was correlated with VEGF (an 
angiogenic stimulator) expression on endothelial cells. Also, a number of RAGE ligands have 
reported to induce other angiogenic factors such as IL-8. Therefore, it appears that RAGE and 
RAGE ligands are key players that participate in the tumour microenvironment (Folkman 1990).  
 
Fibroblasts have been shown to express RAGE in tumour microenvironment.  It is clear that the 
number of fibroblasts present is correlated with increased cancer progression (Rojas et al. 
2010). In addition, they produce growth factors and ECM molecules which facilitate 
angiogenesis within the tumour microenvironment. RAGE has also been reported to influence 
fibroblasts by upregulating fibroblasts growth factor (FGF). In addition, activation of RAGE on 
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fibroblasts was correlated with proliferation and chemotaxis of fibroblasts (Liu et al. 2010). 
However, the correlation of RAGE with cancer-associated myofibroblasts is unknown.  
 
The macrophages are another major cell type stimulated by the activation of RAGE within the 
microenvironment. The macrophages exert their immunomodulatory effect by presenting 
tumour-associated antigens to T-cells and also by expressing immuno-stimulatory cytokines.  
The RAGE activity has been reported to stimulate macrophage function which was correlated 
with inflammation (Hofmann et al. 1999; Hasegawa et al. 2003). 
 
1.3.6   RAGE in cancer 
  
RAGE is expressed in many solid tumours including ovarian, lung, prostate, colonic, brain and 
melanomas. In addition, elevated levels of RAGE have been reported in many pathological 
conditions such as diabetes, arthritis and Alzheimer’s disease (Hofmann et al. 2002; Fukami et 
al. 2015; Liu et al. 2015). These elevated levels are directly linked with the activation of NF-Кβ 
which has been shown to play central role in activating downstream signalling in many tumours 
(Pikarsky et al. 2004). Therefore, this could be one of the reasons why most tumours have 
elevated levels of RAGE. However, there is conflicting evidence regarding the overexpression 
of RAGE in cancers. Some studies support the overexpression of RAGE in many cancers 
including colon, prostate and gastric (Sasahira et al. 2005; Sparvero et al. 2009). Contrary to 
this, no increase in the levels of RAGE in colon and pancreatic cancers has been reported by 
other researchers (Bartling et al. 2005). In addition, significantly low levels of RAGE have been 
observed in lung cancer. In particular, the levels of full length RAGE and esRAGE were 
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significantly low in non-small cell lung cancer (NSCLC). However, RAGE ligands have been 
reported to be increased in most tumours (Bartling et al. 2005). 
 
There is conflicting evidence about the involvement of RAGE in lung cancer as reduced levels 
of RAGE were reported in NSCLC. In addition, esRAGE, which is an antagonist for the full 
length RAGE is downregulated in NSCLC. Furthermore, the overexpression of full-length RAGE 
was correlated with reduction in tumour size (NCI-H358 lung cancer cells) in vivo (Logsdon et 
al. 2007). However, several RAGE ligands such as HMGb1, S100A12 and S100P are 
overexpressed in the lung cancer (Diederichs et al. 2004). Furthermore, S100A4 
overexpression was correlated with poor prognosis resulted from metastatic spread of 
pulmonary adenocarcinoma (Zou et al. 2004). 
 
The role of RAGE in breast cancer is not fully understood. However, RAGE ligands appeared to 
play important roles in progression of the disease. For example, S100A4 has been shown to 
play crucial role in breast cancer growth. In addition, S100A4 negative patients’ survival rate 
was much higher than those of S100A4 positive patients (Rudland et al. 2000). Also, elevated 
levels of HMGb1 were observed in human primary breast carcinoma. Therefore, there is much 
evidence that supports the involvement of RAGE ligands in breast cancer. However, it is 
nuclear that if these ligands mediate their effect via RAGE in breast cancer (Lum and Lee 
2001). 
 
The receptor for advanced glycation end products along with its ligands has been reported to be 
elevated in many stages of prostate cancer. For example, S100A8 and S100A9 have been 
reported to be overexpressed in human prostate cancer. The receptor (RAGE) has been shown 
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to be expressed by prostate cancer cells and its ligands S100A8 and S100A9 are apparently 
also secreted by prostate cancer cells (Gebhardt et al. 2006). In addition, S100s appeared to 
play key role in migration of prostate cancer cells by activating NF-Кβ and MAPK pathway in 
vitro. Also, elevated levels of HMGb1 and RAGE have been reported in prostate cancer tissue 
when compared with normal prostate tissue (Ishiguro et al. 2005). Furthermore, HMGb1 and 
RAGE overexpression was observed in the PC3 prostate cancer cell line, which was related to 
androgen deprivation induced cancer cell invasion (Kuniyasu et al. 2003). Moreover, RAGE 
expression has been shown to be increased at various stages of colon cancer progression 
(Sasahira et al. 2005). 
 
This receptor (RAGE) has been reported to play important role in a neoplastic model of IL-10 
null mouse. The administration of sRAGE (decoy for RAGE ligands) significantly reduced the 
neoplasia related inflammation in IL-10 null mouse model (Berg et al. 1996). In addition, S100P 
and RAGE complex triggered proliferation and migration of SW480 colon cancer cells and 
inhibiting S100P/RAGE abrogated proliferation and migration in the SW480 cells.  Furthermore, 
the expression of S100A4 was correlated with the invasive potential of the colon cancer cells as 
S100A4 is specifically overexpressed in invasive carcinoma. All these findings suggest that 
RAGE might play an important role in the interface between the inflammation and 
carcinogenesis (Yammani et al. 2006).  
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1.3.7   RAGE and HMGb1 
 
RAGE is a multi-ligand receptor that binds to various molecules including HMGb1 and the S100 
family of proteins. Structurally, RAGE has two N-glycosylation sites on its V domain. These N-
glycans undergo carboxylation which enhances the ability of the receptor to bind to HMGb1 with 
subsequent signal transduction. The carbohydrate groups are then removed by PNGase F and 
therefore do not alter the conformation of protein complex. Upon confirmation, the protein 
complex (receptor-ligand complex) can initiate signal transduction necessary for cell growth 
(Wilton et al. 2006).  
 
There is evidence that supports the involvement of RAGE and HMGb1 complex in the cancer. 
For example, blockade of HMGb1 and RAGE by immunoneutralising antibodies suppressed 
tumour growth in murine model of lung cancer (Schlueter et al. 2005). In addition, HMGb1 has 
been shown to induce proliferation and neovascularization in endothelial cells (Chavakis et al. 
2007). Other research has shown that HMGb1 plays an important role in the activation of DCs. 
This activation is mediated via TLR-4 (another receptor for HMGb1). However, HMGb1 induced 
maturation and migration of DCs was shown to involve activation of RAGE via HMGb1 binding 
(Dumitriu et al. 2005).  
 
Various cell surface receptors such as RAGE and TLRs play important roles in signal 
transduction. It was observed that nucleosomes containing HMGb1, derived from secondary 
necrotic cells, play an important role in inflammation by activating macrophages and DCs which 
also express RAGE and TLRs. The mechanism of action of this signal transduction was 
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explored using macrophages with defective RAGE and TLRs. Interestingly, the deletion of TLR-
2 abrogated the activation of macrophages and DCs. This suggests when HMGb1 is associated 
nucleosome, the signal transduction will be strictly through TLR-2 (Urbonaviciute et al. 2008). 
Increased concentration of DNA containing complexes have been observed in autoimmune 
disorders such as Lupus. The HMGb1 interaction with DNA containing immune complexes has 
been extensively studied where these complexes bind to HMGb1 enter into the endosomal 
pathway of plasmacytocoid dendritic cells (pDCs) via CD32 mediated uptake where it 
encounters with TLR-9. Since, HMGb1 can directly bind to DNA, it is possible that when 
HMGb1 is bound to DNA it would signal through RAGE and the activation of TLR-9-MyD88 
pathway (Tian et al. 2007).  
 
The ligand binding of RAGE involves the activation of two major pathways which are 
CDC42/Rac and MAPK.  It is evident that the activation of the MAPK pathway leads to the 
activation of NF-kβ and neurite outgrowth. The CDC42 pathway has been implicated in HMGb1 
induced migration in cancer cells. The HMGb1 induced activation of RAGE lead to the 
activation of CDC42 and Rac1 and facilitates changes in the cytoskeleton. To support this, NF-
kβ gene expression assay was carried out. It was found that expression of dominant negative 
RAGE eliminated the NF-kβ activation induced by HMGb1. Therefore, HMGb1 induced 
activation of RAGE was responsible for NF-kβ activation followed by neurite outgrowth 
(Huttunen et al. 1999). In addition, HMGb1 mediated activation of RAGE may amplify the 
expression of RAGE with subsequent activation of NF-kβ. The NF-kβ responsive genes play 
key role in inflammatory process (such as intracellular adhesion molecule 1 (ICAM-1), vascular 
cell adhesion molecule 1 (VCAM-1) and few other cytokines e.g., TNFα, IL-1β and IL-8). 
Therefore, HMGb1 induced activation of RAGE can induce and sustain a pro-inflammatory 
phenotype (Park et al. 2003; Fiuza, Bustin et al. 2003).  Apparently, RAGE was the first 
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receptor identified for HMGb1 binding but blocking RAGE did not abrogate the effect of HMGb1 
completely in many experimental models. This suggested that an additional receptor for HMGb1 
must exist. Subsequently, Toll like receptors were identified as HMGb1 binding receptors (Park 
et al. 2004). 
 
1.3.8   Toll Like Receptors  
 
The tolls like receptors (TLRs) are conserved proteins that help cells of the innate immune 
system to respond to endogenous danger molecules by activating intracellular signalling 
pathways. TLR signalling might require the receptors to dimerize or oligomerize for signal 
transduction to take place. Endothelial cells have been shown to express different TLRs on their 
membranes such as TLR-4, TLR-2 and TLR-9. These are multi-ligand receptors and when 
associated with HMGb1 and play important roles in activating immune response against 
inflammation via MyD88 pathway (Nogueira-Machado et al. 2011). However, these receptors 
can bind to endotoxin or LPS and gram positive and gram negative bacteria. For example, TLR-
4 is the main receptor for endotoxin and also for gram-negative bacteria whereas TLR-2 is a 
receptor for gram-positive bacteria and also for fungi. Both play important roles in host response 
to fungal or bacterial infections (Yu et al. 2006).  
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1.3.9   TLRs and HMGb1  
 
Various blood borne pathogens and cytokines usually target endothelial cells. Subsequently, 
endothelium expresses TLRs and gets activated. In particular, the activation of endothelium in 
response to microbial stimulation is mediated by TLR-2 (Iwasaki and Medzhitov 2004). In 
addition, it has also been shown that the activation of TLR-2 may lead to the activation and 
translocation of NF-kβ (Smith et al. 2003). The involvement of Rac1 and PI3K has been 
reported to activate TLR-2 in fimbrillin stimulated monocytes. The Rac1 and PI3K were 
recruited to the cytoplasmic domain of TLR followed by subsequent signal transduction 
(Harokopakis et al. 2006). The recruitment of Rac1 and PI3K resulted in CD18-dependent 
adhesion to ICAM-1. In addition, the dominant negative variant of PI3K and Rac1 inhibited the 
expression of NF-kβ reporter gene. This suggested an important role of PI3K and Rac1 in TLR-
2 signalling (Arbibe et al. 2000).  
 
Toll like receptor 2 has been reported as main receptor for HMGb1 in RAW264.7 macrophages. 
This was detected by using fluorescence resonance energy transfer (FRET) and 
immunoprecipitation assays. In addition, it was shown that the stimulation of HMGb1 increased 
TLR-2 mediated activation of NF-kβ. Furthermore, various dominant negative downstream 
regulators of TLR-2 such as MyD88, toll-interleukin 1 receptor domain containing adaptor 
protein (TIRAP), Interleukin-1 receptor-associated kinase 1 (IRAK1), Interleukin-1 receptor-
associated kinase 2 (IRAK2), Interleukin-1 receptor-associated kinase 4 (IRAK4), TNF receptor 
associated factor-6 (TRAF-6) and p38 inhibited HMGb1 induced activation of NF-kβ (Park et al. 
2006). The interaction of HMGb1 was also substantiated by the finding where HMGb1 induced 
TNFα release was compromised in MyD88-/- and TLR-2-/- mice in comparison to wild type 
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mice. This suggests that HMGb1 interaction with TLR-2 can induce other pathways that may 
cross talk at several levels. However, this ultimately results in the activation of NF-kβ (Yu et al. 
2006).  
 
The ligand HMGb1 can signal through either TLR-2 or TLR-4. The signalling through TLR-4 has 
been shown to play important role for MyD88 and IRAK. To investigate the contribution of 
downstream proteins, RAW 264.7 macrophages were transduced with NF-kβ dependent 
luciferase reporter and dominant negative forms of MyD88, TIRAP, IRAK1, IRAK2 and IRAK4. It 
was found that dominant negative MyD88, TIRAP, IRAK1, IRAK2 and IRAK4 inhibited HMGb1 
induced NF-kβ dependent luciferase reporter gene activity. In addition, it has been shown that 
PI3K can directly interact with TLR-4. Therefore, these data suggested key roles of these 
proteins in TLR-4 signalling cascade (van Beijnum et al. 2008; Park et al. 2006).  
 
The signalling cascades that occur in TLR-2 and TLR-4 activation overlap at many points. 
However, the differentiation between two pathways might be visible at the level of proteins 
bound to the TIR domain of TLR. In addition, it has been shown that TLR-4 signalling could be 
MyD88 dependent or independent. However, in both cases, NF-kβ dependent gene expression 
will be seen followed by TLR activation. NF-kβ is a transcription factor belongs to five-member 
family of hetro or homodimers. These dimers remain in the cytoplasm in an inactive form by the 
inhibitor of kappa β kinase (Ikβ). The phosphorylation of Ikβ is required for activation of NF-kβ 
(Park et al. 2004). 
 
The HMGb1 binding to TLR-4 is important in many pathological conditions including 
inflammation. This interaction triggers the activation of proinflammatory cascade. For example, 
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HMGb1 produced in tissues and serum during the inflammation triggers the release of TLR-4 
dependent TNF-α (Tsung et al. 2005). In addition, HMGb1 has been shown to induce migration 
in vascular smooth muscle cells via TLR-4 dependent PI3K/Akt pathway (Inoue et al. 2007). 
The molecular understanding of HMGb1-TLR-4 interaction in inflammation may have significant 
implications for designing targeted therapeutics to suppress HMGb1 mediated tissue injury. 
Anti-HMGb1 antibody is one such example that has been highly effective in tissue injuries to 
animals with sepsis, ischemia and collagen induced arthritis (Yang et al. 2010). Though, TLR-4 
has been implicated in migration and proliferation of neutrophil and vascular smooth muscle 
cells (Reaves et al. 2005; Rönnefarth et al. 2006; Pi et al. 2013). However, its role in cancer-
associated myofibroblasts is not clear.  
 
1.4 Myofibroblasts  
 
Myofibroblasts are one type of mesenchymal cell that constitute a major part of stroma. 
Myoﬁbroblasts are spindle shaped cells transiently found in early to mid-phase wound tissue 
and predominantly derived from mesenchymal stem cells (Quante et al. 2011). By secreting 
cytokines, growth factors and extracellular matrix proteins and proteases, they play important 
role in inflammation, repair and fibrosis (Marangoni et al. 2015). In addition, myofibroblasts play 
important roles in connective tissue remodelling by synthesising ECM components and 
providing cytoskeletal support from smooth muscle cells. It is well established that 
myofibroblasts contribute toward connective tissue remodelling by exerting contractile force, 
synthesise ECM component and undergo apoptosis in wound healing. However, in 
desmoplastic situations, myofibroblasts may persist and cause organ failure (Hinz et al. 2007). 
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The tumour associated myofibroblasts provide that mechanical environment (contractile force 
and ECM remodelling) which promotes tumour progression (Mareel et al. 2009).  
 
The contractile force is necessary for generating tissue contraction. The myofibroblasts 
generate this contractile force by expressing alpha smooth muscle actin (α-SMA) encoded by 
the ACTA gene. This force is stronger than other forces generated by other isoforms of actin in 
myofibroblasts cells. The contractile force exerted by myofibroblasts followed by ECM synthesis 
and connective tissue remodelling is irreversible and thus can produce prolonged contractures 
(Follonier  et al. 2010). It has been shown that myofibroblasts use a lockstep mechanism of 
contractile events that results in strong contractions mediated by RhoA/Rho-associated kinase 
in vitro. This study supported strong isomeric contraction generated in myofibroblast stressed 
collagen (Castella et al. 2010). 
 
The origin of myofibroblasts remains controversial as it has been suggested that myofibroblasts 
originate from progenitor stem cells whereas some other studies suggest that they 
transdifferentiate from tissue fibroblasts (Gabbiani 1996; Powell et al. 1999), (Figure 1.7). 
Furthermore, pericytes and vascular smooth muscles share a close anatomical relationship, 
suggesting more than one route for transdifferentiation of myofibroblasts (Powell 2000).  
 
The transdifferentiation of fibroblasts to myofibroblasts involves proto-myofibroblasts that 
express extra domain A (ED-A) variant of fibronectin at the cell surface (Figure 1.7).  The proto-
myofibroblasts are an intermediate between fibroblasts and myofibroblasts and have been 
shown to form actin containing stress fibres (Tomasek et al. 2002).  These cells are capable of 
generating contractile forces necessary to close the wound during the healing process.  
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Transforming growth factor β1 (TGF-β1) is a multifunctional cytokine that plays a central role in 
natural wound healing process.  It has been shown that TGF-β1 increases the expression of 
ED-A fibronectin and modulates the differentiation of proto-myofibroblasts into myofibroblasts 
with de-novo expression of α smooth muscle actin (αSMA) (Figure 1.7) (Tomasek et al. 2002). 
Proto-myofibroblasts are different to myofibroblasts as myofibroblasts exhibit a higher 
organisation of extracellular fibronectin in fibrils, hence can generate greater contractile force 
than proto-myofibroblasts in vivo (Tomasek et al. 2002).  Their positivity for α-SMA has been 
considered as a most widely used biomarker. However, it is a misconception that 
myofibroblasts must express α-SMA to be ‘myofibroblasts’. The most important defining nature 
of myofibroblasts is the de novo development of stress fibre and contractile force (Follonier et 
al. 2010).  
 
Certain other factors such as interleukin-1 (IL-1), tumour necrosis factor α (TNFα), PDGF and 
TGF-β play an important role at various stages of transdifferentiation of myofibroblasts (Kovacs 
and DiPietro 1994). TGF-β has been shown to be the most important cytokine for the 
transdifferentiation of myoﬁbroblasts from ﬁbroblasts.  Myofibroblasts have been shown to have 
high levels of αSMA (Vaughan et al. 2000) (Figure 1.7).  Although myofibroblasts share many of 
the features of fibroblasts and smooth muscle cells, smoothelin and caldesmon (components of 
smooth muscles) are absent in myofibroblasts (Van der Loop et al. 1996). In addition, several 
other modulators of the myofibroblast phenotype have been suggested such as endosialin in 
tumour associated fibroblasts, osteopontin in dermal fibroblasts and periostin (Gullberg and 
Reed 2011; (Lenga et al. 2008). Expression of these biomarkers has been reported as being 
unique to the myofibroblast phenotypes (Vi et al. 2009). 
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Figure 1.7: TGF-β1 mediated transdifferentiation of myofibroblasts from fibroblasts. Proto-
myofibroblasts share similar features of myofibroblasts but are weaker in generating the 
contractile force necessary for wound healing process.  Myofibroblasts exhibit de novo 
expression of α SMA (Tomasek et al. 2002). 
 
Myofibroblasts play a significant role during the inflammatory response as they can produce 
both chemokines and cytokines (Hogaboam et al. 1998). The myofibroblasts induced secretion 
of cytokines and chemokines can augment or downregulate the inflammatory response 
(Tetsuka et al. 1994).  In addition, myofibroblasts express key adhesion molecules such as 
vascular cell adhesion molecule (VCAM), intracellular adhesion molecule (ICAM) and neural 
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cell adhesion molecule (NCAM). This suggests that the cells like lymphocytes, mast cells and 
neutrophils may get attached onto myofibroblasts to take part in the inflammatory response 
(Schroeder and Page 1972).   
 
Myofibroblasts have been shown to play major roles in the pathogenesis of renal interstitial 
fibrosis (Yang and Liu 2001; Liu 2006). Although it is clear that myofibroblasts play important 
role in the pathogenesis linked to renal failure, the origin of renal myofibroblasts is poorly 
understood. There are several progenitor cells that have been suggested such as local 
fibroblasts, circulating fibrocytes and epithelial cells residing via epithelial to mesenchymal 
transition (EMT) (Zeisberg and Kalluri 2004). However, the presence of epithelial progenitor 
cells via EMT route remains controversial (Inoue et al. 2009). 
   
The role of myofibroblasts in lung fibrosis has been established.  The lung fibrosis may involve 
chronic pulmonary obstructive disease, pleural fibrosis and pulmonary hypertension.  Indeed, 
many studies have shown that lung myofibroblasts are derived from bone marrow progenitor 
cells and lung epithelium cells. However, some studies contradicted the involvement of lung 
myofibroblasts in lung fibrosis. For example, there was no contribution from myofibroblasts in 
acute lung injury involving intra-tracheal instillation of bleomycin in vivo (Rock et al. 2011). The 
involvement of myofibroblasts in lungs may be linked with chronicity and irreversibility of the 
fibrotic process. The fate of myofibroblasts of any origin in lungs may determine the onset of 
normal healing process or end-stage fibrosis (Rock et al. 2011).  
 
Myofibroblasts have been shown to escape immune surveillance and become apoptosis-
resistant in many pathological conditions including liver fibrosis and cancer.  The mechanism for 
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establishment of the apoptosis-resistant myofibroblast phenotype is not clear (Thannickal et al. 
2004). However, various mechanisms have been suggested to play important roles in 
prolonged survival of myofibroblasts including their escape from immune surveillance. For 
example, CD34+ stellate precursor cells induce differentiation to myofibroblasts from 
lymphocytes and plasmocytes.  The CD34+ stellate cells induce apoptosis in Fas-ligand 
positive lymphocytes. Therefore, apoptosis inducing Fas-ligand dependent signals would not be 
available to myofibroblasts. This escape from surveillance would consolidate myofibroblasts 
recruitment and enhance fibrosis.  In addition, NF-Кβ has also been shown to induce 
antiapoptotic effects in myofibroblasts in liver fibrosis (Wallach-Dayan et al. 2007).  
 
It has also been shown that factors responsible for myofibroblast differentiation can also 
promote myofibroblast survival.  For example, NADPH oxidase enzyme has been reported to 
promote TGF-β induced myofibroblast differentiation and the production of ECM components 
(Amara et al. 2010).   
 
1.4.1    Myofibroblasts and cancer 
 
The stroma is fundamental for the maintenance of epithelial tissue. The stroma also changes 
with alterations that occur in the epithelium. In cancer, these changes maintain an environment 
that supports proliferation and metastasis. It is established that desmoplasia, inflammation, and 
angiogenesis make a favourable environment for invasion and metastasis to occur (Mareel and 
Leroy 2003). In normal conditions, fibroblasts exhibit little ECM or cell matrix contacts. However, 
in the event of tissue injury or inflammation, fibroblasts transdifferentiate into myofibroblasts and 
migrate to damaged tissue and help in the formation of the ECM by producing collagen (Hinz et 
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al. 2007). As previously mentioned, myofibroblasts also secrete MMPs, major degraders of 
basement membrane, which also play an important role in the formation of new blood vessels 
(angiogenesis). Angiogenesis requires degradation of the basement membrane and the 
remodelling of the ECM (Rundhaug 2005). 
 
It is evident that myofibroblasts are present in colon cancer, breast cancer, lung cancer, 
prostate cancer and pancreatic cancers (De Wever and Mareel 2003; Cho et al. 2012).  
However, their origin is controversial. Indeed, a number of origins of cancer-associated 
myofibroblasts have been suggested such as resident fibroblasts and bone marrow derived 
mesenchymal stem cells. In addition, endothelial cells, epithelial cancer cells, smooth muscle 
cells, adipocyte and stellate cells have also been suggested. This diverse possible origin of 
myofibroblasts may be related to the heterogeneous myofibroblast population that is observed 
within tumours (De Wever et al. 2008). 
 
  
Myofibroblasts have been reported to refine the information about the response to cancer 
chemotherapy and prognostic outcome in patients with stromal tumours. For example, 
increased levels of α-SMA by myofibroblasts predict reoccurrence of disease in colorectal 
cancer (De Wever et al. 2008). The oncogenes derived paracrine signals trigger tumour growth 
and invasion. These signals may lead to myofibroblasts attraction, proliferation and invasion 
however identifying particular signals that influence myofibroblasts to infiltrate and proliferate on 
tumour site should be investigated (De Wever et al. 2004). The gene expression profile of 
tumour associated host cells including cancer associated fibroblasts and myofibroblasts 
resulted in prognostic signatures which were associated with poor survival in primary breast 
cancers. In the same study, the wound response signature obtained from 50 fibroblasts cultures 
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contained genes associated with tissue remodelling, migration and angiogenesis. In addition, 
breast cancer patients whose tumours expressed the wound response signature had a reduced 
survival rate than those patients whose tumours showed no expression of wound response 
signature. The protein types presented in wound response signature were expressed by 
myofibroblasts. This suggested an important role of myofibroblasts at prognostic front (Bissell 
and Hines 2011). In addition, myofibroblasts have shown to produce low density lipoprotein 
receptor (LOXL2) and α-SMA. The expression of PDGF-β, LOXL2, and CD10 in cancer 
associated with fibroblasts has been correlated with poor prognosis in breast, colon and 
pancreatic cancers (Paulsson, et al. 2009). 
 
The interaction between two key cytokines (TGF-β and PDGF) and myofibroblasts appear to 
play an important role in cancer progression.  It has been shown that PDGF is crucial for the 
development of proto-myofibroblasts at various stages of inflammation and during the wound 
healing process. However, PDGF does not induce the expression of αSMA in myofibroblasts 
(Tomasek et al. 2002).  
 
 
Cancer cell derived TGF-β, an indirect pro-invasive factor has been shown to modulate 
myofibroblasts differentiation in stromal tumours (Mareel and Leroy 2003).  In addition, TGF-β 
has been considered as tumour suppressor for its growth and cell cycle progression inhibitory 
properties in early stage tumours.  However, late stage tumour cells not only become resistant 
to growth inhibition phenomenon induced by TGF-β but also start actively secreting TGF-β 
(Derynck et al. 2001). It has been observed that TGF-β has strong chemoattractant properties 
for fibroblasts. As a result, fibroblasts migrate towards TGF-β secreting cancer cells. This leads 
to transdifferentiation from fibroblasts into cancer associated myofibroblasts (Postlethwaite et al. 
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1987). The α-SMA negative fibroblasts do not stimulate invasion however after the TGF-β 
induced conversion into α-SMA positive myofibroblasts, they do (Watson et al. 2014). In 
addition, reactive oxygen species (ROS) induced oxidative stress has been shown to trigger 
myofibroblasts differentiation and secretion of pro-inflammatory cytokines such as IL-6 and IL-8 
in primary tumours (Lane et al. 2011). 
 
1.4.2   Role of myofibroblasts in metastasis 
 
The tumour microenvironment plays an important role in the final outcome of cancer 
chemotherapy. The tumour stromal cells such as cancer associated fibroblasts (CAFs) have 
been shown to promote tumour proliferation and angiogenesis. Indeed, the inflammatory 
immune cells such dendritic cells and macrophages are highly recruited in carcinomas and play 
important roles in tumour growth and metastasis (Allinen et al. 2004) (Coussens and Werb 
2002). Moreover, the likely role of myofibroblasts in tumour invasion front has been supported 
by a study which revealed that the myofibroblasts population gradually increases with the 
invasive stages of many cancers (Nakayama et al. 1998). In support of previous findings, it has 
been shown that CAFs play a significant role in the enhancement of metastatic spread by 
modulating α-SMA expression. For example, increased expression of α-SMA was seen in 
myofibroblasts present in human epidermal growth factor receptor 2 (HER2) positive breast 
cancers (Toullec et al. 2010). In addition, inactivation of the tumour suppressor, phosphatase 
and tensin homolog (Pten), resulted in increased tumour growth followed by ECM remodelling 
in stromal fibroblasts of tumours in mouse mammary glands (Trimboli et al. 2009). 
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There is evidence that support the involvement of stromal myofibroblasts in tumour 
development. For example, stromal myofibroblasts have been shown to stimulate growth in 
breast cancer cells in vivo. In addition, they have been shown to promote invasion of breast, 
pancreatic and squamous carcinoma cells in vitro (Casey et al. 2008; Hwang et al. 2008). The 
mesenchymal cells and their derivatives including myofibroblasts have been shown to promote 
breast cancer metastasis (Hu et al. 2008). The stromal myofibroblasts have been considered as 
predictors of human disease outcome and their abundance is correlated with poor survival in 
colorectal cancer (Tsujino et al. 2007).  
  
The myofibroblasts population was significantly higher in breast adenocarcinomas and lung 
cancers that had metastasised to lymph nodes. For example, HER2 type invasive 
adenocarcinoma metastasising to lymph nodes have the highest proportion of myofibroblasts 
compared with basal or luminal (BLC or Lum-A) type cancers. This suggested that 
myofibroblasts population is correlated with tumour growth and metastasis (Toullec et al. 2010).   
 
Myofibroblasts express genes that are responsible for the release of certain invasion associated 
factors, ECM proteins and protease. For example, the CAFs have been reported to express 
collagens, MMPs, cell adhesion molecules and cytoskeleton components. In addition, 
myofibroblasts have been shown to trigger deposition and proteolysis of ECM molecules which 
may facilitate migration of cancer cells (Gaggioli et al. 2007). Interestingly, the increased density 
of collagen present in myofibroblasts is directly correlated with tumour formation and this 
increased density of collagen is correlated with the invasive potential of lung cancers 
(Provenzano et al. 2008). These data further suggest an important of role of stromal 
myofibroblasts in cancer metastasis.  
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1.4.3   Interplay between myofibroblasts, the ECM and growth factors 
 
Unlike normal stroma, tumour stroma exhibits an altered ECM and increased numbers of 
fibroblasts and myofibroblasts. In addition, the composition and amount of ECM generated may 
vary amongst tumours (Hinz and Gabbiani 2010). Myofibroblasts are known to play important 
roles in the formation and repair of the ECM. Recently, it has been accepted that the 
mechanical force generated by myofibroblasts is dependent upon the expression of αSMA. This 
mechanical force plays an important role in tissue remodelling, cytokine synthesis and ECM 
component production (Hinz and Gabbiani 2010). The ECM is made up of a mixture of matrix 
proteins including collagen and other glycoproteins and proteoglycans. Most of these proteins 
are produced by myofibroblasts and play important roles in parenchymal or epithelial cell 
differentiation (Fullár et al. 2015). This occurs by persistent accumulation of contractile cells 
(fibroblasts and myofibroblasts) and the formation of collagen in the ECM. This provides a 
scaffold for tissue formation and growth. This phenomenon is called fibrosis and usually 
resistant to treatments however, most of the time in cancer the ECM is remodelled (Hinz and 
Gabbiani 2010).  
 
The mechanical resistance or contractile force generated during the formation of ECM with the 
action of TGF-β has been considered as primary stimulus for myofibroblasts differentiation. It 
has been shown that highly contractile cytoskeleton of myofibroblasts is stiffer than normal ECM 
stiffness threshold. It is known that various fibrotic organs and cancerous tissues exceed this 
threshold support the presence of myofibroblasts in pathological conditions (Hotary et al. 2000). 
The tissue stiffness has been reported as a consequence of myofibroblasts induced ECM 
remodelling. In addition, it has been shown that an increased liver stiffness lead to the activation 
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of fibroblastic cells such myofibroblasts and the accumulation of collagen in vivo. This 
suggested that early mechanical changes are sufficient to induce contraction cascade (Georges 
et al. 2007). In addition, myofibroblasts have been shown to activate TGF-β from stiffened ECM 
by integrin mediated contraction. Therefore, there could be a direct link between mechanical 
and chemical factors regulating myofibroblasts differentiation which can cause fibrosis (Wipff et 
al. 2007).  
 
The degradation of the ECM is a physiologically regulated phenomenon and is important for 
tissue repair and remodelling.  However, a dysregulated degradation of ECM can become a 
cause of many diseases including cancer (Nagase et al. 2006). The matrix metalloproteinase 
(MMP 1-3), major degraders of basement membranes and the matrix, are also secreted by 
myofibroblasts. However, these MMPs are inhibited by endogenous tissue inhibitors of 
metalloproteinases (TIMPs) (Leivonen et al. 2013). Thus, a balance between MMPs and TIMPs 
is important for ECM remodelling in the tissue. These MMPs are classified on the basis of 
substrate they degrade; for example, MMP-1 digests collagen type I, II, and III, MMP-2 digests 
collagen type I, III and IV and MMP-3 degrades laminin, fibronectin and casein. However, many 
growth factors may bind to proteoglycans or collagens and thereby can neutralise the effect of 
MMPs temporarily (Benyon et al. 1996).   
 
The myofibroblasts also secrete growth factors, which play important roles in initiating cell 
mobility and proliferation through paracrine and autocrine mitogenic effect and also in the 
induction of cell differentiation and sometimes apoptosis. It has been shown that certain 
inflammatory cytokines, eicosanoids and growth factors released from damaged tissue may act 
more proximally on myofibroblast and influence myofibroblasts to secrete additional growth 
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factors in vivo (Powell et al. 1999). For example; hepatocyte growth factor (HGF) and 
keratinocyte growth factor (KGF) are secreted by myofibroblasts in response to IL-1 (Chedid et 
al. 1994).  It has also been observed that growth factors such as epidermal growth factor (EGF) 
and TGF-α, insulin like growth factors (IGF-I and IGF-II), fibrosis growth factors (FGF-1, FGF-2, 
KGF), IL-6 and IL-11 are secreted by myofibroblasts and act as major paracrine growth factors 
for epithelial and parenchymal cells (Bamba et al. 2003) . In addition, CXC family of cytokines 
such as IL-6 and FGF family (FGF-1 and FGF-2) secreted by myofibroblasts are particularly 
important as they possess angiogenic properties necessary for wound healing (Powell et al. 
1999). 
 
1.4.4  Myofibroblasts differentiation in the tumour microenvironment 
 
In the tumour microenvironment, cancer cells interact with local and distant host cells. This 
interaction may alter the whole system and trigger tumour initiation, invasion and metastasis. 
This is evident by desmoplastic reactions, response to inflammation by macrophages, 
lymphocytes and dendritic cells and neovascularisation in primary tumours (Mareel and Leroy 
2003). In the tumour microenvironment, myofibroblasts induced secretion of pro-inflammatory 
cytokines may have an impact on the recruitment of inflammatory cells. These inflammatory 
cells may influence the invasive potential of tumour cells.  For example, cancer associated 
fibroblasts isolated from multistep skin tumourigenesis expressed activated levels of IL-6 (Erez 
et al. 2010).  
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The tumour microenvironment undergoes continuous remodelling in primary tumours that 
initiates a metastatic niche and the recruitment of host cells. This suggests an important role for 
circulating secretory products in the microenvironment. The primary tumour signals to the bone 
marrow and triggers the release of mesenchymal cells (MSCs). The MSCs then enter into the 
circulation and are recruited to the tumour site by stromal cell-derived factor-1α (SDF-1α). At 
the tumour site, TGF-β triggers the MSCs to be converted into myofibroblasts (Quante et al. 
2011). 
 
Hypoxia, one of the hallmarks of the tumour microenvironment has also been shown to induce 
the transdifferentiation of fibroblasts to myofibroblasts.  Hypoxia induced stabilisation of HIF-1α 
has been shown to play important role in this process.  The inhibition of HIF-1α in junD deficient 
fibroblasts resulted in reduced expression of αSMA containing stress fibre.  This suggested that 
HIF-1α is crucial for regulating contractile features of fibroblasts which would then 
transdifferentiate into myofibroblasts (Toullec et al. 2010).  
 
JunD, a functional component of the activator protein-1 transcription factor (AP1), has key roles 
in controlling angiogenesis and damage from oxidative stress. The inactivation of JunD results 
in the accumulation of ROS in cells and tissues. In addition, junD inactivation facilitates tumour 
growth followed by extensive modification in the tumour stroma including differentiation of 
myofibroblasts from fibroblasts. In the tumour stroma, junD deletion caused fibroblasts to adopt 
myofibroblastic features such expression of α-SMA with high levels of adherens and focal 
junctions.  This also included the enhanced expression of vinculin, tensin and focal adhesion 
kinase (FAK) contents (Gerald et al. 2004).  
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A large population of granulin-secretory cells are also found in tumours.  The granulin 
accumulation in tumours converts resident fibroblasts to myofibroblasts and promotes tumour 
growth (Elkabets et al. 2011). The secretory cells in the tumour microenvironment recruit 
hematopoietic stem cells from the bone marrow, which can promote myofibroblast 
differentiation at distant sites. For example, TGF-β present in exosomes can convert fibroblasts 
into myofibroblasts in distant organs.  The exosomes are secreted by most cell types including 
cancer cells (Pitt et al. 2014). Thus TGF-β is always in abundance in most cancers and can 
influence the stromal cells within the microenvironment. It has also been suggested that TGF-β 
might facilitate metastasis by producing fibronectin followed by trans-differentiation from proto-
myofibroblasts to myofibroblasts (De Wever et al. 2004). During the process of ECM 
remodelling, cancer associated fibroblasts or myofibroblasts secrete various MMPs which are 
associated with ECM degradation. Some myofibroblasts cells can move along with metastatic 
cancer cells (Figure 1.3) to the distant sites including lungs. These migratory myofibroblasts 
have been shown to produce pro-survival signals in lung site (Duda et al. 2010). Therefore, 
transformed fibroblasts or cancer-associated myofibroblast may influence the tumour 
microenvironment and contribute towards malignant transformation in solid tumours. Although 
myofibroblastic contribution has been established in malignancies, the role of HMGb1 in 
myofibroblasts and the subsequent consequences have not been reported thus far. Therefore, it 
is logical to investigate the role of HMGb1 in myofibroblasts as this may be linked with invasion 
and metastasis of tumour cells. 
 
1.5  Aims and objectives  
 
This research is based on the hypothesis that HMGb1, a novel non-histone chromatin protein 
plays important roles in the stimulation of tumour associated myofibroblasts. Upon stimulation, 
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these myofibroblasts may proliferate in situ followed by their invasion and migration to distant 
sites. This HMGb1 led migration and invasion of tumour associated myofibroblasts might 
facilitate the migration of other neighbouring cells including cancer cells. Therefore, it is also 
likely that the levels of HMGb1 in tumour microenvironment are directly related to metastatic 
potential of those tumours.  
 
The role of HMGb1 in the stimulation of tumour associated myofibroblasts has not been 
reported yet. Thus, the initial aims of this study will be to investigate if the recombinant HMGb1 
can stimulate CCD18 myofibroblast cells to proliferate in vitro. In addition, the pathways 
involved in the proliferation will be investigated. It is known that HMGb1 is released from 
necrotic cancer cells however, if there is any connection of other microenvironmental stresses 
such as glucose starvation/hypoxia/lack of other nutrients such as glutamine with the release of 
HMGb1 is not clear. These stress conditions represent typical intra-tumoral stresses and very 
common in tumour microenvironment. Therefore, an investigation will be carried out to check if 
HMGb1 is released extracellularly from a panel of cell lines when exposed to different 
microenvironmental stress conditions. An investigation into the role of extracellular HMGb1 will 
be carried out to check if this extracellular HMGb1 released from different cancer cells under 
stress conditions can stimulate CCD18 myofibroblast cells to migrate and invade. In addition, 
the involvement of HMGb1 receptors such as RAGE and TLRs along with downstream 
signalling pathways such as PI3K and ERK1/2 will also be investigated. The involvement of 
receptors and/or downstream pathways will be validated by the inclusion of selective 
antagonists in each study to provide ‘proof of concept’ based outcomes. Based on the findings, 
a possible mechanism for tumour spread involving proliferation, migration and invasion of 
myofibroblast cells along with possible activation of some downstream pathways can be 
proposed. 
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Chapter 2 
2. General Materials and Methods 
2.1 Recombinant proteins, antibodies, antibiotics and cells 
 
Human recombinant HMGb1, anti-RAGE, anti-TLR4, and anti-MMP-2 and anti-MMP-9 primary 
antibodies was obtained from R&D Systems. Anti-mouse, anti-goat and anti-rabbit secondary 
antibodies were also obtained from R&D Systems. The MEK1/2 inhibitor (U0126) and PI3K 
inhibitor (LY294002) were obtained from Cell Signaling Technology®. HT29 colon 
adenocarcinoma cells, EJ138 bladder cancer cells, A549 lung cancer cells, MCF-7 breast 
cancer cells and CCD18 myofibroblast cells were purchased from American Type Culture 
Collection (ATCC). 
 
2.2 Cell culture  
 
Myofibroblasts (CCD18) cells were cultured in T75 cm2 flasks in MEM Eagle complete medium 
(Minimum Essential Medium Eagle) (Sigma Aldrich) supplemented with 10% foetal calf serum 
(FCS) (BioSera), 1% glutamine (GlutaMax-100x) (Gibco Ltd) and 1% antibiotic/antimycotic 
solution (100x) (Gibco Ltd) at 37°C, 5% CO2 and 95% humidity. The cells were passaged when 
they had reached about 85-90% confluence. To passage the cells, the complete medium was 
aspirated off and cells were washed twice with phosphate buffered saline (PBS). The PBS was 
then aspirated off and cells were treated with 1ml of Trypsin-EDTA solution (0.025%(w/v)) 
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(Invitrogen). The complete medium contains many substances including Mg2+ and Ca2+, which 
are trypsin inhibitors. Hence, washing cells with PBS prior to the treatment with trypsin is 
important. After the treatment with trypsin, cells were incubated at 37°C until the cells had 
detached from the flask surface. The trypsin-EDTA solution was then neutralized by the addition 
of 5ml of complete medium and this cell suspension was used to seed more flasks.  
 
Other cancer cell lines that were used such as HT29 colon adenocarcinoma cells, A549 lung 
cancer cells, MCF-7 breast cancer cells and EJ138 bladder cancer cells were maintained using 
RPMI1640 complete medium consisting of RPMI1640 (Sigma Aldrich) supplemented with 10% 
foetal calf serum (FCS) (BioSera), 1 % glutamine (GlutaMax-100x) (Gibco Ltd) and 1% 
antibiotic/antimycotic solution (100x) (Gibco Ltd) at 37°C, 5% CO2 and 95% humidity.  
 
2.2.1 Cryopreservation  
 
Cells were routinely stored in liquid nitrogen for later use. After removing the medium from a 
T75 cm2 flask (85-90% confluent), the cells were washed with PBS twice to remove the traces 
of complete medium before treating with 1ml of Trypsin-EDTA. The flask was then allowed to 
incubate at 37°C, 5% CO2 and 95% humidity for a few minutes until the cells had detached from 
the surface of the flask. The trypsin was then neutralized by the addition of 5ml of complete 
medium. The cell suspension was then transferred to a universal tube and centrifuged at 
1000rpm for 5 minutes at 4°C. The supernatant was then carefully discarded without disturbing 
the cell pellet. The cell pellet was then resuspended in 1ml of freeze mix (70% RPMI medium, 
20% FCS and 10% dimethyl sulphoxide (DMSO). DMSO is a cryoprotectant and protects the 
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cells from rupture caused by the formation of ice crystals. The cryovial was then transferred to 
isopropyl alcohol containing ‘Mister Frosty’ which was slowly cooled to -80°C in a freezer before 
being transferred to liquid nitrogen for long term storage. 
 
2.2.2 Treatment of CCD18 cells with recombinant HMGb1 
 
To determine the effect of HMGb1 on proliferation of CCD18 myofibroblasts, cell suspensions of 
CCD18 cells (6x104 cells/ml) were used to seed 24-well plates (1ml/well). The plates were 
incubated at 37°C and 5% CO2 for 24 hours to allow the cells to adhere and begin proliferating. 
After this period, the complete medium was aspirated from each well and the cells were then 
washed twice with PBS. Serum free MEM Eagle medium was added to each well (1ml/well) and 
plates were allowed to incubate for a further 24 hours at 37°C, 5% CO2 and 95% humidity. The 
next day, cells were treated (1ml/well) for 96 hours with a range of concentrations of 
recombinant HMGb1 (R&D systems) (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50 and 100ng/ml) made up 
in serum free MEM Eagle (four wells per treatment per 24-well plate). In addition, four wells per 
plate were treated with serum free MEM Eagle medium as controls (serum free medium without 
HMGb1).   
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2.2.3 Treatment of CCD18 cells with recombinant HMGb1 and PI3K or               
          MEK1/2 inhibitors (LY294002 or U0126)  
 
In order to investigate the likely pathway/s that HMGb1 might utilise to signal proliferation, 
experiments were carried out using HMGb1 alone or in the presence of Phosphatidylinositide 3-
kinases (PI3K) or mitogen-activated protein kinase kinase (MEK1/2) inhibitors. To achieve this, 
CCD18 myofibroblasts were seeded (6x104 cells/ml) into 24-well plates (1ml/well). The plates 
were incubated at 37°C and 5% CO2 for 24 hours to allow the cells to adhere and begin 
proliferating. After this period, the complete medium was aspirated from each well and the cells 
were then washed twice with PBS. MEM Eagle (serum free) was added to each well (1ml/well) 
and plates were allowed to incubate for a further 24 hours at 37°C, 5% CO2 and 95% humidity. 
The next day, the medium was removed and cells were treated (1ml/well) for 48 hours with 
HMGb1 (10ng/ml) alone, HMGb1 (10ng/ml) with LY294002 (5µM) and HMGb1 (10ng) with 
U0126 (50µM) (R&D systems) made up in serum free MEM Eagle medium (8 wells per 
treatment per 24-well plate with either U0126 or LY294002). In addition, eight wells were 
treated with serum free MEM Eagle only as controls (serum free medium without HMGb1, 
LY294002 or U0126).  The 24-well plate treatment scheme was planned using 8 wells for 
controls (serum free medium), 8 wells for HMGb1 (10ng/ml in serum free medium) and 8 wells 
for combination treatment with HMGb1 (10ng/ml) and U0126 (50µM/ml) in serum free medium). 
Similar treatment scheme was implemented for HMGb1 and LY2904002 treatment which 
included 8 wells for controls (serum free medium), 8 wells for HMGb1 (10ng/ml in serum free 
medium) alone and 8 wells for combination treatment with HMGb1 (10ng/ml and LY2904002 
(5µM/ml) in serum free medium).    
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2.2.4 Assessment of proliferation using the neutral red uptake (NRU)  
         assay 
 
The neutral red uptake assay has traditionally been viewed as an assay of toxicity however, it 
can also be used as an assay of proliferation. Neutral red (NR) is a weakly cationic dye which 
enters into the living cells by non-ionic diffusion through the cell membrane. Once internalised, 
the dye then accumulates in the lysosomes of living cells. The NR can then be extracted using 
1% acetic acid and 50% ethanol in dH2O. The absorption spectrum of the supernatant 
containing NR can be measured at 540nm (Borenfreund and Puerner 1985; Borenfreund and 
Puerner 1986).  
 
A neutral red medium mix was made immediately prior to use by the addition of 380ul of neutral 
red solution (Sigma Aldrich, N2889) to 25ml of pre-warmed (37°C) MEM Eagle serum free 
medium to achieve a working concentration of 50ug/ml (w/v). The HMGb1 treatment medium 
was aspirated off from the cells. The neutral red medium mix was added (1ml/well) and the 24-
well plates were returned to the incubator for 2 hours for the dye to be taken up by the cells. 
After 2 hours, the cells were washed with PBS (1ml/well) once and neutral red de-stain (50% 
ethanol, 49% dH2O and 1% glacial acetic acid) was added (350µl/well) to lyse the cells and 
release the dye. Complete cell lysis and a homogenous colour was achieved by gentle shaking 
on a plate shaker. Aliquots of 100µl (x 3 per well) of resulting coloured solution were transferred 
to wells of 96-well plates. The absorbance of the accumulated neutral red was measured at 
540nm using the Titertek Multiscan plate reader. The readings from treated cells were 
compared to those of non-treated control cells and these results expressed as percentages 
taking the control mean value as 100%. 
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2.2.5 Assessment of toxicity and proliferation using the MTT (3-(4, 5-     
         dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay  
 
The MTT assay developed by Mossman (1983) can also be used to determine cytotoxicity or 
proliferation of cells in response to treatment with substances. In the ideal world, colorimetric 
assay for living cells should utilize a colourless substrate which can be converted into a 
coloured product by any living cell. The tetrazolium salt measures the activity of various 
dehydrogenase enzymes and it is cleaved in active mitochondria. MTT is cleaved by all living 
and metabolically active cells however it is not the case with dead cells. Therefore, the reaction 
will only occur in the living cells. The amount of formazan produced by active cells is more than 
the cells underwent senescence. Therefore, it can measure the activation even if the cells are 
not proliferating (Mosmann 1983).   
 
The MTT solution was made prior to use by the addition of 2.5ml of MTT solution (5mg/ml) 
(Sigma Aldrich, M5655) to 25ml of pre-warmed (37°C) minimum essential medium eagle serum 
free medium (working concentration 0.5mg/ml (w/v)). The HMGb1, U0126 and LY294002 
treatment medium was aspirated off from the cells. The MTT mix was added (1ml/well) and the 
24-well plates were returned to the incubator for 2 hours for the dye to be taken up by the cells.  
After 2 hours, 2-propanol was added (350µl/well) to lyse the cells and release the dye. 
Complete cell lysis and a homogenous colour were achieved with help by gentle shaking on a 
plate shaker. Aliquots of 100µl (x 3 per well) of resulting coloured solution were transferred to 
the wells of 96-well plates. The absorbance of the accumulated MTT solution was measured at 
540nm using the Titertek Multiscan plate reader. The readings from treated cells were 
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compared to those of non-treated control cells and these results expressed as percentages 
taking the control mean value as 100%. 
 
2.3 Protein Assay  
2.3.1 Sample preparation from CCD18, HT29, MCF-7, EJ138 and A549  
         cells  
 
CCD18 myofibroblast cells, HT29 colon adenocarcinoma cells, A549 lung cancer cells, EJ138 
bladder cancer cells and MCF-7 breast cancer cells were seeded into 17 x T25 cm2 flasks at a 
density of 4.0x105 per flask and allowed to grow overnight at 37°C, 5% CO2 and 95% humidity. 
The following day, medium was removed and replaced with serum free medium (5ml/flask) and 
incubated for 24h. After 24h, the medium was aspirated off and replaced with fresh medium 
(RPMI 1640) with glucose (1.8 g/L) (9 flasks) and without glucose (8 flasks). The glucose free 
flasks were either incubated in normoxic or anoxic conditions (4 flasks for each condition). The 
flasks with glucose were also treated to the same conditions (4 flasks for each condition). The 
remaining flask was used as day 0 control (serum free medium with glucose). The medium was 
decanted into a labelled universal tube.  This medium was immediately frozen at -80°C.  For 
each of the following 4 days, 1 flask of cells from each condition (anoxia or normoxia with or 
without glucose) was removed and the medium again stored at -80°C.  Between day 2 and 4, in 
some of the conditions, some cells appeared to be floating in the medium, these were 
presumed to be dead cells. These cells were removed from the medium by centrifugation 
(1,000rpm for 5 min) before the medium was frozen at -80°C. The medium was collected for 
investigation at 3 different occasions for each set of flasks.   
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In addition, HT29, A549, MCF-7 and EJ138 cells were treated with and without glutamine to 
assess the release of HMGb1 in low nutrient conditions. Two flasks of each cell type was 
treated with either glutamine (200mM/L) in serum free medium (RPMI 1640) or glutamine and 
serum free medium and incubated in normoxic conditions for 48h. The protocol for the collection 
of medium remained same as described above.  
 
2.3.2 The extraction of proteins from the cells  
 
The extraction of proteins from the flasks of cells (HT29 and CCD18) was carried out. To 
achieve this, a lysis buffer was prepared by adding phosphatase inhibitor cocktail set-II (10µl) 
and protease cocktail set-II (10µl) in RIPA buffer (980 µl) (Calbiochem reagents). To each flask, 
100µl of lysis buffer was added and the cells were scraped using a cell scraper and transferred 
into a labelled eppendorf tube. The contents of the eppendorf tube were then homogenised for 
30 seconds using a pellet pestle motor (Kontas). The eppendorf was then left on ice for 30min 
to achieve complete lysis. After 30 minutes, the tube was centrifuged for 3 minutes 
@10,000rpm at 4°C. The supernatant was carefully collected without disturbing the cell pallet in 
a labelled eppendorf tube before determining the protein concentration. This process was 
repeated for the cells from all flasks. 
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2.3.3 Determination of the sample protein concentration  
 
To determine the protein concentration of the cell lysates and conditioned medium from each 
fl;ask, the BioRad DC protein assay was used. The BioRad protein assay is a colorimetric 
assay, which is modified from protein measurement technique using Folin phenol reagent 
described more than 60 years ago (Lowry, Rosebrough et al. 1951). This assay uses three 
different reagents namely reagent A (alkaline copper tartrate solution), reagent B (diluted Folin 
reagent) and reagent S (10% sodium dodecyl sulfate surfactant solution). This protein assay is 
based on the blue colour which is generated between the reaction of proteins with copper and 
the subsequent reduction of Folin by copper were amino acids, tyrosine and tryptophan are the 
reduced products. These reduced products upon loss of oxygen generate blue colour which is 
measured at 650-750nm. Bovine serum albumin (BSA) was prepared as a stock solution 
(1mg/ml) in dH2O. This was then used to make up protein standards (0, 0.05, 0.1, 0.2, 0.3, 0.5, 
0.75 and 1mg/ml). 
 
To determine the protein concentration in the cell lysates, samples of each cell lysate (5µl) and 
each of the BSA standards (5μl) were added to wells of a 96-well plate (in triplicate). BioRad 
reagent ‘AS’ was prepared by adding reagent S (120µl) to reagent A (6ml).  Reagent AS (25µl) 
was then added to each well of the 96-well plate. Then BioRad reagent B (200µl) was added to 
each well and the reagents were mixed well on orbital shaker for 10 minutes for the colour to 
develop. The absorbance was read on 690nm on a plate reader (Titertek multiscan) and 
background reading was measured for blanks using dH2O. A BSA standard curve was prepared 
and the protein concentration of each sample was determined from this. The protein assay was 
carried out to ensure that all samples used for western blot were of approximately equal total 
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protein content. The same process was repeated to determine protein concentration in 
conditioned medium obtained from flasks of HT29 cells. 
 
2.3.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis      
         (SDS–PAGE)  
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS–PAGE) was carried out 
using the BioRad mini protean II electrophoresis system to separate the protein samples.  
Before pouring the gel, the gap (1.5mm) between the glass plates was filled with dH2O to check 
for leakage. The dH2O was removed and resolving gel was made up (Protogel (30%), 6ml; 4x 
resolving buffer, 5ml; dH2O, 8.78ml; 10% (w/v) Ammonium persulphate (APS), 200µl; 
Tetramethylethylenediamine (TEMED), 20µl) and rapidly mixed without incorporating air 
bubbles quickly poured between the plates. The resolving gel buffer was then overlaid with 1ml 
of water saturated isobutanol and allowed to set. Isobutanol was used to prevent oxygen from 
getting into the gel which could oxidise it and inhibit polymerization. After the gel was set, this 
was removed and the top of the gel was washed with dH2O and this was removed and the 
surface of the gel was carefully dried using filter paper. The stacking gel was again rapidly 
mixed without incorporating air (Protogel (30%), 1.3ml; 4 x stacking buffer, 2.5ml; bromophenol 
blue (0.05 mg/ml), 100µl; dH2O, 6ml; 10% (w/v) APS, 50µl; TEMED, 10µl) was then poured on 
the top of the gel and a comb (10 well space) was inserted in the gel to make spaces for the 
protein sample wells. The gel was left for 30 minutes to set. 
 
The samples were then diluted appropriately with Radioimmunoprecipitation assay (RIPA) 
buffer to make equal concentrations of total protein content (equalising to lowest protein 
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concentration of all the samples used on that occasion). The samples were prepared by mixing 
50µl of sample with 10µl of 6x Laemmli loading buffer-reducing (1.5% SDS, 10% glycerol, 
62.5Mm Tris-HCL (pH6.8), 0.0025% bromophenol blue, 2% β-mercaptoethanol). The samples 
were then denatured at 100˚C for 4 minutes.  The gel was submerged in 1 x running buffer 
(25mM Tris, 192mM Glycine, and 0.1% (w/v) SDS, at pH8.3), and 45µl of each sample was 
loaded in each well in the stacking gel. The gel was run for 30 minutes at 26mA, or until the dye 
front had reached the bottom of the gel.  Whilst the gel was running, 1 litre of transfer buffer was 
prepared by combining 100ml of 10x transfer buffer (Tris/Glycine Buffer, BioRad), 200ml 
methanol, and 700ml dH2O.  Once the gel had run, the gel was removed from the 
electrophoresis apparatus and soaked for about 15 minutes in transfer buffer. 
 
2.3.5 Western blotting 
 
A BioRad transfer tank was used to transfer the proteins from the gel to a nitrocellulose 
membrane (Amersham Hybond-ECL). Following electrophoresis, gels were allowed to soak in 
transfer buffer for 30 min to remove an excess salt. The nitrocellulose membranes and filter 
papers were cut in a size to cover the entire surface of the gel. The nitrocellulose membranes 
and filter papers were pre-soaked in transfer buffer for 20 min and a gel sandwich was prepared 
as illustrated in figure 2.1.   
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                     (+ Positive charge)            (Clear plastic) 
Foam pad 
  Filter paper 
   Nitrocellulose membrane 
  Gel 
  Filter paper 
Foam pad 
                        (- Negative charge)        (Black plastic) 
Figure 2.1  Preparation of a gel/nitrocellulose transfer sandwich 
Note: The arrows denote direction of protein migration with charge  
 
First a sponge was laid on black part of the gel holder, followed by filter paper, gel, 
nitrocellulose membrane, filter paper and finally another sponge, flooding with transfer buffer 
with each layer.  A pasteur pipette was used as a rolling pin to remove any air bubbles from 
between the layers.  A cooling block and the gel sandwich were fitted into the transfer tank and 
the tank filled with transfer buffer.  The transfer of proteins was achieved running the gel at a 
constant 350 mA for 70 minutes.   
 
One litre of Tris-Buffered Saline (TBS) (20mM Tris, 500mM sodium chloride, at pH 7.5) was 
made up. Nitrocellulose blots were washed (3 x 10 minutes) with TBS with 0.1% (v/v) Tween 20 
(T) added (TBS-T).  All non-specific protein binding sites were then blocked by incubating with 
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5% (w/v) non-fat milk (Marvel) in TBS-T for 1 hour at room temperature. Blocking buffer was 
poured off and the blot incubated with 10ng/ml mouse anti-human HMGb1 primary anybody 
(R&D Systems) or goat anti-human RAGE (R&D Systems) or TLR-4 antibody (R&D Systems)  
in 5% (w/v) Marvel (non-fat dry milk) in TBS-T at 4oC overnight. The following day, the blot was 
washed with TBS-T (3 x 10 minutes). A secondary antibody (anti-mouse/goat/rabbit) conjugated 
to horseradish peroxidise (R&D systems) was diluted in 5% (w/v) Marvel in TBS-T (1 in 1000) 
and the blot was incubated in this for 1 hour at room temperature. The blot was then washed in 
TBS-T (3 x 10 minutes).  
 
2.3.6 Blot development 
 
Equal volumes each of ECL reagents (SuperSignal West Pico, Thermo Scientific) were mixed 
and added to the blot for 5 minutes on a shaking platform. Filter paper was used to remove 
excess reagent and the blot was placed on glass plate and wrapped in Clingfilm.  The glass 
plate was placed into a cassette (Kodak) and taken to a dark room.  Hyperfilm (Kodak) was 
loaded under the glass plate and the orientation of the blot was recorded.  The cassette was 
then closed and the Hyperfilm exposed for the appropriate length of time.  After this, the 
Hyperfilm was removed and developed and fixed (Kodak) according to the manufacturer’s 
protocol.  
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2.3.7 Dot Blotting 
 
To determine the working concentration of anti HMGb1, anti-RAGE and Anti-TLR-4 antibodies, 
a dot blot analysis was carried out prior to the western blot for each protein type. The 
nitrocellulose membrane was cut to an appropriate size enough for 8-10 sample dots.    The 
samples were then spotted (2µl) onto the membrane. The nitrocellulose membrane was then 
allowed to air-dry for 2 hours.  From this point on, nitrocellulose blots were treated and 
developed in the same way as western blots (see section 2.3.5).   
 
2.3.8 Quantitative Analysis of Western Blots 
 
The intensity of individual bands of western blots was determined by analysing scanned images 
of membranes using ImageJ software. The intensity is expressed as a percentage in terms of 
“normalised integrated density” of the control band for each blot. The “integrated density” is 
defined as the sum of the pixels in the image. The control was allocated an arbitrary value of 
100%.  
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2.4 Migration assay 
 
It is hypothesised that HMGb1 is released from cancer cells into the culture medium, particularly 
in conditions of glucose starvation.  It is also possible that this release of HMGb1 might trigger 
migration of myofibroblasts. Therefore, a chemotaxis assay (migration assay) was set up. HT29 
colon adenocarcinoma cell lines were seeded in 2 xT75cm2 (2x106 cells per ml). Both flasks 
were incubated over night at 37°C, 95% humidity and 5% CO2 to allow the cells to adhere. The 
following day, the complete medium was aspirated off and cells were washed twice with PBS. 
The medium on the cells was replaced with serum free medium with glucose in one flask and 
without glucose in the other flask. After 48 h, both lots of ‘conditioned medium’ (glucose 
containing and glucose free used medium) were collected into labelled universals and to be 
used to test their chemoattractant properties using the migration assay.  
 
The CCD18 cell suspension was made in serum free medium (4.0x104 per ml).  In a 24-well 
plate, glucose free and glucose containing conditioned medium were added (2 wells of each, 
0.75ml per well). The CCD18 myofibroblast cells were then seeded (0.5ml per insert) in 4 
chamber inserts (Biocoat®, 8µm pores) and 4 inserts were put into the 4 wells in the 24 well 
plate and ensured that insert bottom is touching the conditioned medium in the wells. The plate 
was incubated for 20h in the incubator at 37°C, 95% humidity and 5% CO2.  
 Note: Versene was used to detach myofibroblasts cells undergoing migration and invasion 
assays 
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After the 20h incubation period, the 24-well plates were removed and cells which had migrated 
were stained for counting.  Fixation and staining steps were carried out using ReaStain Quick-
Diff kit.  Each chamber insert was dried with cotton bud from inside and dipped in fixative 
solution for 2 minutes followed by red stain (Reastain Quick-Diff Red) and blue stain (Reastain 
Quick-Diff Blue) for 2 minutes each.  Each chamber insert was then rinsed thoroughly and left 
upside down position on a filter paper to dry for 30 minutes.  Once the chamber inserts are 
dried, membranes were cut out (using a scalpel and tweezers), and mounted on a microscope 
glass slide using a small drop of ‘Microll’ immersion oil followed a cover slip. The membranes 
were viewed using inverted fluorescence and phase contrast microscope (Olympus IMT2) with 
camera (QImaging-MP3.3-RTV-CLR-10) and images of random fields of vision were captured 
from each membrane (x20 magnification) using Image Pro Plus software. The cells that had 
migrated through the membrane were counted using ImageJ cell counter software and the 
average of the 5 fields of vision for each membrane calculated.   
 
In an effort to determine which cytokines or pathways are involved in the migratory response, 
the assay was also carried out using known inhibitors of specific cytokines or pathways. These 
were added to the myofibroblast cell suspension used in the inserts or conditioned medium 
used in the wells.  The ERK1/2 inhibitor U0126 and PI3K inhibitor LY294002 used to block the 
respective pathways (see table 2.7). These inhibitors have been shown to selectively inhibit 
these pathways (Satoh, Nakatsuka et al. 2000; Gottschalk, Doan et al. 2005).  
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2.5 Invasion assay  
 
CCD18 myofibroblasts invasion assays were performed using 8µm pore matrigel matrix 
Biocoat® inserts according to the manufacturer’s instruction (Becton Dickinson). The CCD18 
cell suspension was made in serum free medium (6.0x104 per ml).  The myofibroblasts cells 
were plated onto (0.5ml per insert) inserts in a 24-well plate supplied by the manufacturer.  The 
inserts were put into the wells of 24-well plate. HT29 conditioned medium was used as 
chemoattractant and plated onto the lower chamber (0.5ml) and ensured that inserts were 
touching the conditioned medium (see section 2.4). The plate was incubated for 22h in the 
incubator at 37°C, 95% humidity and 5% CO2.  The myofibroblasts invasion, in response to the 
conditioned medium with and without various inhibitors and antibodies were determined by their 
inclusion in the lower chamber of the 24-well plate. Cells invaded through the matrigel matrix 
membrane were detected on the lower surface by using ReaStain Quick-Diff staining method 
and visualised using at x20 magnification under a microscope using the protocol described for 
migration assay above (same as section 2.4).  In an effort to determine which cytokines or 
pathways are involved in myofibroblast invasion, the assay was also carried out using known 
inhibitors of specific cytokines or pathways added to the myofibroblast cell suspension used in 
the inserts or conditioned medium used in the wells. (see table 2.7) 
 
2.6 Statistics  
 
Results are presented as mean and +SEM. The results were compared using t-test where 
appropriate and were considered significant at p<0.05.  
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2.7 Table of inhibitors and antibodies used in migration and     
        invasion assays  
 
Inhibitor Name Manufacturer Working 
Concentration 
Assay Compartment Used 
Anti-HMGb1 antibody R&D Systems 5µg/ml Inserts and wells 
Anti-RAGE antibody R&D Systems 8µg/ml Inserts 
Anti-TLR-4 antibody R&D Systems 2µg/ml Inserts 
U0126  
(MEK1/2 inhibitor) 
Cell Signalling 50µM/L Inserts and wells 
LY294002 
(PI3K inhibitor) 
Cell Signalling 5µM/L Inserts and wells 
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Chapter 3 
3. Investigating the role of HMGb1 in stimulating  
    CCD18 myofibroblasts proliferation  
 
3.1 Introduction  
 
The high mobility group box 1 protein is a member of the HMGb superfamily. It is expressed in 
all vertebrate and non-vertebrate cells, yeast, plants and bacteria (Bustin et al. 1990). HMGb1 is 
a non-histone protein involved in stabilization of nucleosomes and the bending of DNA, which 
facilitates gene transcription (Lange et al. 2008).  Whilst HMGb1 is a nuclear protein, it is 
released from the cells under certain conditions to take part in the inflammatory process. During 
inflammation, extracellular HMGb1 activates infiltrating macrophages, via the RAGE receptor. In 
addition, activated macrophages/monocytes are also responsible for the release of HMGb1 in 
the extracellular milieu (Andersson et al. 2002; Huttunen and Rauvala 2004).   
 
It has also been suggested that HMGb1 is involved in various diseases including autoimmune 
disorders, sepsis, chronic inflammatory disease and cancer (Wang et al. 2004; Sims et al. 
2009). An investigation into the influence of HMGb1 on fibroblasts and keratinocytes has been 
explored recently, where HMGb1 was shown to act as a cytokine and stimulate keratinocyte 
scratch wound healing in vitro (Clericuzio et al. 2013). The HMGb1 activates various signalling 
pathways such as MAPKs, protein kinase B (AKT) and PI3K. These pathways play important 
roles in proliferation and migration of cells involved in wound healing such as fibroblasts and 
keratinocytes (Taboubi et al. 2007; Song et al. 2012). For example, HMGb1 was shown to 
80 
 
induce proliferation and migration of keratinocytes via ERK1/2 pathway (Ranzato et al. 2009). 
To further support these findings, Ranzto et al. (2009) used anti-RAGE antibodies and selective 
MEK1/2 inhibitor (PD98059) to inhibit HMGb1-RAGE-ERK1/2 pathway. The inhibition of MEK1/2 
by PD98059 abrogated HMGb1 induced wound healing.  Both PI3K and MEK1/2 pathways have 
also been suggested to play important roles in proliferation of colonic myofibroblasts cells 
(Hemers et al. 2005). In addition, the pathways have also been implicated in proliferation and 
migration of cancer cells. Bassi et al. (2008) investigated the role of HMGb1 in glioblastoma 
cells in vitro. The results suggested that HMGb1 triggers proliferation and migration of 
glioblastoma cells via ERK1/2 activation.   
 
 
Ranzato et al. (2010) suggested that HMGb1 could be considered as a potential therapeutic 
target for the development of drugs for chronic inflammatory disease, chronic inflammatory 
autoimmune disorders and severe wounds. Although HMGb1 has been shown to induce 
proliferation and migration in various cancer cells including glioblastoma and colon cancer cells, 
its role and involvement with myofibroblasts has not been explored thus far. 
 
 
The myofibroblasts have been shown to play important roles in wound healing and inflammation 
(Lin et al. 2015). They share similar characteristic features as those of fibroblasts however get 
differentiated by de novo expression of α-SMA and stress fibres during the transition from 
quiescent fibroblasts to myofibroblasts. Other mechanisms may include epithelial to 
mesenchymal or endothelial to mesenchymal transition (Zeisberg et al. 2007). It has been 
established that myofibroblasts play important roles in the formation and repair of the ECM. For 
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example, myofibroblasts have been shown to be involved in connective tissue remodelling by 
synthesising ECM components and providing cytoskeletal support from smooth muscle cells 
(Klingberg et al. 2013). Unlike normal stroma, tumour stroma exhibits an altered extracellular 
matrix (ECM) and an increased expression of myofibroblasts. However, the composition and 
amount of ECM generated may vary amongst tumours (Mehner and Radisky 2013). Although 
myofibroblasts are important cells in the tumour ECM, their role in tumour proliferation remains 
unclear. In addition, little is known about how they interact with tumour cells and why they are 
found generally found on the tumour periphery. 
 
Myofibroblasts play a significant role during inflammatory response as they can produce both 
chemokines and cytokines. This production of cytokines and chemokines by myofibroblasts can 
augment or down regulate the inflammatory response (Tetsuka et al. 1994). Many pathological 
conditions such as liver fibrosis and cancer are characterised by elevated levels of 
myofibroblasts which are able to escape immune surveillance and become apoptosis-resistant 
(Barcellos-de-Souza et al. 2013; Mallat and Lotersztajn 2013). Therefore, it is possible that 
CAFs may receive continuous proliferative signals within the tumour microenvironment and 
subsequently may contribute to tumour progression.  
 
We hypothesise that HMGb1, which is a nuclear protein is released from cancer cells in 
extracellular milieu within microenvironment and trigger proliferation in myofibroblasts.   
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3.2 Aims and objectives  
 
  The aims of this study were to: 
 
a) Determine if HMGb1 can induce proliferation in CCD18 myofibroblast cells. 
b) Determine if the effect seen was time and/or dose dependent.  
c) Investigate the intracellular signalling pathways involved in HMGb1 induced proliferation 
of myofibroblasts.  
 
3.3 Materials and methods 
3.3.1 CCD18 myofibroblasts cell culture  
 
The myofibroblasts (CCD18) cells were cultured in T75 cm2 flasks in complete medium 
(minimum essential medium eagle) (Sigma Aldrich, Dorset UK) supplemented with 10% foetal 
calf serum (FCS) (BioSera, East Sussex UK), 1% glutamine (GlutaMax-100x) (Gibco Ltd, 
Warrington UK) and 1% antibiotic/antimycotic solution (100x) (Gibco Ltd) at 37°C, 5% CO2 and 
95% humidity. The cells were passaged when they had reached 85-90% confluence. While 
growing CCD18 myofibroblast cells, it was observed that the growth slowed down after passage 
12. Therefore, all assays were carried out between passage number 2 and 10.  
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3.3.2 Treatment of CCD18 cells with HMGb1 and PI3K and ERK1/2     
          inhibitors (U0126 and LY294002)  
 
Cell suspensions of CCD18 myofibroblasts (5x104cells/ml) were used to seed into 24-well plates 
(1ml/well). The plates were incubated at 37°C and 5% CO2, 95% humidity for 24 hours to allow 
the cells to adhere and begin proliferating. After this period, the complete medium was aspirated 
from each well and the cells were then washed twice with phosphate buffer saline (PBS). 
Minimum essential medium (MEM) eagle (serum free with no other supplement) was added to 
each well and plates were allowed to incubate for a further 24 hours at 37°C, 5% CO2 and 95% 
humidity. The next day, medium was aspirated off and cells were treated (1ml/well) for 96 hours 
with a range of concentrations of recombinant HMGb1 (R&D systems) (0.01, 0.05, 0.1, 0.5, 1, 5, 
10, 50 and 100ng/ml) made up in serum free minimum essential medium eagle (four wells per 
treatment). In addition, four wells were treated with serum free-minimum essential medium eagle 
only as controls (serum free medium without any supplement and HMGb1).  For proof of 
concept inhibitor assay, cells were treated (1ml/well) for 48 hours with HMGb1 (10ng) alone and 
HMGb1 (10ng) with LY294002 (5µM) and HMGb1 (10ng) with U0126 (50µM) (R&D systems) 
made up in serum free - minimum essential medium eagle (8 wells per treatment).  In addition, 
eight wells were treated with serum free-minimum essential medium eagle only as controls 
(serum free medium without HMGb1).   
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3.3.3 Assessment of proliferation using the NRU assay 
 
The CCD18 myofibroblast cells have population doubling time of 4-5 days (Figure 3). Therefore, 
CCD18 cells were treated for 96h with HMGb1 to give sufficient time for the proliferation. The 
controls were washed with PBS three times and treated with serum free medium 24h prior to the 
treatment and the medium was changed to fresh serum free medium on the day of treatment to 
ensure unavailability of other nutrients to the cells. A neutral red medium mix was made 
immediately prior to use by the addition of 380ul of neutral red solution (Sigma Aldrich, N2889) 
to 25ml of pre-warmed (37°C) minimum essential medium eagle serum free medium (a working 
neutral red concentration of 50ug/ml (w/v)). The HMGb1 treatment medium was aspirated off 
from the cells. The neutral red medium mix was added (1ml/well) and the 24-well plates were 
returned to the incubator for 2 hours for the dye to be taken up by the cells. After 2 hours, the 
cells were washed with PBS (1ml/well) once and neutral red de-stain (50% ethanol, 49% dH2O 
and 1% glacial acetic acid) was added (350µl/well) to lyse the cells and release the dye. 
Complete cell lysis and a homogenous colour were achieved with help by gentle shaking on a 
plate shaker. Aliquots of 100µl (x 3 per well) of resulting coloured solution were transferred to 
wells of 96-well plates. The absorbance of the accumulated neutral red was measured at 540nm 
using a Titertek Multiscan plate reader. 
 
3.3.4 Assessment of toxicity and proliferation using the MTT assay  
 
The MTT solution was made prior to use by the addition of 2.5ml of MTT solution (5mg/ml) 
(Sigma Aldrich, M5655) to 25ml of pre-warmed (37°C) minimum essential medium eagle serum 
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free medium (a working MTT concentration of 0.5mg/ml (w/v)). The HMGb1, U0126 and 
LY294002 treatment medium was aspirated off from the cells. The MTT mix was added 
(1ml/well) and the 24-well plates were returned to the incubator for 2 hours for the dye to be 
taken up by the cells.  After 2 hours, 2-propanol was added (350µl/well) to lyse the cells and 
release the dye. Complete cell lysis and a homogenous colour were achieved with help by 
gentle shaking on a plate shaker. Aliquots of 100µl (x 3 per well) of resulting coloured solution 
were transferred to wells of 96-well plates. The absorbance of the accumulated MTT solution 
was measured at 540nm using a Titertek Multiscan plate reader. 
 
3.4 Results  
3.4.1 HMGb1 triggers proliferation in CCD18 myofibroblasts  
 
The HMGb1 has been shown to play critical roles as cytokines and danger signalling molecules. 
HMGb1 has been shown to be released from necrotic cells but not apoptotic cells and play 
multiple roles in extracellular milieu. In addition, HMGb1 has been shown to induce proliferation 
certain other cancer cells such as glioblastoma and normal cells such as endothelial cells. 
However, the role of HMGb1 in myofibroblasts has not been explored. Thus, determining 
whether HMGb1 can trigger proliferation in CCD18 myofibroblasts would be of interest. 
Therefore, the proliferation assays (NRU and MTT) were carried out to test the proliferative 
effect of recombinant HMGb1 on CCD18 myofibroblast cells. 
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Figure 3.1: CCD18 myofibroblasts growth curve showing growth over 8 days period. The cells 
were grown in MEM complete medium in 8x T25 cell culture flasks. The cells were trypsinised 
and manually counted on haemocytometer. The assay was carried out three times at three 
different occasions using different passage number of the cells each time.  
 
The log phase of the growth of CCD18 myofibroblast cells was determined. The CCD18 
myofibroblast cells were seeded at a density of 3x104 cells/ml in eight T25cm2 flasks. Each flask 
was sacrificed every 24h from day 0-8, where day 0 being the day when cells were seeded. The 
cells were trypsinised and counted on a haemocytometer. The population doubling time of 
CCD18 myofibroblasts was around 3-5 days where log phase started when cells reached a 
density of approximately 4x104 cells/ml (Figure 3.1).  
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Figure 3.2: HMGb1 induced proliferation in CCD18 myofibroblasts (NRU assay- HMGb1 using 
low concentration). Recombinant HMGb1 was used in a dose spectrum of 0ng/ml - 0.5ng/ml, 
where 0ng/ml served as control (serum free medium without HMGb1). The absorbance of 
accumulated NRU dye was measured at 540nm using the plate reader. HMGb1 appeared to 
trigger some proliferation at 0.01 and 0.05ng/ml but this was not statistically significant (P>0.05). 
The standard error of the mean (SEM) displayed as error bars. The student t-test was used to 
determine P values. n=12 from 3 different occasions.  
 
To determine the proliferative effect of HMGb1 on myofibroblasts cells, CCD18 myofibroblast 
cells were treated with HMGb1 with different concentrations for 96h before assessment using 
the NRU assay. It was observed that HMGb1 triggers proliferation in myofibroblasts in a dose-
range of 0.1 to 50ng/ml.   
0 
20 
40 
60 
80 
100 
120 
140 
160 
0 0.01 0.05 0.1 0.5 
%
 M
yo
fi
b
ro
b
la
st
s 
p
ro
lif
er
at
io
n
 (
1
0
0
%
 =
 c
o
n
tr
o
l)
 
HMGb1 (ng/ml) 
* * 
P<0.05=* 
88 
 
 
The proliferation assays were carried out in two parts comprising of lower (0.01-0.5ng/ml) or 
higher doses (1-100ng/ml) of recombinant HMGb1. During the testing of lower doses, HMGb1 
appeared to stimulate myofibroblasts cells in a dose ranging from 0.1 to 0.5ng/ml (Figure 3.2). 
This proliferation was statistically significant (P<0.05). Although, 0.05ng/ml of HMGb1also 
triggered proliferation in myofibroblasts cells however, this proliferation was lower than that of 
0.1ng/ml HMGb1 and was not statistically significant either. In addition, no difference was 
observed between the proliferation induced by the treatment with 0.1ng/ml and 0.5ng/ml of 
HMGb1 (Figure 3.2). Thus, higher dose of HMGb1 were tested for further investigation. 
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Figure 3.3: HMGb1 induced proliferation in CCD18 myofibroblasts (NRU assay- HMGb1 using 
high concentration). Recombinant HMGb1 was used in dose spectrum of 0, 1, 5, 10, 50 and 
100ng/ml where 0ng/ml served as control (serum free medium without HMGb1). The 
absorbance of accumulated NRU solution was measured at 540nm using the plate reader. The 
SEM displayed as error bars. The student t-test was used to determine P values. n=29 from 8 
occasions.  
 
 
 
 
 
0 
20 
40 
60 
80 
100 
120 
140 
160 
0 1 5 10 50 100 
%
 M
yo
fi
b
ro
b
la
st
s 
p
ro
lif
er
at
io
n
 (
1
0
0
%
=c
o
n
tr
o
l)
 
HMGb1 (ng/ml) 
*** 
*** *** 
*** 
P<0.001=*** 
90 
 
                               
                                                                        
 
 
Figure 3.4: HMGb1 induced proliferation in CCD18 myofibroblasts (MTT assay- HMGb1 single 
dose) at 48h. Recombinant HMGb1 was used at 10ng/ml and 0ng/ml served as control (serum 
free medium without HMGb1). The absorbance of accumulated MTT solution was measured at 
540nm using the plate reader. The SEM displayed as error bars. The student t-test was used to 
determine P values. n=30 from 8 occasions.   
 
In the higher dose segment, the cells were treated with 1, 5, 10, 50 and 100ng/ml of HMGb1 
(Figure 3.3). All four (1ng, 5ng, 10ng, 50ng) out of five doses significantly triggered the 
proliferation in CCD18 myofibroblast cells. Although, the results from all four (1ng, 5ng, 10ng 
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and 50ng/ml) doses of HMGb1 were statistically significant however 10ng/ml appeared to be the 
most effective dose. The reason for choosing 10ng/ml as most effective dose was the highest 
statistical significance (P<0.001) and lowest SEM value amongst all other doses which triggered 
proliferation. Approximately 30% increase in the proliferation of the myofibroblasts was 
observed when compared to the controls (serum free media) at 96h.  
 
The 10ng/ml treatment with HMGb1 was also carried out on these cells using less exposure 
time (48h) and proliferation was assessed this time using the MTT assay (Figure 3.4). The 
reason for using MTT assay this time was to confirm that proliferative effect observed was not 
an anomaly found with the NRU assay. In addition, MTT being taken up by mitochondrion of 
living cells could measure different endpoints of proliferation. However, this resulted in a very 
similar proliferative response on the cells as seen after the 96h treatment (Figure 3.3).    
 
3.4.2 HMGb1 triggers proliferation in CCD18 myofibroblasts via   
         MEK1/2 pathway 
 
These results show that recombinant HMGb1 can trigger proliferation in CCD18 myofibroblasts, 
but the mechanisms or pathways involved are not known. Therefore, an investigation into the 
involvement of key pathways was carried out.  A number of pathways involving MEK1/2 have 
been implicated in cell proliferation. The MEK1/2 is a type of MAPK/ERK kinase and they have 
been implicated in a variety of proliferation pathways in cancer and normal cells (Liang et al. 
2011; Li et al. 2015; Liu et al. 2015). Therefore, to determine if MEK1/2 is activated during 
HMGb1 induced proliferation, a selective inhibitor of MEK1/2 (U0126) was used. This was 
carried out using the MTT toxicity and proliferation assay.  
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Figure 3.5: Analysis of the toxicity caused by U0126 (MEK1/2 inhibitor) to CCD18 myofibroblast 
cells using MTT assay at 48h. The SEM displayed as error bars. The student t-test was used to 
determine P values. n=12 from 3 occasions.   
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Figure 3.6: The inhibitory effect of U0126 when combined with HMGb1 on CCD18 cells. The 
proliferation triggered by HMGb1 was 1/3 fold compared to the controls (serum free medium 
without HMGb1) in CCD18 myofibroblast cells. U0126 (50µM/L) completely abrogated the 
proliferative effect of HMGb1 in CCD18 cells at 48h when combined with HMGb1 (10ng/ml). The 
SEM displayed as error bars. The student t-test was used to determine P values. n=12 from 3 
occasions.  
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To determine a non-toxic dose of U0126, various concentration of U0126 were used to treat 
CCD18 myofibroblasts for 48h and toxicity was assessed using the MTT assay. The results 
suggested that U0126 (50µM/L) is not toxic to CCD18 myofibroblasts at 48h (Figure 3.5). This 
non-toxic dose (50µM/L) was used to inhibit the MEK1/2 pathway when combined a proliferative 
dose of HMGb1 (10ng/ml) in serum free medium.  The CCD18 myofibroblast cells were treated 
with HMGb1 (10ng/ml) alone (as positive control), in combination with U0126 (50µM/L) or with 
serum free medium only (as negative control) for 48h before assessment using the MTT assay 
(Figure 3.6).  
 
The proliferation triggered by HMGb1 (positive control) was approximately 30% compared to the 
negative control (serum free medium without HMGb1) in CCD18 myofibroblast cells at 48h. 
However, U0126 (50µM/L) completely abrogated the proliferative effect of HMGb1 in CCD18 
cells at 48h when combined with HMGb1@10ng/ml. Therefore, results obtained from MTT 
assays suggested that HMGb1 induced proliferation in CCD18 myofibroblasts involves the 
MAPK/ERK pathway.  
 
 
3.4.3 HMGb1 triggers proliferation in CCD18 myofibroblasts via the     
         PI3K pathway 
 
 
In addition to MEK1/2, role of intracellular signal transducer enzymes (PI3Ks) was explored 
using MTT toxicity and proliferation assays on CCD18 myofibroblasts. PI3Ks are a family 
of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, 
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motility, survival and intracellular trafficking, which in turn are involved in cancer (Foukas et al. 
2010). They have been implicated in variety of proliferation pathways in cancer and normal cells 
(Ohashi et al. 2015; Song et al. 2015).  
                                                           
 
 
Figure 3.7: Statistical analysis of the toxicity caused by LY294002 (PI3K inhibitor) to CCD18 
myofibroblast cells using MTT assay at 48h. The SEM displayed as error bars. The treatment 
with LY294002 was slightly toxic at 5µM/Lat 48h. The student t-test was used to determine P 
values. n=12 from 3 occasions.    
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Figure 3.8: Statistical analysis of inhibitory effect of LY294002 when combined with HMGb1 on 
CCD18 cells. The proliferation triggered by HMGb1 was 1/3 fold compared to the controls 
(serum free medium without HMGb1) in CCD18 myofibroblast cells. The student t-test was used 
to determine P values. This proliferation was statistically significant (P<0.001). The SEM 
displayed as error bars.  
 
Therefore, to investigate if PI3Ks are activated during HMGb1 induced proliferation, a selective 
inhibitor of PI3K (LY294002) was used. In addition, toxicity of LY294002 was determined using 
MTT toxicity assay on CCD18 cells. The results suggested that LY294002 (5µM/L) does not 
cause cell death in myofibroblasts at 48h (Figure 3.7). This non-toxic dose (5µM/L) was used to 
inhibit the PI3K pathway and combined with HMGb1 proliferative dose (10ng/ml) in serum free 
medium. The myofibroblasts cells were treated with HMGb1 (10ng/ml) alone and in combination 
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with LY294002 (5µM/L) for 48h and absorbance of accumulated MTT solution was measured at 
540nm (Figure 3.8).  
 
The results from MTT assays suggested that HMGb1 induced proliferation in CCD18 
myofibroblasts involves PI3K pathway. The proliferation triggered by HMGb1 was 1/3 fold 
compared to the controls (serum free medium without HMGb1) in CCD18 myofibroblast cells. 
However, when combined with HMGb1@10ng/ml, LY294002 (5µM/L) completely abrogated the 
proliferative effect of HMGb1 in CCD18 cells at 48h (Figure 3.8).   
 
3.5 Discussion 
 
Myofibroblasts are present in colon cancer, breast cancer, lung cancer, prostate cancer and 
pancreatic cancer (Martin et al. 1996; Tuxhorn et al. 2002; Allinen et al. 2004; Bailey et al. 2008) 
and they are also useful in predicting the prognostic outcome in response to cancer 
chemotherapy (De Wever and Mareel 2003).  However, the origin of cancer associated 
myofibroblasts is still controversial. Indeed, multiple origins of cancer associated myofibroblasts 
have been suggested such as transition from resident fibroblasts within tumour or from bone 
marrow derived mesenchymal stem cells. It has been proposed that the multiple origin of 
myofibroblasts may be related to the heterogeneous myofibroblasts population observed within 
tumours (De Wever et al. 2008). 
 
Myofibroblasts have been shown to stimulate growth in breast cancer cells in vivo. In addition, 
they have also appeared to promote invasion of breast, pancreas and squamous carcinoma 
cells in vitro (Casey et al. 2008; Hwang et al. 2008). It has been shown that myofibroblasts 
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promote invasive breast carcinoma in situ (Hu et al. 2008). Furthermore cancer epithelial cells 
and their derivatives, including myofibroblasts have shown to promote breast cancer metastasis 
(Muehlberg et al. 2009). In addition, stromal myofibroblasts have been considered as predictors 
of human disease outcome and their abundance is correlated with poor survival in colorectal 
cancer (Tsujino et al. 2007).  
 
 
Several solid tumours including melanoma, prostate cancer, breast cancer, pancreatic cancer 
and colon cancer exhibit markedly elevated levels of HMGb1 (Völp et al. 2006). These elevated 
levels of HMGb1 are associated with tumour formation, proliferation and metastasis and 
chemotherapeutic response (Sims et al. 2009). In addition, HMGb1 is involved in various 
diseases including autoimmune disorders, sepsis and chronic inflammatory disease (Wang et al. 
2004; Sims et al. 2009). HMGb1 has been shown to trigger proliferation in many cells such as 
periodontal ligament fibroblasts, endothelial cells, keratinocytes and glioblastoma cells (Bassi et 
al. 2008; Ranzato et al. 2009; Chitanuwat et al. 2013; Hayakawa et al. 2015). Furthermore, 
HMGb1 has been shown to induce migration in endothelial cells and glioblastoma cells. HMGb1 
activates various signalling pathways such as MAPK-AKT and PI3K (He et al. 2012; Kim et al. 
2012). These pathways play an important role in the proliferation and migration of tumour cells. 
It is evident that HMGb1 activates the PI3K pathway in neutrophils and colon cancer cells 
(Kuniyasu et al. 2003).  
 
The role of HMGb1 in myofibroblasts has not been explored thus far. Considering the 
proliferative effect of HMGb1 on other cell types such as dendritic cells, endothelial cells and 
glioblastoma cells, it was hypothesised that HMGb1 may trigger proliferation in myofibroblasts. 
Therefore, NRU proliferation assay was carried out using recombinant HMGb1 in a range of 
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doses (0-100ng/ml) for 96h. This dose and time range of HMGb1 has been shown to trigger 
proliferation in fibroblasts recently (Chitanuwat et al. 2013). The NRU assay revealed that 
HMGb1 treatment for 96h was able to trigger approximately a 30% increase in proliferation in 
CCD18 myofibroblasts over a range of doses over 96h (0.1ng/ml to up to a concentration of 
50ng/ml) (Figures 3.2 and 3.3). However, 10ng/ml of HMGb1 appeared to trigger proliferation 
with the minimum variation in data (SEM). With 10ng/ml HMGb1, in keeping with the other 
doses within the effective range, an increase of approximately 30% in the cell number was seen 
when compared to the controls (Figures 3.2 and 3.3).  
 
The NRU assay measures viability/proliferation of cells by the ability of the cells to take up the 
neutral red dye into the cellular lysosomes within the cells (Repetto et al. 2008).  However, it is 
prudent to carry out a 2nd viability assay that measures a different endpoint to ensure confidence 
in findings. Unlike NRU assay, MTT assay measure viability/proliferation of cells by the ability of 
the cells to enzymatically reduce MTT solution to a blue crystalline formazan product. The 
previous NRU proliferation assays showed that HMGb1 could trigger proliferation in CCD18 
myofibroblasts over 96h. However, this time the MTT assay was used to assess proliferation at 
48h (HMGb1 10ng/ml). The similar dose (10ng/ml) and exposure time (48h) of HMGb1 has been 
shown to trigger proliferation in smooth muscle cells of atherosclerotic plaques previously (Porto 
et al. 2006). 
 
The results from MTT assay show that HMGb1 (10ng/ml) triggers proliferation in CCD18 
myofibroblast cells at 48h. This proliferation was observed as similar to that observed at 96h 
(approximately a 30% increase in proliferation) (Figure 3.4).  In addition, U0126 (MEK1/2 
inhibitor) and LY294002 (PI3K inhibitor) have been shown to inhibit their respective pathways in 
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24-48 hour in various cell lines including fibroblasts (DeSilva et al. 1998; Wu et al. 2006). Thus, 
proliferation/inhibition assays were carried out using MTT at 48h to ensure sufficient time for 
measurable proliferation and inhibition to occur. The inhibitory effect on proliferation of  cells 
including keratinocytes  and lymphocytes using U0126 and LY294002 has previously been 
described at 48h using 10, 25 and 50µM/L of U0126 (Dolci et al. 2001; Yano et al. 2003) or 1, 5 
and 10µM/L of LY294002 (Dolci et al. 2001; Du et al. 2001; Squires et al. 2003). Using this 
information, MTT assays were carried to find a non-toxic dose in CCD18 myofibroblasts of each 
of the inhibitors at 48h that might be an effective inhibitor. MTT assay revealed that U0126 at 
50µM/L was non-toxic to CCD18 myofibroblasts (Figure 3.5). Similarly, a 5µM/L dose of 
LY294002 appeared to be non-toxic to CCD18 myofibroblasts (Figure 3.7). These non-toxic 
doses were selected to study whether MAPK/ERK (also known as MEK1/2) and PI3K pathways 
are involved in HMGb1 triggered proliferation in CCD18 myofibroblasts. 
 
The CCD18 myofibroblast cells were treated with HMGb1 alone or in combination with U0126 or 
LY294002. The results obtained from MTT assays revealed that U0126 (50µM/L) completely 
abrogated the proliferative effect of HMGb1 on myofibroblasts cells (Figure 3.6). However, a 
slightly toxic effect was also seen using the combination of HMGb1 with U0126 (a reduction of 
about 10% in cell viability compared to control (P<0.05) however, this was not seen when 
CCD18 cells were treated with U0126 (50µM/L) alone. This suggested that U0126 (50µM/L) was 
not toxic to myofibroblasts cells. U0126 is described as a highly selective inhibitor of MEK1/2 
however, its selectivity has been questioned recently by some research groups (Bain et al. 
2007; Qin et al. 2010).  Thus, the marginal toxic effect of combination treatment of HMGb1 and 
U0126 might be linked to the blockade of additional proliferative pathways involved in HMGb1 
induced proliferation in myofibroblasts cells.    
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The proliferation triggered by HMGb1 in CCD18 myofibroblasts was also abrogated by 
LY294002, the selective inhibitor of PI3K (Figure 3.8). LY294002 was non-toxic to CCD18 
myofibroblast cells when used alone at a concentration of 5µM/L (Figure 3.7). This dose of 
LY294002 successfully blocked the proliferative effect of HMGb1 at 10ng/ml on myofibroblast 
cells. The results obtained from MTT assay suggest that MEK1/2 or MAPK/ERK and PI3K 
pathways are involved in HMGb1 induced proliferation in CCD18 myofibroblast cells. These 
results are in line with previous observations establishing these pathways as most common 
signalling pathways involved in the proliferation and migration of various cells including colon 
cancer cells (Greenhough et al. 2007; Lai et al. 2010; Lee et al. 2010). Considering the 
contribution of myofibroblasts in the proliferation of tumours, these results provide a new insight 
of myofibroblasts biology in relation to the tumour microenvironment. The HMGb1 and its role in 
cancer has been explored to some extent, but it would be interesting to see how HMGb1 
influenced normal cells such, as how myofibroblasts can contribute to the tumour spread after 
getting proliferative signals from HMGb1. In this study, an investigation into the role of HMGb1 
in proliferation of myofibroblast cells was carried out and based on the results it is now clear that 
HMGb1 triggers proliferation in myofibroblast cells. In addition, this HMGb1 induced proliferation 
involves the activation of MEK1/2 and PI3K pathways.  
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Chapter 4 
4. Investigation into the release of HMGb1 from cancer       
    cells exposed to various microenvironmental stress   
    conditions 
 
4.1 Introduction  
 
The HMGb1 is a non-histone protein involved in stabilization of nucleosomes and the bending 
of DNA and hence facilitating gene transcription (Lange et al. 2008). HMGb1 binds to the minor 
grove of DNA without sequence specificity, and thereby induces bends in the helical structure of 
the DNA. The formation of HMGb1-DNA complex facilitates interaction between DNA and other 
factors such as p53, NF-kβ, recombination activating proteins 1/2 (RAG1/2) and some hormone 
receptors (Bianchi 2004). Whilst HMGb1 is a nuclear protein, it is released from the cells under 
certain conditions to take part in the inflammatory process. During inflammation, extracellular 
HMGb1 activates infiltrating macrophages via the RAGE receptor.  In addition, activated 
macrophages/monocytes are also responsible for the release of HMGb1 in the extracellular 
milieu (Andersson et al. 2002). Furthermore, HMGb1 is passively released by necrotic cells 
(Huttunen and Rauvala 2004; Andersson et al. 2002).  The release of HMGb1 involves following 
steps; 1) exit from the nucleus to the cytoplasm, 2) translocation from the cytosol in to 
cytoplasmic organelles, and 3) exocytosis. Macrophages/monocytes upon activation by 
proinflammatory cytokines acetylate HMGb1 at lysine-rich nuclear localization sequences.  This 
leads to the translocation of HMGb1 into the cytoplasmic vesicles followed by extracellular 
release (Gardella et al. 2002) 
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Several solid tumours including melanoma, prostate cancer, breast cancer, pancreatic cancer 
and colon cancer exhibit noticeably elevated levels of HMGb1 (Völp et al. 2006; Gnanasekar et 
al. 2009; Kostova et al. 2010). These elevated levels of HMGb1 are associated with tumour 
formation, proliferation and metastasis and chemotherapeutic response (Lotze and Tracey 
2005). It has been suggested that HMGb1 might have a direct impact on migration of cells 
because of its ability to modulate the adhesive properties of the cells and ECM components 
(Ellerman et al. 2007). 
 
Receptor for advanced glycation end products (RAGE) is the most commonly known receptor 
for HMGb1.  The receptor belongs to immunoglobulin superfamily and is expressed in many 
cells including monocytes, macrophages, smooth muscle cells, dendritic cells and endothelial 
cells. RAGE is multi-ligand receptor that can be activated by several ligands including HMGb1. 
However, the effects of this activation are dependent of the type of the cell it is expressed upon.  
Activation of RAGE in monocytes/macrophages has been reported to trigger the inflammatory 
response and to trigger neoplastic transformation and metastasis in neuroepithelial tumour cells 
(Taguchi et al. 2000). It has been shown that RAGE overexpression is associated with chronic 
degenerative disease and cancer (Tanaka et al. 2000; Onyeagucha et al. 2013). The HMGb1-
RAGE complex has recently been shown to enhance ATP production in tumours which then 
facilitates tumour proliferation and migration (Kang et al. 2013). RAGE is not the only receptor 
for HMGb1 and others include the toll-like receptors 2 and 4 (TLR-2 and TLR-4). Park et al. 
(2004) demonstrated that blockage or knockdown of these receptors resulted in decreased 
HMGb1 activation in vitro and in vivo (Park et al. 2004). In addition, HMGb1 has been shown to 
activate TLR-4 and p38MAPK pathways which play an important role in mediating acute lung 
injury (Yang et al. 2013). The effect of extracellular HMGb1 followed by its binding to RAGE and 
TLR-4 which also involves activation of NF-κB has been implicated in tumour cell growth and 
migration (Palumbo et al. 2007). However, the release of HMGb1 in the extracellular 
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environment and subsequent effects on myofibroblast cells in the tumour stroma remain 
unclear. In addition, the release of HMGb1 in response to low glucose conditions has not been 
explored.  
 
4.2   Aims 
 
The aims of this study were to: 
a) Investigate whether HMGb1 is released from HT29 colon carcinoma cells in response to 
different stress conditions such as anoxia and/or the absence of nutrients such as 
glucose or glutamine. 
b) Investigate if the release of HMGb1 is cell line specific or it is a common phenomenon 
that occurs in most of other cancer cell lines. 
c) Investigate if CCD18 myofibroblast cells express RAGE and TLR-4 (receptors for 
HMGb1) and therefore might interact with HMGb1 released from tumour cells.  
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4.3   Material and methods 
4.3.1 Cell culture  
 
Myofibroblasts (CCD18) cells, HT29 colon adenocarcinoma cells, A549 lung cancer cells, 
EJ138 bladder cancer cells and MCF-7 breast cancer cells were cultured in T75 cm2 flasks in 
complete medium (minimum essential medium eagle and RPMI1640) (Sigma Aldrich) 
supplemented with 10% foetal calf serum (FCS) (BioSera) and 1% antibiotic/antimycotic 
solution (100x) (Gibco Ltd) at 37°C, 5% CO2 and 95% humidity as discussed in section 2.2. 
 
4.3.2 Sample preparation  
 
HT29 colon adenocarcinoma cells were seeded into 17 x T25 cm2 flasks at a density of 4.0x105 
per flask and allowed to grow overnight at 37°C, 5% CO2 and 95% humidity. The following day, 
medium was removed and replaced with serum free medium (5ml/flask) and incubated for 24h. 
After 24h, the medium was aspirated off and replaced with fresh medium (RPMI 1640) with 
glucose (9 flasks) and without glucose (8 flasks). The glucose free flasks were either incubated 
in normoxic or anoxic conditions (4 flasks for each condition). The flasks with glucose were also 
treated to the same conditions (4 flasks for each condition). The remaining flask was used as 
day 0 control (serum free medium with glucose).  The medium from this flask was collected into 
a labelled universal tube and stored at -80oC for later analysis. In addition, two flasks of each 
cell types (A549 lung cancer cells, MCF-7 breast cancer cells and EJ138 bladder cancer cells) 
were treated with serum free medium with and without glucose in normoxic conditions for 48h 
and medium were collected in labelled universal tubes and stored at -80oC. In addition, HT29 
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cells were treated with and without glutamine incubated in normoxic conditions for 48h to 
assess the release of HMGb1 in low nutrient conditions. The protocol for the collection of 
medium remained same as discussed in section 2.3.1. The myofibroblast cells (CCD18) were 
treated with serum free medium for one day before incubating in normoxia with and without 
glucose for 24 and 48h. The medium from CCD18 cells were discarded and proteins were 
extracted from the cells to investigate if RAGE and TLR-4 are present on the myofibroblasts. 
This investigation was carried out using western blot analysis.  
 
4.3.3 The extraction of cellular proteins  
 
The extraction of proteins from the flasks of cells (CCD18) was carried out as discussed in 
2.3.2.  
 
4.3.4 Determination of cellular protein concentration 
 
To determine the protein concentration of the cell lysates and conditioned medium, a BioRad 
DC protein assay was used (see section 2.3.3). 
 
4.3.5 Dot Blot analysis for the detection of HMGb1, RAGE and TLR-4  
 
A dot blot analysis was carried out to optimise the concentration of primary antibodies against 
HMGb1, RAGE and TLR-4 (See section 2.3.7). 
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4.3.6 SDS–PAGE and western blot analysis for the detection of  
         HMGb1, RAGE and TLR-4  
 
The protein extracts from CCD18 myofibroblasts and the culture medium from HT29, MCF-7, 
EJ138 and A549 were prepared as described in section 2.3.2 and subjected to western blot 
analysis (section 2.3.4). The samples were incubated with appropriate antibodies listed in 
section 2.7.  
 
4.4   Results  
4.4.1 The release of HMGb1 is triggered by glucose deprivation in   
         HT29 colon adenocarcinoma cells 
 
The extracellular HMGb1 has been shown to play important role in many diseases including 
cancer. A number of cells including inflammatory immune cells actively secrete HMGb1 as an 
immune response (Lu et al. 2014). However, necrotic cells have been reported to release 
HMGb1 passively in the extracellular environment (Scaffidi et al. 2002). In addition, HMGb1 has 
previously been shown to be released from cancer cells in hypoxic conditions (Kang et al. 
2013). However, the release of HMGb1 under low glucose conditions has never been reported. 
It has been established that most solid tumours are acidic and hypoxic at placed within their 
tumour mass (Pellegrini et al. 2014). In addition, low glucose areas are characteristic feature of 
an aggressive tumour mass (Laderoute et al. 2006). Most solid tumours are composed of 
number cells with major part consisting of stromal cells such as myofibroblasts (Micke 2004). 
Thus, it was hypothesised that certain cancer cells may release HMGb1 into their 
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microenvironment and this HMGb1 might stimulate tumour grow by stimulating resident 
myofibroblasts. To this notion, a western blot analysis was developed to investigate if HT29 
colon adenocarcinoma cells release HMGb1 into their culture medium under different stress 
conditions commonly observed in tumour microenvironment.  
 
Our western blot analysis showed that HT29 cell release HMGb1 into their culture medium. This 
release of HMGb1 is triggered by glucose deprivation under normoxic conditions. This study 
compared the release of HMGb1 from HT29 cells under glucose deprivation or normal levels of 
glucose in anoxic and normoxic conditions. Surprisingly, the amount of HMGb1 released from 
the colon adenocarcinoma cell line under normoxic conditions without glucose was greater than 
the anoxic conditions with or without glucose. This release was triggered between 24 to 48h.  
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Figure 4.1: Western blot analysis showing release of HMGb1 in the culture medium of HT29 
cells. The samples were normalised to the lowest protein content in a sample. The recombinant 
HMGb1 was used at 50ng (total protein loaded). The assay was repeated more than 3 times. 
A. Recombinant HMGb1  
B. 24N+ (Normoxia with glucose)  
C. 24N-  (Normoxia without glucose) 
D. 24A+ (Anoxia with glucose) 
E. 24A-  (Anoxia without glucose) 
F. 48N+ (Normoxia with glucose) 
G. 48N-  (Normoxia without glucose) 
H. 48A+ (Anoxia with glucose) 
I. 48A-  (Anoxia without glucose) 
 
 
For western blot analysis, recombinant HMGb1 (50ng) was used as a positive control. Using 
western blot, recombinant HMGb1 and the HMGb1 in our samples was detected at 28kDa. The 
lack of glucose even in presence of oxygen had a major impact on the release of HMGb1. This 
was compared with the impact of glucose containing medium treatment in presence of oxygen. 
A. Recombinant 
HMGb1 
B. 24N+ 
C. 24N- 
D. 24A+ 
E. 24A- 
F. 48N+ 
G. 48N- 
H. 48A+ 
I. 48A- 
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There appeared to be a major quantitative difference amongst these two conditions with more 
HMGb1 being released when cells were treated with no glucose conditions (Figure 4.1). In 
addition, the presence of glucose appeared to trigger the release of HMGb1 but only after 24h 
(Figure 4.1). Interestingly, figure 4.1 also shows that harsher condition such as lack of oxygen 
(anoxia) did not show any significant impact on the release of HMGb1 when compared to 
oxygen rich conditions.  
 
4.4.2 The release of HMGb1 in response to lack of glucose is a  
          phenomenon in common with other cancer cell types 
 
Western blot analysis from this study showed that glucose deprivation triggers the release of 
HMGb1 in HT29 cells (Figure 4.1). This release was greater than the release of HMGb1 in 
response to anoxia, a condition which is a known cause of HMGb1 release. To investigate 
whether this HMGb1 release in response to low glucose levels was specific to the colon 
adenocarcinoma cell line or whether it is a common phenomenon, other cancer cells were 
analysed. MCF-7 (breast adenocarcinoma), EJ138 (bladder carcinoma) and A549 (lung 
carcinoma) cells were treated with similar conditions and their culture medium at 48h were 
collected. A western blot was carried out to determine whether these cell lines followed the 
same pattern of HMGb1 release in response to glucose deprivation in HT29 cells.  
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Figure 4.2: Western blot analysis showing the release of HMGb1 from three different cancer 
cell lines in normoxia. The cells were treated with medium with glucose and without glucose for 
48h. The protein concentration was normalised using BioRad protein assay in both conditions 
and compared.  
 
The western blot analysis suggested that glucose deprivation triggers the release of HMGb1 
from some of these cell lines. The MCF-7 and A549 cells followed the same pattern with an 
increased amount of HMGb1 released in response to glucose starvation. The MCF-7 cells 
showed the greatest difference in the quantity of HMGb1 released. There was apparently no 
HMGb1 being released from the cell line in normoxia with normal glucose levels at 48h and yet 
a very strong band for HMGb1 was seen from the medium of the glucose starved cells in 
normoxia at the same time point. However, no major difference in HMGb1 release was 
observed between the normal and the glucose starved EJ138 cells in normoxia at 48h (Figure 
4.2).  Therefore, 3 out 4 cell lines investigated appeared to follow the same pattern of HMGb1 
release in normoxic conditions without glucose.  
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4.4.3 Glutamine deprivation also stimulated the release of HMGb1 
 
The results from western blot analysis suggested that HMGb1 was released from a selection of 
cancer cells including HT29, MCF-7, and A549 in glucose deprivation conditions under 
normoxia. However, whether HMGb1 also released in response to other nutrient deprived 
conditions is unclear.  Therefore, the release of HMGb1 from HT29 cells was compared 
between normal and glutamine deprived conditions at 48h. 
 
The western blot was set up in two sets; one was to compare the release of HMGb1 in 
response to glutamine deprived versus normal medium. The other one was to compare HMGb1 
release in medium deprived of glutamine versus glucose. The results from the first set of 
western blot suggest that HMGb1 is released in glutamine deprived culture medium of HT29 
cells (Figure 4.3 A).This release of HMGb1 was compared to glutamine deprived and glutamine 
containing medium. It was found that there was no major difference in the release of HMGb1 in 
glutamine deprived conditions compared to normal glutamine conditions. However, the second 
set of western blot comparing the release of HMGb1 between from HT29 cells in glucose and 
glutamine deprived medium revealed that only glucose deprivation triggers the release of 
HMGb1 (Figure 4.3 B).  
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A) 
                        
                                                                  
    
 
 
 
B) 
 
 
 
 
 
 
Figure 4.3: A) Western blot showing release of HMGb1 in the culture medium from HT29 cells 
under glucose and glutamine deprived and normoxic conditions for 48h. The samples were 
equalised to the lowest protein content in each segment (glutamine and Glucose). B) Western 
blot analysis on samples equalised to lowest protein content in one sample (all 4 samples were 
equalised using Biorad protein assay) 
 
 
 
 
 
HMGb1 (28kDa) 
             -          +                  -          + 
             Glutamine                          Glucose 
      +               -              +             - 
 
Glutamine                                Glucose 
HMGb1 (28kDa) 
Normalised Normalised 
Normalised to lowest protein content 
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4.4.4 The CC18 myofibroblast cells express advanced glycation end  
         product (RAGE)  
 
Receptor for advanced glycation end products, a multiligand receptor and is also a receptor for 
HMGb1. The HMGb1 and RAGE complex has been implicated in many diseases including 
cancer (Nienhuis et al. 2009; Sims et al. 2009; Dzaman et al. 2015). The results from western 
blot analysis confirmed the presence of HMGb1 in the conditioned medium of cancer cells 
including HT29 cells. This study has shown that recombinant HMGb1 triggers proliferation in 
myofibroblasts cells. Therefore, there is a possibility that HMGb1 induced proliferation of 
myofibroblasts cells involves activation of RAGE which might be present on the membrane of 
CCD18 myofibroblast cells.  
 
The CCD18 myofibroblast cells were treated with glucose free and normal glucose conditions in 
normoxia and anoxia for 24h and 48h and the cell lysates were collected for protein analysis. 
The protein concentration was equalised so that all samples contained the same concentration 
of total cellular protein before western blot analysis on all samples. Detection of GAPDH was 
used as loading control for the samples. The results from western blot analysis suggested that 
RAGE is present on myofibroblasts cells. The samples included with and without glucose in 
normoxic and with anoxic conditions. All conditions including 48h normoxia without glucose 
showed some levels of RAGE. There was no significant difference observed between any 
specific treatment but relatively higher levels of RAGE appeared to be correlated with high 
glucose levels (Figure 4.4). The ligand HMGb1 controlled upregulation or downregulation of 
RAGE would be difficult to investigate in this case because RAGE is a multiligand receptor and 
might be interacting with other ligands as well as HMGb1. Similarly, HMGb1 might be 
interacting with other receptors which may be present on myofibroblasts. Therefore, HMGb1 
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signalling in response to glucose deprivation might involve one or more other receptors which 
are present on myofibroblasts.  Although, this study was focused on investigating similar 
conditions which triggered the release of HMGb1 from HT29 cells but there was always a 
possibility for HMGb1 binding to certain receptors which may not be upregulated in similar 
conditions as those with HT29 cells. Those receptors may include RAGE and TLR-4 amongst 
others. However, this experiment confirmed that CCD18 myofibroblast cells express RAGE in 
all treatment conditions (Figure 4.4).  
 
 
 
                         
                         
Figure 4.4: Western blot confirming the presence of RAGE in the CCD18 cell lysates. The cells 
were treated with different conditions for 24 and 48h. The protein concentration was normalised 
using BioRad assay and GAPDH was used as loading control. 
A. 24N+ (Normoxia with glucose) 
B. 24N-  (Normoxia without glucose) 
C. 24A+ (Anoxia with glucose) 
D. 24A-  (Anoxia without glucose) 
E. 48N+ (Normoxia with glucose) 
F. 48N-  (Normoxia without glucose) 
G. 48A+ (Anoxia with glucose) 
 
 
           A             B                C              D            E               F               G 
RAGE 
GAPDH
H 
42KDa 
40KDa 
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4.4.5 The CCD18 myofibroblast cells express toll like receptor-4  
        (TLR-4)  
 
It has been shown that the interaction between HMGb1 and TLR-4 triggers signalling pathways 
that may activate NF-Kb. The activation of NF-kB has been implicated in tumour cell survival 
and migration (Wu and Zhou 2010). In addition, TLR-4 mediated signalling has been shown to 
play important role in stimulating myofibroblasts (Pulskens et al. 2010). The western blot 
analysis has confirmed that myofibroblasts cells express RAGE. RAGE is not the only receptor 
for HMGb1 and TLR-4 has also been reported to interact with HMGb1. Therefore, a western 
blot was developed to investigate if CCD18 myofibroblast cells also express TLR-4. 
 
 
                                         
 
Figure 4.5: Western blot confirming the presence of TLR-4 in CCD18 cell lysates. Lane A and 
lane B showing TLR-4 in cell lysates of CCD18 treated with glucose and without glucose in 
serum free medium for 24h followed by 22h treatment with glucose free and glucose containing 
serum free conditioned medium from HT29 cells. Lane C and Lane D showing TLR-4 under 48h 
treatment with glucose free and glucose containing serum free medium. Predicted molecular 
weight of TLR-4 is 95 kDa however soluble TLR-4 lacking a transmembrane domain has been 
detected at 70kDa previously (Hyakushima, Mitsuzawa et al. 2004)  
 
A. 24N+ followed by treatment with conditioned media from HT29 cells for 22h 
B. 24N- followed by treatment with conditioned media from HT29 cells for 22h 
C. 48N+ 
D. 48N- 
 
TLR-4 (70kDa)         TLR-4 (95kDa) 
  A                        B                    C                       D 
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The results from western blot confirmed that myofibroblasts cells express TLR-4. The cells were 
treated with glucose and without glucose for 24h in the absence of serum. The expression of 
TLR-4 was observed in both conditions (Figure 4.5).The cells were also treated with serum free 
medium with glucose for 24h followed by 22h treatment with medium taken from HT29 grown 
for 48h in the absence of glucose. As western blot analysis showed that TLR-4 is present in 
stress conditions such as lack of glucose and then it is possible that it might interact with 
HMGb1 to initiate signalling cascade in microenvironment. The TLR-4 was observed in at two 
different places at 95kDa with 48h treatment with glucose free and glucose rich conditions and 
70kDa with fresh medium and HT29 conditioned medium treatment (24h+22h) (Figure 4.5). The 
predicted molecular weight of TLR-4 is 95kDa and therefore the 70kDa could be proteolytic 
degraded product that lacks transmembrane domain. The soluble TLR-4 which lacks 
transmembrane domain has been identified at 70kDa previously (Hyakushima et al. 2004).  
 
4.5   Discussion  
 
Tumour hypoxia facilitates the release of intracellular moieties including HMGb1 from tumours.  
It has also been shown that hypoxic regions of tumours attract macrophages that have strong 
pro-angiogenic properties which then facilitate the release of HMGb1. This facilitates more 
effective proliferation and metastatic spread in tumours (Ellerman et al. 2007).  There is an 
increasing body of evidence that supports the hypothesis that neoplastic tissues utilise a large 
quantity of glucose. The effect of glucose deprivation and acidosis has been shown to increase 
metastasis in murine tumour cell lines in vivo. However, the underlying mechanism of glucose 
deprivation induced metastatic spread remains unknown (Schlappack et al. 1991; Xie and 
Huang 2003). Glioblastoma cells do not release HMGb1 in their culture medium. However, 
118 
 
necrotic glioma cells can release HMGb1 after its translocation from nucleus to cytosol (Bassi et 
al. 2008). The release of HMGb1 from immune cells as danger signal is well documented 
(Manfredi et al. 2009; Pisetsky 2011; Ganz et al. 2015). However, the release of HMGb1 from 
cancer cells under glucose starving conditions has, so far, not been reported. 
 
A western blotting method was developed to detect the release of HMGb1 from HT29 cells.  
The western blot results showed that HMGb1 is released from HT29 cells when exposed to 
different stress conditions such as anoxia and/or the absence of glucose. Interestingly, absence 
of glucose appeared to stimulate the release of HMGb1 even in presence of oxygen at early 
time points (24 to 48h) in our system (Figure 4.1). This release of HGMb1 was compared to the 
release of HMGb1 in absence of oxygen. It was found that glucose deprivation is the main 
stimulus which facilitates the release of HMGb1 from HT29 cells.   
 
The release of HGMb1 in anoxic conditions though appeared to be time dependent but it was 
slower than the normoxic conditions with glucose starvation. In addition, in an attempt to 
investigate the release of HMGb1 at higher time points (72 and 96h) it was found that number of 
cells were floating in the flasks. These cells were presumed to be dead cells. In that case, even 
if HMGb1 was released, being a nuclear protein, it was apparent that HMGb1 would have 
passively been released or spilled out from the dead cells into the culture medium. Therefore, 
carrying out an investigation using western blot would not represent the true data as actively 
and passively released HMGb1 can not be differentiated in terms of structure and molecular 
weight. Therefore, a western blot was not carried out on those samples.  
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The other aim was to investigate whether this release of HMGb1 is cell line specific or it’s a 
common phenomenon that occurs in other cell lines derived from other types of tumour. The 
hypoxia induced HMGb1 release has been seen in a number of cells such as RAW264.7 
macrophages, WM9 melanoma cells and hepatocytes (Wang et al. 2004; Tsung et al. 2007; Ito 
et al. 2007). The results from western blot analysis showed that the release of HMGb1 under 
glucose free normoxic conditions is not cell line specific and other cells such as MCF-7 and 
A549 followed the same pattern. However, EJ138 did not appear to release more HMGb1 in 
glucose free conditions. The levels of HMGb1 observed in the culture medium taken from 
EJ138 were not different in both glucose containing and glucose free conditions.  
 
It has been documented that hypoxic or semi hypoxic regions inside the tumours are glucose 
deprived. However, glutamine is also an important nutrient for the cells to compete their cycle. 
The nutrient deprived conditions such as lack of glutamine in solid tumours have been shown to 
induce autophagy in the cells which in turn helps tumour cells to proliferate in the 
microenvironment (Ye et al. 2010). It has been shown that the glioblastoma cells that are 
destined to die (autophagy) release HMGb1 in their culture medium without the lysis of 
membrane or necrosis (Thorburn et al. 2008). Therefore, there is a possibility that HT29 cells 
were undergoing autophagy but it can not be confirmed because of poor understanding of the 
mechanism of autophagic cell death. However, the drivers of autophagic cell death such as lack 
of nutrients (glutamine) and oxygen were tested. Glutamine has been considered as major 
regulator of autophagy and lack of glutamine may promote cell death via apoptosis (Sakiyama 
et al. 2009). Therefore, it was also investigated whether this release of HMGb1 was triggered by 
absence of the nutrient glutamine or whether release was specific to the absence of the nutrient 
glucose. The results from our western blot showed that HMGb1 is released from both glutamine 
deprived and glutamine containing conditions and there was no major difference in release 
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observed between the two conditions. However, when glutamine deprived and glutamine 
containing conditions were compared with glucose deprived and glucose containing conditions, 
it was found that glucose deprived conditions serve as major stimulus which facilitates the 
release of HMGb1. These findings are novel and have not been published thus far. 
 
Receptor for advanced glycation end products (RAGE) is the most commonly known receptor 
for HMGb1. RAGE is multi-ligand receptor, expressed in many cells including monocytes, 
macrophages and smooth muscle cells can be activated by several ligands including HMGb1.  
The activation of RAGE in monocytes/macrophages has been reported to trigger the 
inflammatory response and to trigger neoplastic transformation and metastasis in 
neuroepithelial tumour cells (Taguchi et al. 2000). A recent study has shown that HMGb1 binds 
to RAGE and not to the TLR-4 to promote resistance to Melphan by inducing beclin-1 
dependent autophagy (Tang et al. 2010). The data from our proliferation assays demonstrated 
that HMGb1 triggers proliferation in myofibroblasts cells where blocking both MEK1/2 and PI3K 
pathways with selective inhibitors abrogated the proliferative effect of HMGb1 in CCD18 
myofibroblast cells (Figure 3.6 and 3.8). Recently, it has been shown that HMGb1-RAGE 
complex increases the production of ATP, which is required by tumour cells to grow and migrate 
to the distant sites. This production of ATP was blocked by either inhibiting RAGE or HMGb1 by 
immunoneutralising antibodies which resulted in diminished proliferation and migration of 
tumour cells (Kang et al. 2013). The data from our western blot suggested that RAGE is 
expressed on myofibroblasts cells.  
 
Although, the expression of RAGE was not correlated with the release of HMGb1 in different 
stress conditions from cancer cells but it was detected in all stress conditions such as glucose 
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deprivation and/or anoxia. Thus, there is a possibility for the activation of HMGb1-RAGE and 
subsequent activation of downstream signalling which facilitates proliferation in myofibroblasts 
cells such as activation of MAPK/ERK pathway in the HMGb1 induced proliferation in 
myofibroblasts shown in this study.  Recently, it has been shown that RAGE expression is 
upregulated at various stages of transdifferentiation from hepatic stellate cells (HSCs) to 
myofibroblasts (Wang et al. 2013). However, here it is not confirmed yet whether HMGb1 
induced proliferation of myofibroblasts involves activation of HMGb1-RAGE complex. The 
HMGb1-RAGE complex has been successfully detected by co-immunoprecipitation technique 
recently (Lai et al. 2013; Kang et al. 2014). Therefore, to further validate the interaction of 
RAGE and HMGb1 to trigger proliferation in myofibroblasts, co-immunoprecipitation should be 
carried out myofibroblasts cell lysates followed by affinity chromatography to elute RAGE or 
HMGb1 or both. The co-immunoprecipitation is a technique which detects the interaction of a 
protein with other proteins in a sample (Kaboord and Perr 2008).  
 
RAGE is not the only receptor for HMGb1 and others include the toll-like receptors 2 and 4 
(TLR-2 and TLR-4). Park et al. (2004) demonstrated that blockage or knockdown of these 
receptors resulted in decreased HMGb1 activation in vitro and in vivo (Park et al. 2004). The 
activation of HMGb1-TLR-4 complex has been shown to trigger migration in HSC cells via the 
activation of PI3K-AKT pathway (Wang et al. 2013). The results from our western blot 
suggested that TLR-4 is present on myofibroblasts cells treated with both conditions i,e. glucose 
containing and glucose deprived conditions for 48h. In addition, we also investigated whether 
TLR-4 is expressed on the CCD18 cells treated with serum fee medium for 24 hr then treated 
for 22h with used serum free medium taken from HT29 after 48h. These conditions mimic the 
migration assay conditions where inhibition TLR-4 significantly affected the migration response 
in myofibroblasts cells (explained in chapter 5).  
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The results from our western blot suggested that TLR-4 is present on the myofibroblasts cells 
that underwent treatment mimicking (treatment with HT29 culture medium) the migration assay 
treatment. However, the protein bands for TLR-4 were also observed at 70kDa which is 
presumably a proteolytic degraded product of TLR-4. This 70kDa band corresponding TLR-4 
has previously been observed by others (Hyakushima et al. 2004). The role of HMGb1-TLR-4 
complex has been implicated in predicting the outcome of cancer chemotherapy. The activation 
of this complex is correlated with relapse after the anthracycline based chemotherapy in breast 
cancer patients (Apetoh et al. 2007). The activation of HMGb-TLR-4 complex on dendritic cells 
was detected by co-immunoprecipitation technique (Apetoh et al. 2007). Therefore, it would be 
logical approach to apply co-immunoprecipitation to selectively detect the HMGb-TLR-4 
complex in myofibroblast cell lysates. This would further confirm whether HMGb1 induced 
proliferation and migration of myofibroblasts cells involved the activation of HMGb1-TLR-4 
complex. 
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Chapter 5 
5. Role of HMGb1 in myofibroblasts migration and   
    invasion  
 
5.1 Introduction  
 
Presence of stromal cells such as fibroblasts and myofibroblast in solid tumours plays an 
important role in predicting the metastatic behaviour of solid tumours. It has been established 
that stromal cells play important roles in carcinogenesis. The stromal myofibroblasts have been 
considered as predictors of human disease outcome and their abundance is correlated with 
poor survival in colorectal cancer (Tsujino et al. 2007). The likely role of myofibroblasts in 
tumour invasion has been explored in the past and it was found that the myofibroblasts 
population gradually increases with the invasive stages of many cancers (Nakayama et al. 
1998). The expression of α-SMA, which is a biomarker for myofibroblasts, has been correlated 
with enhanced metastatic spread of tumours whose characterisation involves CAFs.  For 
example, an increased expression of α-SMA has been seen in fibroblasts present in HER2 
breast cancers (Toullec et al. 2010).  
 
 
There is evidence that support the involvement of stromal myofibroblasts in tumour 
development. For example, myofibroblasts have been shown to stimulate proliferation in breast 
cancer cells in vivo (Khanna et al. 2015). In addition, they have also been shown to promote 
invasion of breast, pancreas and squamous carcinoma cells in vitro (Casey et al. 2008; Hu et al. 
2008; Hwang et al. 2008). Furthermore, mesenchymal cells and their derivatives, including 
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myofibroblasts, have been shown to promote breast cancer metastasis. The myofibroblasts 
population was significantly high in breast adenocarcinoma and lung cancer that metastasised 
to lymph nodes compared to the non-metastatic tumours. This suggested that myofibroblasts 
contribute toward the spreading of tumours through metastasis (Toullec et al. 2010). Cancer 
cells have been shown to stimulate stromal cells such as myofibroblasts to produce proteases 
(Tuxhorn et al. 2002; Anborgh et al. 2010). These proteases cleave ECM components and 
remodel the ECM in the microenvironment (Hinz et al. 2012). A number of protease have been 
shown to degrade ECM in the tumour microenvironment however, gelatinase (MMP-2) and 
MMP-9 are two major proteases released from myofibroblasts and have been shown to 
degrade basement membrane (Cheng and Lovett 2003; Takahra et al. 2004). 
 
 
The cytokine TGF-β is present in exosomes which are secreted by most cell types including 
cancer cells trigger the conversion of fibroblasts to myofibroblasts at distant organs. It has also 
been suggested that TGF-β might facilitate metastasis by stimulating cells to produce 
fibronectin. However, tumour cells may (also) move along with myofibroblasts to the distant 
sites, such as the lungs. These migrated myofibroblasts have been shown to produce pro-
survival signals in the lung site (Duda et al. 2010). Therefore, transformed fibroblasts or cancer 
associated myofibroblasts may influence tumour microenvironment and may contribute towards 
malignant transformation in solid tumours. Therefore, it is logical to investigate the role of 
HMGb1 in myofibroblasts which may be linked with invasion and metastasis of tumour cells.  
 
Necrotic areas are characteristic features of rapidly growing tumours. The necrotic areas within 
tumour not only produce angiogenic factors such as VEGF but also attract macrophages. In 
stress conditions such as necrosis, these macrophages release HMGb1 within the 
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microenvironment (van Beijnum et al. 2006). Several solid tumours including melanoma, 
prostate cancer, breast cancer, pancreatic cancer and colon cancer exhibit markedly elevated 
levels of HMGb1 (Völp et al. 2006). These elevated levels of HMGb1 are associated with 
tumour formation, proliferation and metastasis and chemotherapeutic response. In addition, 
presence of HMGb1 in the extracellular medium of cells is indicative of stress conditions (Lotze 
and Tracey 2005).  
 
 
The direct inhibition of HMGb1 with immunoneutralising antibodies has been reported to inhibit 
angiogenesis in vivo and in vitro (Van Beijnum et al. 2006). The HMGb1 interacts with RAGE, 
TLRs (TLR-2 and TLR-4) and may be with other unknown receptors and activates various 
factors and kinases such as NF-κB and MAPK. It has been shown that HMGb1 can increase 
the metastatic potential of tumour cells by activating NF-κB pathway (Sasahira et al. 2008). In 
addition, HMGb1 can modulate the adhesive properties of cells and ECM components and thus 
can directly affect the migration of cells (Ellerman et al. 2007).   
 
 
The HMGb1 activates various signalling pathways that involve the activation of MAPKs, AKT 
and PI3K. These protein kinases play an important role in the proliferation and migration of 
tumour cells. Supporting evidence includes HMGb1 activated PI3K pathway in neutrophils and 
colon cancer cells (Kuniyasu et al. 2003). In addition, HMGb1 has been shown to induce TLR-4 
mediated activation of MyD88-IRAK4-p38 and Myd88-IRAK4-AKT pathways (Fan et al. 2007). 
These pathways have been implicated in tumour cell proliferation and survival. The HMGb1-
RAGE complex has been shown to activate NF-ƘB, Jun N terminus kinase (JNK) and ERK1/2 
pathways (Degryse et al. 2001). The activation of JNK is correlated with an increase in cell 
migration in different cell types including rat bladder tumour cells, keratinocytes and human 
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dermal fibroblasts. It has also been shown that MEK1 which is an upstream kinase in the JNK 
signalling pathway is essential for cell migration (Van Beijnum et al. 2008).  
 
The data presented in chapter 3 suggested that HMGb1 triggers proliferation in myofibroblasts. 
This proliferation was inhibited by U0126 and LY294002 selective inhibitors of MEK1/2 and 
PI3K respectively. It has been established that HMGb1 is released in hypoxia, which is 
characteristic feature of most solid tumours (Tsung et al. 2007). Glucose deprivation is also a 
hallmark of tumour microenvironment. The central core of most solid tumours is characterised 
by lack of glucose and acidosis (Cuvier et al. 1997). Glucose deprivation in the solid tumour 
microenvironment and its consequences within and outside tumour microenvironment are 
largely unexplored. The data presented in chapter 4 indicates that HMGb1 is released from 
cancer cells in glucose deprived conditions and not from depravation of the nutrient glutamine. 
Previous studies have shown a correlation between myofibroblasts and metastasis in many 
solid tumours including breast cancer (Allinen et al. 2004; Muehlberg et al. 2009). Thus, there is 
a possibility that HMGb1 once released from cancer cells might influence the other stromal cells 
such as myofibroblasts to migrate and invade. In addition, MAPKs, which play a central role in 
migration of many cells including fibroblasts, might have a role in migration of myofibroblasts.  
 
The HMGb1 and its interaction with RAGE and TLRs have important roles in intracellular 
signalling of various pathways including PI3K (Fan et al. 2007). Therefore, neutralising 
antibodies to these receptors will be used to confirm their role in migration and invasion of 
myofibroblasts 
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5.2   Aims and objectives  
 
The aims of this study were to; 
 
a) Investigate if glucose deprived conditioned medium of HT29 cells can induce migration 
and invasion in CCD18 myofibroblast cells. 
b) Compare the impact of used medium, derived from HT29 cells deprived of glucose or 
rich in glucose with fresh medium rich in glucose on CCD18 myofibroblast cells 
migration and invasion. 
c) Investigate whether recombinant HMGb1 can induce migration in myofibroblasts cells 
d) Investigate whether HMGb1 present in the conditioned medium of HT29 cells is 
responsible for apparent migration and invasion in myofibroblasts.  
e) Investigate whether inhibiting HMGb1 in the conditioned medium of HT29 cells by anti-
HMGb1 neutralizing antibody can reduce migration and invasion in CCD18 cells. 
f) Investigate whether Inhibition of RAGE by neutralizing antibodies can have negative 
impact of myofibroblasts migration and invasion.  
g) Investigate whether inhibition of TLR-4 results in reduction in myofibroblastic migration 
and invasion.  
h) Investigate whether MEK1/2 and PI3K pathways are involved in HMGb1 induced 
migration and invasion in myofibroblasts. 
i) Investigate whether MMP-2 and MMP-9 are released from CCD18 myofibroblast cells 
following the treatment with HMGb1 containing conditioned medium collected from HT29 
cells. 
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5.3 Material and Methods  
5.3.1 Cell culture  
 
The CCD18 myofibroblast cells were cultured in T75 cm2 flasks in complete medium (minimum 
essential medium eagle) supplemented with foetal bovine serum (10% v/v). The cells were 
passaged when they had reached about 80-90% confluence. In order to carry out migration or 
invasion assays, the myofibroblast cells were first serum starved for 24h before they were used. 
The cells were dislodged from flasks using versene. Versene (1x) is less aggressive than 
trypsin and was used to dissociate the cells in the flask before plating them onto the 24-well 
plate. Versene is a chelating agent that binds to calcium and prevents joining 
of cadherins between cells thereby prevents clumping of cells in the medium. The cells 
suspension in versene was diluted with serum free medium to a concentration of 4.0x104 cells 
per ml for use in migration assays or 6.0x104 cells per ml for used in the invasion assays. 
 
5.3.2 Migration assay 
 
HT29 colon adenocarcinoma cell lines were seeded in 2xT75cm2 (2x106 cells per ml). Both 
flasks were incubated over night at 37°C, 95% humidity and 5% CO2 to allow the cells to 
adhere. The following day, the complete medium was aspirated off and cells were washed twice 
with PBS. The medium on the cells was replaced with serum free medium with glucose in one 
flask and without glucose in the other flask. After 48h, the conditioned medium from both flasks 
were collected into labelled universals and used as potential chemoattractants for the migration 
assay.  
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The CCD18 cell suspension was made in serum free medium (4.0x104 per ml) (see section 
5.2.1 above).  The CCD18 myofibroblast cells were then seeded (0.5ml per insert) in 2x2 
chamber inserts (Biocoat®, 8µm pores) which were then transferred to 4 wells of the 24 well 
plate and ensured that insert bottom is touching the HT29 conditioned medium (0.75ml per well) 
in the wells. The plate was incubated for 20h in the incubator at 37°C, 95% humidity and 5% 
CO2.  The CCD18 cell suspension in the inserts and media at the bottom chamber were 
supplemented with antibodies and inhibitors to investigate the various pathways involved in 
myofibroblast migration (see chapter 2, table 2.7).  
 
After 20h of incubation period, plates were removed and cells were stained (QuickDiff) for 
counting. The images of random fields of vision were captured from each membrane. The cells 
that had migrated through the membrane were counted using ImageJ cell counter software and 
the average of the 5 fields of vision for each membrane calculated.   
 
5.3.3 Invasion assay  
 
The invasion assays for CCD18 myofibroblasts were performed using 8µm pore matrigel matrix 
Biocoat® inserts according to the manufacturer’s instruction (Becton Dickinson). The CCD18 
cell suspension was made in serum free medium (6.0x104 per ml).  The myofibroblasts cells 
were plated onto (0.5ml per insert) inserts in a 24-well plate supplied by the manufacturer.  The 
inserts were put into the wells of 24-well plate. HT29 conditioned medium was used as 
chemoattractant and plated onto the lower chamber (0.5ml) and ensured that inserts were 
touching the conditioned medium (see section 2.4). The plate was incubated for 22h in the 
incubator at 37°C, 95% humidity and 5% CO2.  The myofibroblasts invasion, in response to the 
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conditioned medium with and without various inhibitors and antibodies were determined by their 
inclusion in the lower chamber of the 24-well plate. Cells invaded through the matrigel matrix 
membrane were detected on the lower surface by using ReaStain Quick-Diff staining method 
and visualised at x20 magnification under a microscope. The CCD18 cell suspension in the 
inserts and media at the bottom chamber were supplemented with antibodies and inhibitors to 
investigate the various pathways involved in myofibroblast invasion (see table 2.7) 
 
5.4 Results  
 5.4.1 Culture medium from HT29 cancer cells starved of glucose  
         triggers migration in CCD18 myofibroblast cells 
 
The glucose deprivation has been considered as hallmark in most solid tumours and has been 
reported to induce migration of cancer cells. The western blot results discussed in chapter 4 
suggested that HMGb1 is released from cancer cells in glucose deprived conditions. However, 
the subsequent effect on tumour stromal cells such as myofibroblasts has not been explored. 
The myofibroblasts are stromal cells and constitute a major part of tumour stroma. In addition, 
they have been found in abundance at metastatic sites of solid tumours. Therefore, it is 
hypothesised that HMGb1 once released from cancer cells, reaches to the stroma to influence 
myofibroblasts to proliferate, migrate and invade along with neighbouring cancer cells by 
digesting the basement membrane. This might allow cancer cells to escape from their original 
location to the distant organs.  
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A migration assay was set up according to the instructions described in method section (section 
5.2). HT29 colon cancer cells were grown in medium containing no glucose for 48h.  This 
medium was then collected from the HT29 cells. This HT29 conditioned medium was used as 
chemoattractant as this was shown to contain the highest levels of HMGb1 when compared to 
medium that had been used on HT29 cells containing glucose or fresh unused medium with or 
without glucose (Chapter 4). This conditioned medium served as positive control (therefore 
counted as 100% migration) and was compared to myofibroblast migration in response to 
conditioned medium that contained glucose or the fresh serum free medium with and without 
glucose. The results obtained from this migration assay suggest that HT29 cells undergoing 
glucose deprivation release chemoattractants that trigger migration in myofibroblasts cells. In 
addition, conditioned medium with glucose does trigger migration in myofibroblasts cells; 
however, this migration was approximately 60% less than the conditioned medium without 
glucose at 100% (Figure 5.1 A). In addition, the effects of fresh serum free medium with and 
without glucose were examined. A negligible number of myofibroblasts cells migrated across 
the 8µm pore membrane when exposed to the fresh serum free medium with and without 
glucose (Figure 5.1 D and E). The data suggests that absence or presence of glucose in a fresh 
medium does not influence the myofibroblasts cells to migrate. All these results are statistically 
significant (Figure 5.1A). 
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D) Serum free fresh medium with glucose           E) Serum free medium without glucose   
      
 
Figure 5.1: CCD18 myofibroblast cells migration assay in response to HT29 conditioned 
medium. A) The migration assay carried out using HT29 conditioned medium as 
chemoattractant. The HT29 conditioned medium (-glucose) served as control. The conditioned 
medium with glucose and fresh serum free medium with and without glucose were compared to 
the control (100%). The assay was carried out three times with 2 inserts per condition per 
occasion (5 random fields of vision counted per insert). Student’s t-test was used to determine 
statistical significance of the results. SEMs were displayed as error bars.  
 
Typical microscope images captured showing the underside of the membrane after completion 
of the migration assay.  Cells that had migrated though the 8µm pores of the membrane were 
stained blue using the ReaStain Quick-Diff staining method.  The white dots are 8µm pores 
through which cells have not migrated. B) Representative images from migration assays 
showing cells migrated in response to conditioned medium without glucose (Control=100%), C) 
cells migrated in response to the conditioned medium with glucose, D) cells migrated in 
response to fresh serum free medium with glucose and E) cells migrated in response to fresh 
glucose free and serum free medium. Cells that had migrated on these and other images were 
counted and the results were presented in A) of this figure. The photographs were taken under 
x20 magnification.  
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5.4.2 HMGb1 released from HT29 colon adenocarcinoma cells triggers   
         migration in CCD18 myofibroblasts  
 
The results discussed in chapter 3 suggested that recombinant HMGb1 triggers proliferation in 
CCD18 myofibroblast cells in a dose dependent manner. In addition, results from western 
blotting suggested that HMGb1 is released from HT29 and other cancer cells including MCF-7 
and A549 cells under glucose deprivation normoxic conditions. To investigate whether HMGb1 
present in the culture medium of HT29 cells can trigger migration in myofibroblasts, HT29 
conditioned medium was used as chemoattractant. The glucose starving-conditioned medium 
worked as a strong chemoattractant in our migration assay. However, to validate HMGb1 
mediated signalling in the migration of myofibroblasts cells, anti-HMGb1 antibody (5µg/ml) was 
added to the conditioned medium at the bottom chamber to neutralise the effect of HMGb1.  If 
the HMGb1 was involved in the migration of myofibroblast cells, a decrease in the migration of 
cells was expected. 
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Figure 5.2: CCD18 myofibroblasts migration assay in response to HMGb1 present in the 
glucose free conditioned medium of HT29 cells. A) The migration assay carried out using HT29 
conditioned medium as chemoattractant. The HT29 conditioned medium (-glucose) served as 
control. The conditioned medium with anti HMGb1 antibody (5µg/ml) was compared to the 
control (100%). The assay was carried out three times with 2 inserts per condition per occasion 
(5 random fields of vision counted per insert).Student’s t-test was used to determine statistical 
significance of the results. SEMs were displayed as error bars. Representative images captured 
showing the underside of the membrane after completion of the migration assay. Cells that had 
migrated though the 8µm pores of the membrane were stained blue using the ReaStain Quick-
Diff staining method. B) Figure showing cells migrated through the membrane and C) cells 
migrated when anti-HMGb1 antibody was added to the medium. Cells that had migrated on 
these and other images were counted and the results were presented in A) of this figure. The 
photographs were taken under x20 magnification. 
 
The results from the migration assay using the anti-HMGb1 antibody in conditioned medium 
suggested that HMGb1 play an important role in the migration of myofibroblast cells. This 
migratory effect was significantly inhibited by the addition of anti-HMGb1 antibody (5µg/ml) in 
the medium. This inhibition was 1/3 fold compared to the controls (Figure 5.2A). The results 
obtained from the migration assay are statistically significant (Figure 5.2 A). 
 
5.4.3 HMGb1 triggers migration in myofibroblasts cells via RAGE    
         signalling   
 
HMGb1 has been reported to interact with RAGE and this interaction has been implicated in 
variety of diseases including cancer (Stoetzer et al. 2013; Ingels et al. 2015). In addition, 
HMGb1 has been reported to trigger migration in mouse fibroblasts cells via RAGE receptor 
(Ranzato, et al. 2010). The presence of HMGb1 in conditioned medium (glucose deprived) from 
HT29 cells was confirmed by the western blotting (Chapter 4). In addition, the results from 
previous migration assay suggested HMGb1 mediated signalling play an important role in the 
migration of CCD18 myofibroblast cells.  
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One of the aims of this migration assay was to determine the involvement of RAGE in the 
HMGb1 induced migration of CCD18 myofibroblast cells. RAGE is the main receptor for HMGb1 
however; HMGb1 does interact with other receptors including TLR-4. The expression of these 
receptors by CCD18 myofibroblast cells was confirmed by western blotting (Chapter 4). 
Therefore, it is likely that HMGb1 mediated migration of CCD18 myofibroblast cells involves 
activation of HMGb1-RAGE complex. This interaction may trigger downstream signalling 
cascade, which may facilitate the migration of myofibroblast cells.   
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B) Control                                                             C) Anti RAGE antibody  
        
                                 D) Combination of anti RAGE and anti HMGb1 antibodies 
 
 
Figure 5.3: Effect of inhibiting RAGE and HMGb1 by neutralising antibodies on CCD18 
myofibroblast cells migration.  
 
A) Migration assay carried out using HT29 conditioned medium as chemoattractant. The HT29 
conditioned medium (-glucose) served as control. The conditioned medium with 
immunoneutralising anti RAGE antibody was compared to the control (100%). A combination of 
anti RAGE and anti HMGb1 antibodies were also supplied to the conditioned medium and 
compared to the controls. The assay was carried out three times with 2 inserts per condition per 
occasion (5 random fields of vision counted per insert). Student’s t-test was used to determine 
statistical significance of the results. SEMs were displayed as error bars. Student’s t-test was 
used to determine statistical significance of the results. SEMs were displayed as error bars.  
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Representative images captured showing the underside of the membrane after completion of 
the migration assay.  Cells that had migrated though the 8µm pores of the membrane were 
stained blue using the ReaStain Quick-Diff staining method.  The white dots are 8µm pores 
through which cells have not migrated. B) Cells migrated in response to conditioned medium 
without glucose, C) cells migrated in response to immunoneutralising RAGE antibody in the 
conditioned medium without glucose and in the cell suspension in the inserts and D) cells 
migrated in response to the combination of immunoneutralising RAGE and HMGb1 antibodies 
in the medium and RAGE antibody in the cell suspension. Cells that had migrated on these and 
other images were counted and the results were presented in A) of this figure. The photographs 
were taken under x20 magnification. 
 
The effect of conditioned medium (control) on myofibroblast migration was compared to 
myofibroblast migration in response to two other treatments. In the first treatment, 
immunoneutralising anti-RAGE antibody (8µg/ml) was added to the conditioned medium and 
myofibroblast migration compared to that of the controls. In addition, another treatment, 
conditioned medium with a combination of anti-RAGE (8µg/ml) and anti-HMGb1 (5µg/ml) 
antibodies were used and the resulting myofibroblast migration was compared to the RAGE 
antibodies only treatments and controls. The results obtained from migration assay suggested 
that RAGE is involved in the migration of myofibroblasts cells as anti-RAGE antibodies 
significantly inhibited (approximately 38%) the migration of myofibroblasts. This inhibition was 
further increased by 10% when a combination of anti HMGb1 antibody and anti-RAGE 
antibodies were added to the chemoattractant (conditioned medium), confirming the 
involvement of HMGb1-RAGE complex in HT29 conditioned medium triggered migration of 
CCD18 myofibroblast cells. All results were statistically significant (Figure 5.3 A). 
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5.4.4   HMGb1 present in the conditioned medium triggers migration  
           in CCD18 myofibroblast cells via TLR-4 signalling 
 
The HMGb1 has been reported to interact with many receptors including RAGE and TLRs 
previously (TLR-2 and TLR-4) (Yu et al. 2006; Tian et al. 2007). The glucose free conditioned 
medium obtained from HT29 cells at 48h served as chemoattractant for myofibroblast migration 
as evident from this study. In addition, this study has also suggested the fact that conditioned 
medium obtained from HT29 contains significant amount of HMGb1 (Chapter 4). The results 
from migration assays suggested that both HMGb1 and RAGE are involved in the migration of 
CCD18 myofibroblast cells. In addition, inhibiting both (HMGb1 and RAGE) resulted in additive 
inhibition of migration in CCD18 myofibroblast cells. Therefore, it was important to investigate 
the involvement of another receptor TLR-4, which has been implicated in migration of other cell 
types previously (Fan and Malik 2003; Liu et al. 2014).  
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D) Combination of anti HMGb1 and anti TLR-4 antibodies 
 
 
Figure 5.4: Comparative analysis of CCD18 myofibroblast cells migration assay in response to 
HT29 conditioned medium and blocking TLR-4 or HMGb1/TLR-4 complex using 
immunoneutralising anti-HMGb1 or a combination of anti-HMGb1 and anti-TLR-4 antibodies. 
  
A) Migration assay carried out using HT29 conditioned medium as chemoattractant. The HT29 
conditioned medium (-glucose) served as control (control=100%). Student’s t-test was used to 
determine statistical significance of the results. SEMs were displayed as error bars.  
 
Representative images captured showing the underside of the membrane after completion of 
the migration assay.  Cells that had migrated though the 8µm pores of the membrane were 
stained blue using the ReaStain Quick-Diff staining method.  The white dots are 8µm pores 
through which cells have not migrated. B) Cells migrated in response to conditioned medium 
without glucose (Control=100%), C) cells migrated in response to immunoneutralising anti-TLR-
4 antibody in the conditioned medium without glucose and in the cell suspension in the inserts 
and C) cells migrated in response to the combination of immunoneutralising anti-TLR-4 and 
anti-HMGb1 antibodies in the conditioned medium and in the cell suspension. Cells that had 
migrated on these and other images were counted and the results were presented in A) of this 
figure. The assay was carried out three times with 2 inserts per condition per occasion (5 
random fields of vision counted per insert). The photographs were taken under x20 
magnification. 
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The conditioned medium (-glucose) served as a positive control and the number of 
myofibroblast cells migrating in response taken as 100% migration. Immunoneutralising 
antibodies against HMGb1 and TLR-4 were used to neutralise the effect of receptor and the 
ligand. In addition, both antibodies were also used in combination. The results obtained from 
this migration assay suggested that TLR-4 is involved in the migration of the myofibroblasts 
cells. However, results from combination treatment didn’t show additive effect on the inhibition 
of migration of myofibroblasts. The results suggested that HMGb1 might bind to TLR-4 to 
induce migration in CCD18 myofibroblast cells. However, the inhibitory effects seen with both 
treatments (TLR-4 antibody alone and in combination with HMGb1 antibody) were statistically 
significant with approximately 40% reduction in migration of myofibroblasts cells (Figure 5.4 A). 
 
5.4.5 HMGb1 triggers migration in CCD18 myofibroblast cells via    
         MEK1/2 and PI3K pathways 
 
The results from previous assays suggested that HT29 cells release HMGb1 in their glucose 
deprived culture medium (chapter 4). This conditioned medium worked as a strong 
chemoattractant for myofibroblasts in our migration assays. The results from migration assays 
suggest that HMGb1 binds to its receptor RAGE and triggers migration in myofibroblasts cells. 
However, involvement of downstream signalling pathways is not clear. MEK1/2 and PI3K are 
two kinases that have been implicated in migration of many other cell types including 
glioblastoma cells, keratinocytes and rat fibroblasts (Jeong and Kim 2004; Mitchell et al. 2007; 
Bassi et al. 2008). Therefore, to investigate the involvement of these two kinases in the 
migration of CCD18 myofibroblast cells would be the next logical step.  
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D) LY294002 (PI3K inhibitor) 
 
Figure 5.5: Comparative analysis of CCD18 migration assay in response to the treatment with 
HT29 conditioned medium and MEK1/2 and PI3K inhibitors in the medium.  
 
A) Migration assay carried out using HT29 conditioned medium as chemoattractant. The HT29 
conditioned medium (-glucose) served as control (100%). The assay was carried out three 
times with 2 inserts per condition per occasion (5 random fields of vision counted per insert). 
Student’s t-test was used to determine statistical significance of the results. SEMs were 
displayed as error bars. The conditioned medium with MEK1/2 inhibitor (U0126) and PI3K 
inhibitor (LY294002) were compared to the control (100%). Representative images captured 
showing the underside of the membrane after completion of the migration assay.  Cells that had 
migrated though the 8µm pores of the membrane were stained blue using the ReaStain Quick-
Diff staining method. The white dots are 8µm pores through which cells have not migrated. B) 
Conditioned media without glucose showing cell migration (control=100%), C) migration of cells 
in response to U0126 MEK1/2 inhibitor and D) LY294002, PI3K inhibitor. Cells that had 
migrated on these and other images were counted and the results were presented in A) of this 
figure. The photographs were taken under x20 magnification.  
 
 
The involvement of MEK1/2 and PI3K was evaluated by comparing myofibroblast migration in 
conditioned medium without inhibitors (controls) with migration in the presence of inhibitors. The 
inhibitors U0126, a potent, selective and uncompetitive MEK 1/2 inhibitor was added to the 
conditioned medium used in the migration assay and LY294002, a selective inhibitor of PI3K 
was also added to the conditioned medium also used in the migration assay. The results from 
146 
 
the migration assay showed more than 55% reduction in the migration of CCD18 myofibroblast 
cells when treated with U0126 (50µM/ml) (Figure 5.5 A). However, LY294002 (10µM/ml) 
appeared to play major role with approximately 75% reduction in the migration of myofibroblasts 
cells (Figure 5.5 A). Therefore, results from these migration assays suggest that these 
pathways are activated during HMGb1 triggered migration in CCD18 myofibroblast cells. 
 
5.4.6 CCD18 myofibroblast cells invade through the matrigel matrix  
  in response to conditioned medium 
 
Myofibroblasts are stromal cells that are also found within tumours and their population also 
gradually increases in metastatic sites (Morotti et al. 2005). Previous migration assays carried 
out in this study has suggested that HT29 glucose starved conditioned medium containing 
HMGb1 triggers migration in CCD18 myofibroblast cells. Therefore, it was logical approach to 
determine whether this HT29 glucose starved conditioned medium can stimulate CCD18 
myofibroblast cells to invade through the basement membrane. Thus, we developed Boyden 
chamber inserts invasion assays to determine whether CCD18 myofibroblast cells can degrade 
the basement membrane. If this was the case, then this may allow myofibroblasts to enter into 
the circulation to facilitate the metastasis of tumour cells. These invasion assays were based on 
a similar principle to the migration assay which involved placing a chemoattractant (conditioned 
medium without glucose) in the bottom chamber of the inserts. However, the insert membrane 
was different than the previously used migration kit. These inserts had matrigel matrix coating 
on top of the 8µm pores which is a well established basement membrane mimic available to 
test in vitro (Benton et al. 2011).  
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D) Fresh serum free medium (without glucose) 
 
 
Figure 5.6: CCD18 myofibroblasts invasion assay in response to the treatment with HT29 
conditioned medium with and without glucose and fresh medium without glucose.  
 
A) Invasion assay carried out using HT29 conditioned medium as chemoattractant. The HT29 
conditioned medium (-glucose) served as control. The conditioned medium with glucose and 
fresh serum free medium without glucose were compared to the control (100%). Student’s t-test 
was used to determine statistical significance of the results. SEMs were displayed as error bars. 
The assay was carried out three times with 2 inserts per condition per occasion (5 random fields 
of vision counted per insert).  
 
Representative images captured showing the underside of the membrane after completion of 
the invasion assay.  Cells that had migrated though the 8µm pores of the membrane were 
stained blue using the ReaStain Quick-Diff staining method.  The white dots are 8µm pores 
through which cells have not migrated. B) Cells invaded in response to conditioned medium 
without glucose (Control=100%), C) cells invaded in response to the conditioned medium with 
glucose and D) cells invaded in response to the fresh serum free medium without glucose. Cells 
that had migrated on these and other images were counted and the results were presented in 
A) of this figure. The photographs were taken under x20 magnification.  
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The conditioned medium (without glucose) from HT29 cells served as control (100%). The 
conditioned medium (with glucose) and fresh serum free medium (without glucose) were 
compared to the conditioned medium (without glucose). The results suggested that the 
conditioned medium (with glucose) although able to trigger invasion in myofibroblasts cells with 
approximately 30% invasion as compared to the conditioned medium (without glucose) at 100% 
(Figure 5.6 A). In addition, fresh serum medium (without glucose) was investigated against 
conditioned medium (without glucose). It was observed that cells did not invade through the 
matrigel membrane when exposed to glucose free fresh serum free medium (Figure 5.6 D). The 
results suggested that glucose deprivation on its own is not a trigger for migration. However, 
HT29 cells exposed to glucose deprivation appear to release of certain factors and/or 
chemokines which trigger myofibroblasts to invade. The results from this invasion assay support 
the results obtained from migration assays carried out using myofibroblasts cells.  
 
5.4.7 HMGb1 in conditioned medium triggers invasion in CCD18   
         myofibroblast cells 
 
Glucose deprivation triggers the release of HMGb1 from HT29 cells in normoxia. The 
chemoattractive properties of HMGb1 have been validated by migration assays carried out in 
our lab previously where anti-HMGb1 antibodies significantly reduced the migratory potential of 
myofibroblasts cells (Figure 5.2). The conditioned medium (without glucose) has shown positive 
results in our invasion assays and therefore investigating the involvement of HMGb1 in glucose 
free conditioned medium-induced invasion of myofibroblasts was important.  
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The immunoneutralising anti HMGb1 antibodies (5µg/ml) were added to the conditioned 
medium (without glucose) in the bottom chambers of the assay and the results compared to the 
control (conditioned medium without glucose). The results suggested that HMGb1 present in 
the conditioned medium stimulated CCD18 myofibroblast cells to invade through the matrigel 
matrix. A significant reduction in the number of cells that had invaded though the matrigel matrix 
was seen with the addition of the HMGb1 immunoneutralising polyclonal anti-HMGb1 antibodies 
into the conditioned medium (without glucose) at 22h. This reduction was more than 50% and 
statistically significant (Figure 5.7A).  
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B) Conditioned medium (Control)        C) Anti HMGb1 antibody in the medium 
        
Figure 5.7: CCD18 myofibroblasts invasion assay in response to HT29 conditioned medium 
and anti-HMGb1 antibodies in the medium. 
 
A) Invasion assay carried out using HT29 conditioned medium as chemoattractant. The HT29 
conditioned medium (-glucose) served as control. The immunoneutralising HMGb1 antibody in 
the conditioned medium without glucose was compared to the control (100%). The assay was 
carried out three times with 2 inserts per condition per occasion (5 random fields of vision 
counted per insert). Student’s t-test was used to determine statistical significance of the results. 
SEMs were displayed as error bars. Student’s t-test was used to determine statistical 
significance of the results. SEMs were displayed as error bars.  
 
Representative microscopic images captured showing the underside of the membrane after 
completion of the invasion assay.  Cells that had invaded though the 8µm pores of the 
membrane were stained blue using the ReaStain Quick-Diff staining method.  The white dots 
are 8µm pores through which cells have not migrated. B) Photographs showing number of cells 
invaded in response to the conditioned medium without glucose and C) HMGb1 antibody in the 
medium. Cells that had migrated on these and other images were counted and the results were 
presented in A) of this figure. The photographs were taken at x20 magnification. 
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5.4.8   RAGE and TLR-4 facilitate CCD18 myofibroblast cells   
           to invade through matrigel matrix  
 
HMGb1 has been shown to interact with RAGE and TLR-4 and this interaction has been 
implicated in various malignancies including cancer (Wang et al. 2012; Zhang et al. 2012; 
Stoetzer et al. 2013; Agalave et al. 2014). Our western blot analysis has confirmed the 
presence of both RAGE and TLR-4 receptors expressed by CCD18 myofibroblast cells. In 
addition, previous migration assay carried out in our lab suggested that RAGE and TLR-4 are 
involved in the migration of CCD18 myofibroblast cells (Figure 5.3 and 5.4) therefore it is 
possible that these two receptors might also be involved invasion. Thus, investigating the 
involvement of RAGE and TLR-4 in the invasion of myofibroblasts cells would be a logical 
approach.  
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D) Anti TLR-4 antibody in the medium 
 
Figure 5.8: CCD18 myofibroblasts invasion assay in response to the treatment with HT29 
conditioned medium and anti-RAGE and anti-TLR-4 antibodies in the medium.  
 
A) Invasion assay carried out using HT29 conditioned medium as chemoattractant. The HT29 
conditioned medium (-glucose) served as control. The conditioned medium with glucose and 
RAGE and TLR-4 antibodies in the medium and inserts were compared to the control (100%). 
The assay was carried out three times with 2 inserts per condition per occasion (5 random fields 
of vision counted per insert). Student’s t-test was used to determine statistical significance of 
the results. SEMs were displayed as error bars. Student’s t-test was used to determine 
statistical significance of the results. SEMs were displayed as error bars.  
 
Representative images captured showing the underside of the membrane after completion of 
the invasion assay.  Cells that had migrated though the 8µm pores of the membrane were 
stained blue using the ReaStain Quick-Diff staining method.  The white dots are 8µm pores 
through which cells have not migrated. B) Cells invaded in response to the conditioned medium 
without glucose (Control=100%), C) immunoneutralising RAGE antibody in the conditioned 
medium without glucose and D) in response to immunoneutralising TLR-4 antibody in the 
conditioned medium without glucose. Cells that had migrated on these and other images were 
counted and the results were presented in A) of this figure. The photographs were taken at x20 
magnification. 
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The invasion assay carried out using immunoneutralising anti RAGE antibodies (8µg/ml) and 
anti TLR-4 antibodies (2µg/ml). The antibodies were added to conditioned medium in the wells 
and in CCD18 myofibroblast cell suspension in the inserts. The results after 22h of incubation 
suggested that RAGE plays an important role in the HMGb1 mediated invasion of 
myofibroblasts as immunoneutralising anti-RAGE antibodies significantly reduced the number 
cells invaded through the matrigel matrix. The addition of immunoneutralising anti-TLR-4 
antibodies also resulted in significant reduction in number of cells invaded through the matrigel 
matrix. However, immunoneutralising RAGE appeared to be the most effective with marked 
reduction in invasion of more than 50% whereas immunoneutralising TLR-4 it was 
approximately 40% (Figure 5.8 A). These findings are in line with previous findings from the 
migration assays where inhibition of RAGE gave greater reduction in migration than inhibition of 
TLR-4 (Figure 5.3 and 5.4)  
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5.4.9   The invasion in CCD18 myofibroblast cells take place via    
            activation of the MEK1/2 and PI3K signalling pathways 
 
The activation of MEK1/2 and PI3K has been implicated in migration of many cells types 
including cancer cells (Yao et al. 2004; Ptak et al. 2014; Sobolik et al. 2014). Phosphorylation of 
these kinases activates many downstream signalling pathways including NF-kB. The migration 
assay carried out in our lab showed that MEK1/2 and PI3K are activated and involved in 
migration of CCD18 myofibroblast cells and inhibiting these pathways with selective inhibitors 
significantly reduced migration of myofibroblasts cells. Thus, it is possible that these pathways 
are involved HMGb1 induced invasion of CCD18 myofibroblast cells.  
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C) LY294002 in medium (top and bottom) 
 
Figure 5.9: A) Effect of MEK1/2 and PI3K inhibitors on CCD18 myofibroblasts invasion in 
response to HT29 conditioned medium as chemoattractant.  
 
The HT29 conditioned medium (-glucose) served as control. The MEK1/2 and PI3K inhibitors in 
the conditioned medium without glucose and in the inserts were compared to the control 
(100%). The assay was carried out three times with 2 inserts per condition per occasion (5 
random fields of vision counted per insert). Student’s t-test was used to determine statistical 
significance of the results. SEMs were displayed as error bars. Student’s t-test was used to 
determine statistical significance of the results. SEMs were displayed as error bars.  
 
Representative images captured showing the underside of the membrane after completion of 
the invasion assay.  Cells that had migrated though the 8µm pores of the membrane were 
stained blue using the ReaStain Quick-Diff staining method.  The white dots are 8µm pores 
through which cells have not migrated. B) Cells invaded in response to the conditioned medium 
without glucose (Control=100%), C) MEK1/2 inhibitor (U0126) in the conditioned medium 
without glucose and D) in response to PI3K inhibitor (LY294002) in the conditioned medium 
without glucose. Cells that had migrated on these and other images were counted and the 
results were presented in A) of this figure. The photographs were taken under x20 
magnification.  
 
 
The invasion assay was carried out using selective inhibitors of MEK1/2 and PI3K. These 
inhibitors were added to medium in the bottom chambers and in the CCD18 cell suspension in 
the upper inserts. The data suggested that inhibiting MEK1/2 by its selective inhibitor U0126 
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(50µM/ml) significantly reduced the number of cells that invaded through the matrigel matrix. 
There was approximately an 80% reduction in the number of myofibroblasts invading through 
compared to the controls (100%). In addition, LY294002 (10µM/ml), a selective inhibitor of 
PI3K, resulted in a significant reduction (90%) in number of cells invading through the matrigel 
matrix (Figure 5.9A). The results suggested that both MEK1/2 and PI3K are involved in the 
invasion of myofibroblasts cells. However, based on the data from migration and invasion 
assays, it appears that PI3K-AKT pathways play an important role in CCD18 myofibroblast cells 
migration and invasion. Though, the involvement of MAPK-ERK pathway is also significant.  
 
5.4.10 MMP-2 but not MMP-9 is produced and secreted by CCD18  
           Myofibroblast cells 
 
The other aim was based on the novel findings from the invasion assays. The results from 
invasion assays suggested that CCD18 myofibroblasts are able invade through the matrigel 
matrix in response to glucose deprived conditioned medium taken from HT29 cells. Many 
MMPs including MMP-1,-2,-3,-7,-8, and MMP-9 have been shown to cleave the substrate 
during the invasion assay in vitro (Lutolf et al. 2003) and myofibroblasts have been shown to 
secrete MMP-2 and MMP-9 previously (Lewis et al. 2004; Turner et al. 2007). Thus we decided 
to investigate release of MMP-2 and MMP-9 from CCD18 cells.   
 
Here, we investigate the release of MMP-2 and MMP-9 as these forms of MMPs have shown to 
degrade basement membrane previously (Lee et al. 2015; Shen et al. 2015). The CCD18 
myofibroblast cells were treated with glucose free and glucose containing medium. In addition, 
the myofibroblasts cells were also treated with same conditions as those of migration assays 
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i.e., treatment with serum free medium for 24h followed by treatment with HT29 conditioned 
medium.  
 
A)  
 
                                  
B)  
 
                             
 
Figure 5.10: (A) Western blot showing the release of MMP-2 from CCD18 cells. The CCD18 
cells were also treated with HT29 conditioned medium (medium containing glucose and glucose 
free medium collected at 48h) for 22h. 
 A= Recombinant MMP-2, B=CCD18 (+Glucose), C=CCD18 (-Glucose, D=CCD18 treatment 
with HT29 conditioned medium (+Glucose), E=CCD18 treatment with HT29 conditioned 
medium (–Glucose)  
 
B) Western blot analysis of the release of MMP-9 from HT29 cells and CCD18 cells. The cells 
were treated with presence and absence of glucose for 24h. The CCD18 cells were also treated 
with HT29 conditioned medium for 22h. The protein concentration was equalised in both 
conditions and compared.   
(+glucose = with glucose*) (-glucose = without glucose*).  A= Recombinant MMP-9, B=HT29 (+ 
Glucose), C=HT29 (–Glucose), D=CCD18 (+ Glucose), E=CCD18 (–Glucose), F=CCD18 
treatment with HT29 conditioned medium (+ Glucose), G=CCD18 treatment with HT29 
conditioned medium (–Glucose) 
 
 72kDa 
     A              B           C           D           E             F             G 
92kDa 
                A               B                C               D                E     
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The results from western blot suggest that CCD18 myofibroblast cells express and release 
MMP2 but not MMP-9. The protein bands for MMP-2 were detected at 74kDa (predicted 
molecular weight) resembling the molecular weight of recombinant MMP-2. A polyclonal primary 
antibody specific to MMP-2 was used to detect MMP-2. The recombinant MMP-2 served as 
positive control. The protein concentration of the medium from the treated CCD18 myofibroblast 
cells used in the western blot was equalised using BioRad protein assay. There was no 
difference observed in protein bands observed in treatment with glucose free fresh serum free 
medium and with glucose containing serum free medium at 24h. However, with conditions 
mimicking migration and invasion assay conditions, it appeared that MMP-2 is downregulated in 
response to glucose free conditioned medium taken from HT29 cells that had previously been 
cultured for 48h (Figure 5.10A).  
 
Similar assay conditions were implemented to investigate the presence or upregulation or 
downregulation of MMP-9. The protein concentration of the medium from the CCD-18 cells was 
again equalised using the BioRad protein assay. A polyclonal primary anti-MMP-9 antibody was 
used to detect MMP-9 in the conditioned media samples. The results from western blot 
suggested that MMP-9 is not released from CCD18 cells in any of the conditions investigated 
i.e., first treatment being the treatment with fresh glucose free or glucose containing treatment 
for 24h and second treatment with glucose free condition treatment for 24h plus another 22h 
treatment with HT29 conditioned medium which was obtained at 48h (glucose free and glucose 
rich). Recombinant MMP-9 was detected at predicted molecular weight of 92kDa (Figure 6B). 
Therefore, both western blots were validated with positive controls being detected at correct 
molecular weight. These findings are indicative of possibilities for the involvement of other 
proteases in facilitating the HMGb1 induced migration and invasion of myofibroblasts.  
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5.5   Discussion  
 
The tumour stromal cells such as fibroblasts and myofibroblasts play an important role in 
predicting the outcome of cancer chemotherapy (Yamashita et al. 2012). Cancer metastasis is a 
major hurdle in the treatment of cancer (Davidson et al. 1999; Spaderna et al. 2006; Li et al. 
2011). It has been established that tumour stromal cells such as CAFs or myofibroblasts 
promote tumour proliferation and angiogenesis (Coussens and Werb 2002; Allinen et al. 2004). 
In addition, it has been shown that the myofibroblast population gradually increases with the 
invasive stages of many cancers (Nakayama et al. 1998). The degradation of ECM is one of the 
major events that occur during the migration of cells from one organ to another. 
 
 
Myofibroblasts are known to play important roles in the formation and repair of the ECM 
(Vedrenne et al. 2012; Mia et al. 2014). The ECM is made up of various matrix proteins 
including collagen and other glycoproteins and proteoglycans (Robert 2015). Most of these 
proteins are produced by myofibroblasts and play important roles in epithelial cell migration and 
differentiation (Hinz and Gabbiani 2010). In addition, myofibroblasts have been shown to 
secrete MMPs (1-3). These MMPs are major degraders of basement membrane. However, the 
action of MMPs is inhibited by TIMPs during the ECM remodelling. Thus, a balance between 
MMPs and TIMPs is important for ECM remodelling in the tissue (Benyon et al. 1996).   
 
 
Most solid tumours are characterised by hypoxic and glucose deprived areas in their central 
core within the microenvironment (Laderoute et al. 2006; Jamieson et al. 2015). These 
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conditions have been shown to trigger the release various growth factors such as VEGF, which 
then can facilitate angiogenesis and metastasis. The results from our western blot analysis 
suggest that various cancer cell lines including HT29 (colon adenocarcinoma), MCF-7 (breast 
cancer), EJ138 (Bladder cancer) and A549 (Lung cancer) cells release HMGb1 under glucose 
deprivation in normoxia. HMGb1 is an inflammatory cytokine that is released as a danger signal 
during inflammation (Hreggvidsdottir et al. 2009; Lu et al. 2014). We have explored 
myofibroblast proliferation and found that HMGb1 appeared to drive proliferation in CCD18 
myofibroblast cells. Other studies have shown that HMGb1 can trigger migration in many other 
cells including glioblastoma and neutrophils (Bassi et al. 2008; Berthelot, et al. 2011). However, 
its role in myofibroblasts migration and invasion had previously not been explored. Therefore, 
considering the cytokine-like activity of HMGb1, it was important to investigate its role in 
signalling migration and invasion of myofibroblasts cells.  
 
 
The HMGb1 activates various signalling pathways such as MAPK-ERK and PI3K-AKT. These 
pathways play an important role in the proliferation and migration of tumour cells. Supporting 
evidence includes HMGb1 activated PI3K pathway in neutrophils and colon cancer cells 
(Kuniyasu et al. 2003). In addition, HMGb1 has been shown to induce TLR-4 mediated 
activation of MyD88-IRAK4-p38 and Myd88-IRAK4-AKT pathways. Also, HMGb1-RAGE 
complex has been shown to activate ERK1/2 pathways in rat smooth muscle cells (Degryse et 
al. 2001).   
 
 
The presence of HMGb1 released into the culture medium from HT29 colon adenocarcinoma 
cells might contribute to advancing our knowledge of the cellular cross talk within tumours in 
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response to HMGb1 and subsequent impacts within the tumour microenvironment. One main 
question that has been answered by this work is that HMGb1 triggers proliferation in 
myofibroblasts and plays an important role in the activation of PI3K and MAPK-ERK pathways. 
In addition, presence of RAGE and TLR-4 on the membrane of myofibroblasts further indicates 
a possible interaction between HMGb1 and its receptors RAGE and TLR-4. Therefore, 
validating the involvement of these proteins by using immunoneutralising antibodies was a 
logical approach in our migration assays. The migration assays were carried using Boyden 
chamber inserts with 8µm pores membrane. This system has been used widely by many other 
researchers in vitro (Chen 2005).   
 
The preliminary data from the CCD18 myofibroblast migration assays using the conditioned 
medium without glucose as a chemoattractant (conditioned by growing HT29 colon 
adenocarcinoma cells in it for 48h) showed significant migration of the myofibroblast cells during 
a 20h incubation period (Figure 5.1). Indeed, there was a reasonable chance for the existence 
of chemoattractants in the culture medium before exposure to the HT29 cells. However, the 
results from our western blots have confirmed the presence of HMGb1 in the culture medium of 
HT29 cells but not in the fresh medium (Chapter 4, Figure 4.1). A number of studies have 
shown the chemoattractant properties of HMGb1 in relation to a number of cells including 
mesoangioblasts and fibroblasts in vitro (Palumbo et al. 2007; Schiraldi et al. 2012).  
 
Since our results suggested that HMGb1 present in the conditioned medium can trigger 
migration in myofibroblast cells, a selective immunoneutralising antibody to HMGb1 (5 µg/ml) 
was used to block HMGb1 in the conditioned medium to back up our findings. The antibody was 
allowed to interact with HMGb1 present in the conditioned medium for 20h. The results from this 
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migration assay revealed that HMGb1 present in the conditioned medium triggers migration in 
myofibroblasts cells. The addition of immunoneutralising antibody to HMGb1 (5µg/ml) to 
conditioned medium at the bottom chamber significantly reduced the number of myofibroblasts 
cells migrated through the membrane. This inhibition was approximately 40% when compared 
to the controls (100%) (Figure 5.2).  
 
The interaction of HMGb1 with RAGE and TLR-4 has been established previously. For 
example, a recent study showed that HMGb1 is released from necrotic and severely stressed 
inflammatory cells and bind to TLR-4 and triggers migration in NIH/3T3 fibroblasts to the site of 
necrosis (Schiraldi et al. 2012). However, whilst this was shown in fibroblasts, whether the 
migration of myofibroblasts is facilitated by HMGb1 interaction with either RAGE or TLR-4 
receptor interaction remained questionable. Therefore, it was logical to explore this by using 
immunoneutralising antibodies to RAGE and TLR-4 to specifically block these receptors.  
 
In addition, HMGb1 antibodies were also used in combination with RAGE and TLR-4 antibodies 
to investigate synergistic effect. The RAGE and TLR-4 antibodies were added to both chambers 
in the migration assay (top chamber containing myofibroblast cell suspension and bottom 
chamber containing conditioned medium). The HMGb1 antibodies were added to medium at the 
bottom chambers. RAGE and TLR-4, both are multiligand receptors and known to activate 
various downstream signalling pathways (Palumbo et al. 2004). The blockade of RAGE by the 
use of immunoneutralising antibodies significantly reduced the number of myofibroblast cells 
that had migrated through the membrane (Figure 5.3). Interestingly, similar results were seen 
with the blockade of TLR-4 with immunoneutralising antibodies (Figure 5.4). This suggested 
that both receptors are present on the myofibroblasts cells and take part in signal transduction 
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necessary for the cells to migrate. In addition, an increased inhibition of migration was seen 
when both RAGE and HMGb1 were blocked by antibodies (Figure 5.3). This strengthens our 
evidence for the involvement of RAGE receptor interaction with HMGb1 and that HMGb1 
primarily binds to RAGE to signal migration in CCD18 myofibroblast cells. However, blocking 
TLR-4 and HMGb1 together did not show any better inhibition than blocking TLR-4 alone. This 
suggests that TLR-4 might take part in signalling pathways in myofibroblasts cells but not 
primarily with HMGb1. Therefore it is possible that TLR-4 might interact with other proteins in 
the conditioned medium in addition to HMGb1.  
 
The signalling pathways involved in the migration potential of the myofibroblast cells were also 
investigated. Our evidence suggests that CCD18 myofibroblast cells migrate in response to 
HMGb1 found at relatively high levels in the glucose-deprived medium conditioned by use on 
HT29 colon adenocarcinoma in the migration assay. Two key pathways MAPK-ERK and PI3K-
AKT have been implicated widely in the study of migration of a variety of cells including 
endothelial, glioblastoma and colon cancer cells (Crean et al. 2002). Selective inhibitors of 
these pathways (U126 and LY294002) have been used by many researchers (Hayashi et al. 
2008; Ghobrial 2009; Kobayashi et al. 2009) investigating the roles of MAPK-ERK or PI3K-AKT 
pathways. In this work, the inhibitors were added to the cell suspension and the medium to 
block the action of MEK1/2 and PI3K in CCD18 myofibroblast cells.  
 
The results from the migration assays using these inhibitors revealed that both pathways are 
involved in HMGb1 triggered migration of CCD18 myofibroblast cells (Figure 5.5). However, 
inhibiting PI3K with LY294002 significantly blocked the migration by 80%, which suggested that 
migration of CCD18 myofibroblast cells involves PI3K and associated downstream signalling 
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which may include NF-kB. In addition MAPK-ERK pathway also plays an important role in the 
migration of CCD18 myofibroblast cells. The inhibition of MEK1/2 by U0126 significantly 
reduced the number of cells (55%) in our migration assay. Thus, according the results from 
these migration assays, it is likely that MEK1/2 is activated as a result of the interaction of 
HMGb1 and RAGE to trigger the migration of CCD18 myofibroblast cells.  
 
Ability to invade plays a central role in metastasis. This occurs by the degradation of basement 
membrane followed by penetration of cells into the circulation or lymphatic system. The results 
from this work using western blotting analysis of CCD18 culture medium suggest that CCD18 
myofibroblast cells produce and release MMP-2 (Figure 5.10 A). The MMP-2 has been 
implicated in the degradation of collagen type I, III and IV (Benyon et al. 1996).  
 
The results from the invasion assays show that CCD18 myofibroblast cells invade through the 
matrigel matrix to reach to the bottom part of the membrane (Figure 5.6). This further suggests 
that CCD18 myofibroblast cells might release some MMPs which degrade the matrigel matrix 
that mimics the basement membrane in the invasion assay setup. However, treatment of 
myofibroblast with glucose free conditioned medium obtained from HT29 cells showed that 
there was a downregulation in the release of MMP-2 by CCD18 myofibroblast cells (Figure 5.10 
A).  However, there was a downregulation in MMP-2 levels in the culture medium of CCD18 
myofibroblast cells when treated with conditioned medium with glucose (conditioned on HT29 
colon adenocarcinoma cells) (Figure 5.10 A). In addition, MMP-9 another potential degrader of 
basement membrane was invested and our western blot results suggested that CCD18 cells do 
not produce or release MMP-9 when treated with either with or without glucose conditioned 
medium treatment (Figure 5.10 B). This suggested that the invasion which occurred in response 
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to the HT29 cell conditioned medium without glucose might upregulate the release of proteases 
other than MMP-2 or MMP-9, which might play important roles in degradation of basement 
membrane and facilitate invasion by myofibroblasts cells.  
 
Interestingly, when HT29 cell conditioned medium with glucose was analysed for its 
chemoattractive properties, it was found that only 30% cells could invade through in comparison 
to the controls (100%) (HT29 conditioned medium without glucose) (Figure 5.6). This further 
raised a possibility for the release of additional proteases other than MMP-2 and MMP-9 that 
might have been released from the colon adenocarcinoma cell line during the glucose 
starvation. In addition, the results from invasion assays suggested that glucose deprivation on 
its own does not influence CCD18 cells to invade across the matrigel matrix because no cells 
invaded across the membrane when fresh medium without glucose was placed at the bottom 
chamber (Figure 5.6). Therefore, it was concluded that it’s not the lack of glucose that is 
responsible for the invasive properties of CCD18 myofibroblast cells, rather it is the factors that 
are being released from the colon adenocarcinoma cells in response to glucose deprivation that 
give the myofibroblasts invasive properties. 
 
Like migration, involvement of HMGb1 present in the conditioned medium of HT29 colon 
adenocarcinoma was analysed for invasion in myofibroblasts cells. It has been shown 
previously in chapter 4 that HMGb1 is present in the conditioned medium of HT29 cells 
especially in the glucose free conditioned medium. It was found that addition of anti-HMGb1 
antibodies into the conditioned medium (without glucose) at the bottom chamber significantly 
reduced the number of cells invading through (Figure 5.7). In addition, RAGE and TLR-4 also 
appeared to be involved in initiating the signalling cascade that lead the degradation of the 
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matrigel matrix membrane and invasion of myofibroblast cells. Interestingly, the results from 
invasion assays were in line with those of migration assays when comparing the involvement of 
RAGE and TLR-4. The blockade of RAGE resulted in greater inhibition than TLR-4 (Figure 5.8). 
Though, a combination treatment with anti-HMGb1 antibodies was not investigated but would 
be logical approach to see if there is any synergistic effect.  
 
The activation of MAPK-ERK and PI3K-AKT pathways have been implicated in the invasion of 
hepatocellular carcinoma and prostate cancer (Chen et al. 2005) The inhibitors of PI3K and 
MEK1/2 were used to selectively to inhibit both kinases in our invasion assay. The inhibition of 
both kinases resulted in marked reduction in invasion of CCD18 cells (Figure 5.9). However, 
PI3K inhibition by LY294002 was more effective than the U0126 like the migration assay. It has 
been shown that inhibition of PI3K and MAPKs results in the downregulation of MMP-2 and u-
PA (urokinase-type plasminogen activator) which might suggest that why inhibiting PI3K and 
MEK1/2 result in the inhibition of invasion (Chen et al. 2005). However, in our invasion setup, 
glucose free HT29 cell conditioned medium triggered myofibroblast invasion and migration but 
our western blotting analysis revealed a downregulation of MMP-2 in these conditions. 
Therefore, it is likely that other MMPs or factors are involved and should be the subject of future 
work.  
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Chapter 6 
6. Conclusions and future work 
6.1 Major Findings  
 
The HMGb1 is a nuclear protein has been shown to take part in the inflammatory process when 
released from immune cells (Scaffidi et al. 2002). In addition, it has recently been shown that 
the necrotic cells and the cells undergoing autophagy also release HMGb1 in the extracellular 
environment (Fiuza et al. 2003; Thorburn et al. 2009).  Although, the release of HMGb1 from 
cancer cells has been shown previously (Ito et al. 2007) however, the conditions that promote 
HMGb1 release were unclear. The data presented in this thesis suggest that HMGb1 is 
released from HT29 colon adenocarcinoma cells grown under anoxic conditions and also from 
these cells grown under glucose deprivation particularly in presence of oxygen. In fact, the 
results from western blots show that glucose deprivation rather than anoxia is a major stimulus 
which triggers the release of HMGb1 from 3 out of 4 cancer cells tested (HT29 colon 
adenocarcimona), A549 lung cancer cells and MCF-7 breast cancer cells but not EJ138 bladder 
cancer cells) (Chapter 4, Figure 4.1 and 4.2). Therefore, it is possible that glucose deprivation 
induced HMGb1 release from cancer cells could be a common phenomenon in the tumour 
microenvironment of many tumour types.  
 
In the tumour microenvironment, cancer cells and neighbouring tumour associated cells often 
undergo harsh ischemic conditions have alternate strategies to try to survive. For example, 
cancer cells are often exposed to an environment where there is not enough glucose and/or 
oxygen, especially in the core of tumour and so switch over to aerobic glycolysis (Warburg 
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effect). With anaerobic glycolysis, the tumour cells rapidly consume glucose and oxygen from 
the blood supply in order to get energy to survive (Vander Heiden et al. 2009). According to the 
data from this work, it may be likely that most cancer cells may release HMGb1 in within areas 
of the tumour microenvironment particularly where there is the shortage of glucose.  
 
Glutamine deprivation has previously been shown to induce autophagy in cells (Sakiyama et al. 
2009). The autophagy could result in translocation of HMGb1 from the nucleus followed by 
exocytosis in cancer and normal cells (Tang et al. 2010). The data presented here suggested 
that glucose deprivation should not be confused with glutamine deprivation that may be 
responsible for HMGb1 release from cancer cells via autophagy. The glutamine deprivation was 
also compared with glucose deprivation of the HT29 adenocarcinoma cell line and it was found 
that glucose alone serves as stimulating factor for HMGb1 release not glutamine. There was no 
evidence that glutamine deprivation resulted in additional HMGb1 being released into the 
medium when compared to normal glutamine and glucose conditions (control).  
 
The HMGb1 has previously been shown to trigger proliferation in many cells including T 
lymphocytes, mesoangioblasts and smooth muscle cells (Palumbo et al. 2004; Porto et al. 
2006; Sundberg et al. 2009). However, the role of HMGb1 interaction with myofibroblasts, a 
type of major mucosal but also tumour stromal cell is still unclear. The results from the 
proliferation assays suggest that recombinant HMGb1 triggers proliferation in myofibroblasts in 
a dose spectrum of 0.1 to 50ng/ml (Chapter 3, Figure 3.1B). Two major signalling pathways 
PI3K-AKT and MAPK were investigated for their role in HMGb1 induced proliferation in 
myofibroblasts. Both pathways have previously been reported to play active roles in HMGb1 
induced proliferation and migration in glioblastoma and mesoangioblast cells (Feng et al. 2014). 
Thus, it was important to investigate the involvement of these pathways in HMGb1 induced 
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proliferation of myofibroblasts. The Inhibition of both pathways by selective inhibitors 
significantly reduced HMGb1 induced proliferation in myofibroblasts (Chapter 3, Figure 3.2 A 
and 3.2 B). This suggested that PI3K and MAPK both play important roles in the proliferation of 
myofibroblasts. Therefore, the data presented here in this thesis suggests that HMGb1 triggers 
proliferation in myofibroblasts via PI3K-AKT and MAPK-ERK pathways.  
 
The results from western blot suggested that HMGb1 is present in the conditioned medium 
taken from HT29 colon adenocarcinoma cells after 48hrs. Therefore, HMGb1 containing 
conditioned media was chosen for use to investigate the effect of HMGb1 on myofibroblasts 
migration and invasion. After all, in the actual colon tumour environment, one would expect 
tumours to release factors (including HMGb1), that influence the behaviour of tumour-
associated cells such as myofibroblasts. The HMGb1 released into the HT29 cell conditioned 
(glucose free) media triggered a chemotactic response in myofibroblasts in our transwell 
membrane migration assay setup (Chapter 5, Figure 5.2). The direct involvement of HMGb1 
was demonstrated during migration assay by using immunoneutralising antibody against 
HMGb1. Neutralising the effect of HMGb1 by antibody significantly reduced migration response 
of myofibroblasts cells to the HT29 glucose free conditioned media (Chapter 5, Figure 5.2).  
 
Once the involvement of HMGb1 in migration of myofibroblasts was validated, it was important 
to investigate which HMGb1 associated receptors that are being activated during the migration 
response in myofibroblasts. Thus, two well-known receptors, RAGE and TLR-4, were 
investigated for involvement in HMGb1 induced migration response in myofibroblasts. The 
presence of both receptors on myofibroblasts cell membrane was confirmed by western blotting 
(Chapter 4, Figure 4.4 and 4.5). The immunoneutralising antibodies against RAGE and TLR-4 
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were added to the myofibroblasts cells suspension in an attempt to inhibit the activation of both 
receptors present on the cell membrane of myofibroblasts. The blockade of RAGE or TLR-4 
receptors individually by immunoneutralising antibodies significantly reduced migration in 
myofibroblasts cells in response to HT29 glucose free conditioned media (Chapter 5, Figure 5.3 
and 5.4). In addition, combined inhibition of HMGb1 with RAGE showed some additive inhibition 
of migration of myofibroblasts cells (Chapter 5, Figure 5.3). However, no additive effect was 
seen with combined inhibition of HMGb1 and TLR-4 using immunoneutralising antibodies 
(Chapter 5, Figure 5.4). This further suggested the preferred route of HMGb1 induced migration 
of myofibroblasts may act via the activation of HMGb1-RAGE complex and subsequent 
downstream signalling leading to migration of myofibroblasts cells. 
 
Indeed, PI3K and MAPK-ERK pathways are most widely studied pathways for migration in 
many cell types. The use of selective inhibitors of these pathways validated the involvement of 
these pathways in our migration assays. Blocking these pathways with selective inhibitors 
significantly reduced HMGb1 induced migration of myofibroblasts cells (Chapter 5, Figure 5.5). 
However, the inhibitor for PI3K-AKT pathways appeared to more greatly inhibit myofibroblasts 
migration when compared to the inhibitor for MEK1/2 pathways at non-toxic doses. Thus, based 
on this finding, it appeared that PI3K-AKT might be the main pathway involved in HMGb1 
induced migration of myofibroblasts. However, whilst to a lesser extent, the inhibitor of MEK1/2 
significantly reduced migration in myofibroblasts suggesting MEK1/2 is also an important 
signalling pathway in HMGb1 induced myofibroblasts migration.  
 
Invasion assays were also carried out to investigate the invasive behaviour of myofibroblasts 
cells and the role of HMGb1 in promoting invasiveness of myofibroblasts. The results from 
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invasion assays suggested that HMGb1 present in the conditioned medium of HT29 cells 
triggers myofibroblasts cells to invade (Chapter 5, Figure 5.7). It was logical to investigate the 
role of the receptors that were reported to be involved in our migration assay. The resulting data 
suggested that HMGb1 mediated invasion of myofibroblasts cells again involved the activation 
of RAGE and TLR-4. The involvement of RAGE and TLR-4 was validated by 
immunoneutralising antibodies against RAGE and TLR-4 which significantly inhibited invasion 
of myofibroblasts cells through ECM mimicking matrigel membrane. In addition both pathways 
PI3K-AKT and MAPK-ERK which showed positive results in our migration assay were also 
investigated. Inhibiting both pathways by using selective inhibitors in the cell suspension 
significantly reduced HMGb1 induced invasion in myofibroblasts cells (Chapter 5, Figure 5.9). 
Thus, based on the findings, it appeared that HMGb1 mediated invasion take place via both the 
PI3K-AKT and MAPK-ERK pathways.  
 
The results from the invasion assays suggest that myofibroblasts can invade through the 
basement membrane. To achieve that, basement membrane must be digested by proteases 
released from the cells that are responsible for ECM remodelling to facilitate the cells to move 
through the matrigel membrane. Hence, it was empirical to look for most prominent MMPs that 
might be released from myofibroblasts following the HMGb1 containing HT29 glucose free 
conditioned media treatment. Our western blot analysis suggested that MMP-2 is being 
released in the culture medium of myofibroblasts cells following the treatment with normal 
glucose containing conditioned medium from HT29 cells (Chapter 5, Figure 5.10). However, the 
levels of MMP-2 appeared to be reduced when myofibroblasts were treated with low glucose 
conditioned medium from HT29 cells (Chapter 5, Figure 5.10 A); a medium that we have 
previously shown to have strong chemo-attractive properties for myofibroblasts. In addition, 
MMP-9 another major degrader of basement membrane was also investigated. Our western 
175 
 
blot data suggested that MMP-9 is not being released from myofibroblasts following the 
treatment with glucose free or normal glucose conditioned medium of HT29 cells (Chapter 5, 
Figure 5.10 B). This further suggests that myofibroblasts are secreting MMPs other than MMP-2 
and MMP-9 or other proteases that are actively taking part in the basement degradation and 
facilitating invasion of myofibroblasts cells.  
 
On the basis of this work, we postulate that HMGb1 is released from the areas of low or no 
glucose rather than hypoxia in cancer cells. This areas typically found in the central core of 
most solid tumours which is also acidic (Schlappack et al. 1991; Rajendran et al. 2004). Once 
released from these areas, HMGb1 can reach to the myofibroblasts (may be due to interstitial 
fluid pressure) which are present in the stroma of most solid tumours. HMGb1 then can 
stimulate myofibroblasts to proliferate on site. The stromal myofibroblasts has been shown to 
release proteases to degrade basement membrane and have been related to poor prognosis in 
breast cancer (De Wever et al. 2008; Yamashita et al. 2012). Once the ECM has been 
digested, myofibroblasts along with other cells can make their way out of the tumour to the 
distant sites (Nielsen et al. 1996; Malik et al. 2015). The data presented in this thesis suggest 
that increasing number of myofibroblasts after getting signal from HMGb1 would likely to 
remodel basement membrane rapidly which would have then facilitate the migration of other 
cells too. In addition, levels of glucose in myofibroblastic tumours can become predictive tools 
for measuring the release of HMGb1 and its effects on the spreading of tumours. Increasing 
population of myofibroblasts on the tumour periphery will increase the tumour mass. It is also 
likely that larger tumour mass would have more glucose deprived areas and hence more 
HMGb1 being released. This HMGb1 then can further influence myofibroblasts and other 
cancer cells to grow, migrate and invade to the distant sites. Although, there is a clear need to 
identify other factors that may influence myofibroblasts and cancer cells migration and invasion 
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but the importance of HMGb1 and its crucial role in proliferation, migration and invasion of 
myofibroblasts can not be neglected. 
 
6.2   Conceptual Advances  
 
The tumour stroma in many solid tumour including colon cancer and breast cancer comprises a 
major part of the tumour mass (Peña et al. 2013). The myofibroblasts are predominant cell 
types in most carcinomas found on the periphery of most solid tumours (Desmoulière et al. 
2004; Tripathi et al. 2012). The myofibroblasts have been shown to take part in tumour 
proliferation by secreting a number of growth factors including IGF-1, IGF-II and HGF (Hinz et 
al. 2007). These growth factors may play important roles in initiating certain pathways which are 
necessary for tumour cell survival and proliferation (Vanamala et al. 2010). However, contrary 
to this, the role of cancer cells in proliferation of myofibroblasts has not been explored, 
especially in the microenvironmental stress conditions. 
 
The microenvironment of a tumour represents a number of conditions which may be unique to 
certain types of tumour such as hypoxic tumours. The hypoxic tumour may be characterised by 
a specific microenvironmental condition of glucose and oxygen deprivation in some parts within 
the tumour mass (Rajendran et al. 2004). In addition, the hypoxic tumours have been thought to 
be more aggressive in nature due to the adaptation of alternate survival strategy and are more 
prone to migrate and invade to the distant organs (Joseph et al. 2015). Although glucose 
deprivation has been considered as major hallmark of solid tumour microenvironment, yet this 
area remained unexplored with no major developments having been reported in the last decade 
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(Schlappack et al. 1991; Jang and Hill 1997). It has been established that hypoxic tumours are 
more likely to spread to distant sites because of the adaptation to adverse conditions and 
altered survival strategy (Jögi 2015) However, little is known about glucose deprivation related 
upregulation or downregulation of certain factors including ligands, receptors and proteases 
which may play important roles in aiding tumour survival, growth and tumour spread or 
metastasis in these conditions.  
 
The data presented in this thesis shows that HMGb1, which is known to have role in bending of 
DNA in the nucleus of cells, is released from cancer cells that are deprived of glucose. The 
results of this work also yield evidence that HMGb1, a non-histone nuclear protein, is actively 
secreted by cancer cells that are not undergoing necrosis however may be under the state of 
reversible quiescence. This secreted HMGb1 may reach myofibroblasts present within the 
tumour stroma and attract myofibroblasts from elsewhere. Previous work has shown that 
necrotic cells are able to release HMGb1 in the extracellular environment (Vogel et al. 2015). 
Also, the cytoplasmic HMGb1 has been reported to regulate autophagy and may promote 
cancer cell survival (Zhang et al. 2015). The proliferative properties of HMGb1 has been 
explored recently and it has been shown that HMGb1 once released from damaged cells 
triggers proliferation in gingival fibroblasts (Chitanuwat et al. 2013). However, the stimulus for 
the release of HMGb1 from tumour cells and the interaction between HMGb1 and 
myofibroblasts has not previously been explored. The results from this work suggest that 
recombinant HMGb1 at 10ng/ml significantly stimulates proliferation, migration and invasion in 
myofibroblasts (Chapter 3, Figure 3.1, 3.2 and 3.3).  
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The tumour microenvironmental stress plays an important role in the outcome to chemotherapy. 
Within this microenvironment, it is likely that most solid tumours may have interstitial fluid 
pressure building up within which helps cell debris and some live cells to come out from internal 
core (Mori et al. 2015). It has been established that the central core of tumours is often hypoxic, 
acidic and may lack nutrients to feed the cells within (Sun et al. 2015). As a result, few cells 
may die but a few can become adaptive to the microenvironmental stress and continue to grow 
via altered route for survival (HIF pathway triggered by hypoxia and other physiological 
adaptations). Thus, one of the reasons for treatment failure while treating such tumours may be 
linked to interstitial fluid pressure led transfer of cells from the core to the periphery resulting in 
the expansion of tumour mass. Therefore, there is a strong possibility that interstitial fluid 
pressure inside the tumours may facilitate the transfer of HMGb1 towards the myofibroblasts 
from the glucose starving regions of solid tumour (Discussed in Chapter 1 – The interstitial fluid 
pressure). Once HMGb1 has reached to the myofibroblasts, it may trigger proliferation in 
myofibroblasts which then can result in further expansion of tumour mass.  
 
Previously, it has been shown that the cells undergoing autophagy or necrosis release HMGb1 
in the microenvironment (Dong et al. 2007; Ito et al. 2007; Thorburn et al. 2009; Beyer et al. 
2012). Autophagy is induced by starvation, which may be caused by a lack of glucose, 
glutamine, pyruvate, oxygen and serum (Janji et al. 2013).  However, it is not clear that which of 
these factors trigger the release of HMGb1 in microenvironment. The data presented in this 
thesis suggests that glucose deprivation is the trigger for the release of HMGb1 from HT29 cells 
in normoxic conditions. However, it is also released from anoxic cells. These cells (anoxic cells) 
represent typical oxidative stress conditions and therefore could undergo autophagy in order to 
fuel themselves. Surprisingly, the amount of HMGb1 released under glucose deprivation in 
normoxic conditions was much higher than any other conditions such as hypoxic or anoxic 
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conditions. In addition, cells exposed to low glucose but not anoxia were able to proliferate 
when treated with normal conditions i.e. with culture medium containing serum, glutamine and 
glucose after 48h. Therefore, this release of HMGb1 in glucose deprived normoxic conditions in 
our experimental design was an active release instead of passive released caused by necrosis.  
 
The tumour metabolism is fundamental to cancer cell survival, growth and behaviour. It has 
been shown that tumour cells have enhanced demand for nutrients to provide energy to sustain 
their proliferative status (Brahimi-Horn and Pouysségur 2006). Increased glutamine intake is 
one of the key traits that has been reported in wide range of cancers (Márquez et al. 2015). In 
addition, glutamine deprivation has been considered as a potential inducer of autophagy and 
therefore may facilitate the release of HMGb1 out of the cells even though when cell membrane 
is intact (Thorburn et al. 2009; Zhang et al. 2015). Thus, the effect of glutamine deprivation was 
also investigated in this work. The data suggests that HMGb1 is released from glutamine-
deprived conditions in normoxia (Chapter 4, Figure 4.3 A). However, when this release was 
compared to the release of HMGb1 in glucose deprivation conditions, a negligible amount of 
HMGb1 was detected in glutamine deprivation conditions (Chapter 4, Figure 4.3 B). This further 
suggests that the release of HMGb1 in glucose starving conditions may not be autophagic. The 
next question about this release could be if the cells were undergoing necrosis because HMGb1 
has been reported to be released by necrotic cells previously (Scaffidi et al. 2002). In our 
experimental setup, the cancer cells investigated were not dead under glucose deprivation and 
were able to grow again when treated with fresh medium supplied with appropriate nutrients. 
Therefore, this release was suggested to be independent of necrosis and possibly involving a 
novel release mechanism. However, the underlying mechanism for this glucose dependent 
release of HMGb1 from cancer cells is not clear. Though, it is possible that low glucose may 
actively stimulate the release of HMGb1 demonstrates the likelihood that intracellular signalling 
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pathways maybe involved, which may facilitate the release of HMGb1 from the nucleus to the 
cytosol followed by translocation into the extracellular environment of the cells.  
 
HMGb1 release has been linked with a number of cells including apoptotic jurkat cells (human T 
cell leukaemia) and U937 cells (human promonocytic) previously (Bell et al. 2006; Liu et al. 
2011). However, release under glucose depravation has not been reported previously. It was 
important to check whether this release of HMGb1 was not cancer cell type specific, few other 
cancer cell lines (MCF-7 (breast cancer), A549 (lung cancer) and EJ138 (bladder cancer) were 
examined for their response to glucose depravation and compared to the response in the HT29 
(colon adenocarcinoma) cell line. It was found that out of the four cell lines, three cell lines 
(HT29, MCF-7 and A549) followed the same pattern for HMGb1 release in response to low 
glucose. Although EJ138 cells did not appear to follow the same pattern, with increased HMGb1 
release under glucose depravation, but showed an equal amount of HMGb1 was being 
released under normal and glucose deprived conditions (Chapter 4, Figure 4.2). With three out 
of the four cell lines investigated showing an increase in the HMGb1 release in response to low 
glucose, suggested that majority of cancer cells might release HMGb1 under glucose 
deprivation. Therefore, based on the results presented in this thesis, it is also likely that a large 
population of cancer cells will exhibit elevated levels of HMGb1 released in the tumour 
microenvironment. In addition, the stromal cells that are present on the periphery of tumour are 
potential targets for HMGb1. The data presented in this study suggest that HMGb1 can 
stimulate these stromal myofibroblasts, which might in turn facilitate tumour spread, invasion 
and metastasis.  
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The data from migration and invasion assays suggest that HMGb1 present in the glucose free 
culture medium of used on HT29 cells and collected at 48h triggers level of migration and 
invasion in myofibroblasts cells (Chapter 5, Figure 5.1 and 5.6). The presence of HMGb1 in the 
culture medium was supported by western blot data (Chapter 4, Figure 4.1). HMGb1 has 
previously been observed in culture medium of other cell types, macrophages and monocytes. 
However, this release was not due any microenvironmental stress conditions (Tang et al. 2007). 
The involvement of HMGb1 in migration and invasion of myofibroblasts was validated by 
immunoneutralising antibodies against HMGb1 (Chapter 5, Figure 5.2 and 5.7). The addition of 
immunoneutralising antibodies significantly reduced the migration of myofibroblasts cells, 
suggesting a key role of HMGb1 in stimulating myofibroblasts to migrate. Indeed, there is a 
potential chance that other factors are in the glucose and serum free culture medium taken from 
HT29 cells that could promote migration of myofibroblasts cells. However, the data from 
western blot confirmed that HMGb1 is present and at relatively high levels in the used glucose 
free medium than any other microenvironmental stress condition investigated. In addition, 
proliferation, migration and invasion are also relatively high in myofibroblasts exposed to this 
glucose free used medium. Furthermore, the fact that myofibroblast proliferation, migration and 
invasion were significantly reduced when HMGb1 immunoneutralising antibodies were used 
gives strong evidence that it is the HMGb1 that is interacting with the myofibroblasts.  
 
The stimulation of myofibroblasts following the treatment with conditioned medium containing 
HMGb1 must involve activation of various receptors for HMGb1. Thus, known receptors (RAGE 
and TLR-4) for HMGb1 were investigated for their involvement. The western blot data indicates 
that myofibroblasts express both RAGE and TLR-4 (Chapter 4, Figure 4.4. and 4.5). The 
activation of TLR-4 has previously been shown to trigger migration in vascular smooth muscle 
cells (Yang et al. 2012). However, the activation of TLR-4 by HMGb1 has also been shown to 
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inhibit migration of enterocytes and endothelial cells (Bauer et al. 2013; Dai et al. 2010); 
Whereas, activation of RAGE by HMGb1 has been shown to modulate migratory properties in 
dendritic cells (DCs) and myoblasts (Dumitriu et al. 2007; Riuzzi, et al. 2006). Thus, it appears 
that the role of HMGb1 and its interaction with receptors might be cell-type specific. Here, in our 
migration assay setup, combined blockade of RAGE and HMGb1 resulted in additive inhibition 
in migration of CCD18 myofibroblasts (Chapter 5, Figure 5.4). This suggested that HMGb1 
binds to RAGE which then may activate some downstream signalling pathways. However, 
combined blockade of TLR-4 and HMGb1 did not show any additive inhibitory effect on the 
migration of myofibroblasts (Chapter 5, Figure 5.5).  
 
Though, it is possible that the effect of the antibodies used to block each of these pathways 
might have different efficiencies to each other or at completely different concentrations from 
each other. However, the concentration used for antibodies was enough to block more than 
50% of the target protein according to the manufacturer data sheet (BioRad Laboratories UK). 
Therefore, the concentration of antibodies used was sufficient to block the target protein by at 
least 50%. The data suggests that HMGb1 binds to RAGE to trigger migration. However, it is 
also possible that some HMGb1 may also bind to TLR-4 and activate some downstream 
signalling. Another possibility behind signalling cascade following the interaction of HMGb1 with 
TLR-4 could be the involvement of TIRAP and Myd88 which are adaptor proteins for TLR-4. 
These downstream signalling molecules have been shown to play important roles in migration 
and invasion following the interaction with HMGb1 activated RAGE previously (Sakaguchi et al. 
2011). Therefore, it is possible that both adaptor proteins may bind to HMGb1 activated RAGE 
and transduce signals to downstream molecules such as PI3K and MEK1/2.  
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The HMGb1 has been shown to interact with many receptors including RAGE and TLR-4 
(Apetoh et al. 2007). The interaction of HMGb1 with TLR-4 has been implicated in proliferation 
of hepatic stellate cells (HSC) via PI3K-AKT pathway (Wang et al. 2013). Indeed, HMGb1 
induced proliferation in myofibroblasts must involve receptor-ligand interaction. Therefore, 
future work should be to further investigate ligand-receptor interaction using the ligand-receptor 
binding assays (BiaCore) and co-immunoprecipitation followed by selective purification using 
affinity chromatography. This approach would further validate the activation and involvement of 
the HMGb1-RAGE complex. In addition, the potential involvement of other receptors such as 
CXCR4 (chemokine receptor 4) would be interesting because the role of CXCR4 in the 
recruitment of inflammatory cells has been explored recently where HMGb1 appeared to form a 
complex with CXCL12 (chemokine ligand 12) and triggered signalling via the activation of 
CXCR4 (Schiraldi et al. 2012). In addition, chemokine receptor CCR7 has been shown to play 
an important role in migration of DCs following the release of HMGb1 (Saïdi et al. 2008). 
Therefore, it is possible that both receptors (CCR7 and CXCR4) could play individual or 
combined roles in HMGb1 induced migration and invasion of myofibroblasts cells alongside of 
RAGE. Based on the data presented in this thesis, we propose a possible mechanism for 
tumour spread involving proliferation, migration and invasion of myofibroblasts (Figure 6.1)   
 
Phosphorylation of ERK1/2 has been reported in HMGb1 induced migration of 3T3 fibroblasts 
and mesoangioblasts (Palumbo et al. 2007). The migration and invasion reported in this thesis 
also validated the involvement of PI3K and MAPK-ERK pathways. The role of proteases 
especially metalloproteases in degradation of basement membrane to facilitate migration was 
first established in 1983 (Kalebic et al. 1983). Therefore, Two major degraders (MMP-2 and 
MMP-9) of basement membrane were investigated and found not be involved in HMGb1 
induced myofibroblasts migration and invasion. Recently, both proteases (MMP-2 and MMP-9) 
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have been shown to play important roles in promoting migration and invasion of prostate cancer 
cells (Ding et al. 2015). However, they do not play a significant role in HMGb1 induced 
migration and invasion of myofibroblasts in response to HMGb1 stimulation according to our 
western blot results (Chapter 5, Figure 5.10). Therefore, the next logical step for future work 
would be further investigation of all other potential proteases in the culture medium of 
myofibroblasts which have been treated with glucose free conditioned medium of HT29 cells 
collected at 48h.  
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Figure 6.1: Proposed mechanism of HMGb1 induced proliferation, migration and invasion in 
myofibroblasts  
 
The tumour cells starved of glucose in the tumour stroma release HMGb1 into the 
microenvironment. This HMGb1 then can interact with myofibroblasts (possibly by interstitial 
fluid pressure) and may bind to receptors RAGE, or RAGE and TLR-4. Once activated, these 
receptor complexes can activate downstream signalling pathways which may facilitate 
myofibroblasts proliferation, migration and invasion. Once myofibroblasts had made their way 
through the ECM, it is possible that some cancer cells can also spread out of the initial tumour 
site and possibly migrate towards distant organs. 
 
 
Activation 
of PI3K and 
MEK1/2  
 
Upregulation 
of proteases  
 
186 
 
Other researchers have reported these pathways  (PI3K and MAPK) in both migration and 
proliferation in cells such as human melanoma cells, glioblastoma cells and renal cell carcinoma 
cells (Chen et al. 2015; Ji et al. 2015; Sun et al. 2015) However, involvement of these pathways 
in HMGb1 induced stimulation of myofibroblasts has not been reported. The data presented in 
this thesis suggests that HMGb1 induced proliferation in myofibroblasts involves activation of 
PI3K and MEK1/2 pathways. Although, PI3K appeared to be a preferential pathway in both 
settings (migration and invasion), however, it is possible that the effect of the antibodies or 
inhibitors used to block each of these pathways might have different efficiencies to each other 
or at completely different concentrations from each other. For example, the IC50 value for PI3K 
inhibitor could be less than the MAPK-ERK inhibitor. Therefore, it is difficult to estimate to what 
extent both pathways could have been inhibited using these antibodies. It was possible that an 
effective dose of these inhibitors might have been toxic to myofibroblasts. Therefore, we 
determined a non-toxic dose for both inhibitors that was able to inhibit the activation of these 
pathways.  
 
Considering all evidence presented in this thesis, it is clear that both pathways and receptor 
RAGE and TLR-4 play important roles in HMGb1 induced proliferation, migration and invasion 
of myofibroblasts cells. Therefore, based on the findings presented in this thesis, the 
involvement of both pathways and receptors and a possible signalling flow path in HMGb1 
induced proliferation, migration and invasion of myofibroblasts have been proposed using a 
schematic diagram (Figure 6.2).   
 
 
 
187 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
   
 
  
 
 
Figure 6.2: Proposed activation of the pathways involved in proliferation, migration and 
invasion of myofibroblasts cells.  
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